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ABSTRACT  
 
Patients with emphysema frequently complain of exertional dyspnoea despite 
maximal medical therapy.   Destruction of the elastic tissue of the lung leads to 
enlargement of airspaces, small airway collapse, and progressive hyperinflation.  This 
results in impaired respiratory mechanics and reduced inspiratory capacity, which 
together cause worsening dyspnoea and impaired exercise tolerance.   
 
Lung volume reduction surgery has been shown to improve lung function and 
exercise capacity in selected patients with upper lobe predominant emphysema by 
removing the most hyperexpanded areas of lung.  However, there is a 5% mortality 
and considerable morbidity.  Several bronchoscopic lung volume reduction 
procedures have been developed In order to achieve similar results without surgery.  
This thesis brings together a number of trials of novel devices or techniques designed 
to achieve volume reduction whilst reducing the risk of significant morbidity or 
death.   
 
Investigations of new treatment strategies and indications for the one-way 
endobronchial valves are presented, and the problems of collateral ventilation 
explored.   Studies of bilateral incomplete lobar exclusion (no benefit seen in any 
measured parameter) and subsequent complete unilateral lobar occlusion (marked 
benefit in selected patients) are presented, together with a clinical review of single 
lung transplant patients with native lung hyperinflation with findings showing a 
range of patient responses and suggesting a larger prospective study should be 
undertaken.   
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Techniques designed to either act independently of, or take advantage of, collateral 
ventilation are then investigated, with one novel approach being the use of 
autologous blood to achieve volume reduction.  This technique uses no foreign 
implants, and could deliver dramatic cost savings.  Overall short-term results 
presented here in patients with heterogenous emphysema are disappointing, but a 
potential signal for longer-term benefit is identified.  Accessory airways allow venting 
trapped gas via non-collapsible artificial airways, using collateral ventilation to 
achieve whole lung deflation.  Immediate results are dramatic, but the benefits are 
short lived with no difference in end-points between real and sham treatments, and 
attention to device design is needed. 
 
The most promising technique investigated in this thesis is the use of lung volume 
reduction coils, designed to achieve lung volume reduction by improving the elastic 
recoil forces of the lung, splinting open small collapsible airways, and improving lung 
mechanics. Significant improvements in lung function, exercise tolerance, and 
symptom scores over and above best medical care were seen at 3 months post-
procedure with an acceptable safety profile, and longer term results are awaited. 
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CHAPTER  1::   IINTRODUCTII ON   
 
1.1 OVERVIEW 
 
The aim of the work in this thesis was to investigate several new approaches to 
bronchoscopic lung volume reduction in patients with severe emphysema, in order 
to improve availability and tailor treatments to individual patients.  It brings together 
a number of trials of new indications or techniques, each discussed in its own 
chapter. 
 
1.1.1 HYPOTHESES 
1. That patients with advanced heterogeneous emphysema could benefit from a 
strategy of bilateral incomplete lobar occlusions with the Spiration Intrabronchial 
Valve (IBV).  
 
2. That patients could derive an incremental benefit from unilateral complete lobar 
occlusion with the Spiration IBV after initial bilateral incomplete occlusions. 
 
3. That single lung transplant recipients with native lung hyperinflation could 
benefit from endobronchial valve treatment of the native lung. 
 
4. That patients with advanced emphysema could have evidence of scarring on 
computed tomography scanning in the treated segments with blood lung volume 
reduction when compared with placebo.  
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5. That patients with severe homogeneous emphysema could have a significant 
improvement in dynamic hyperinflation at 6 months, and lung function 
parameters, exercise tolerance, and breathlessness at 6 months and 1 year 
following treatment with the Exhale© drug-eluting stent. 
  
6. That patients with advanced emphysema could have improvements in quality of 
life, lung function parameters and exercise tolerance when compared to best 
medical care following treatment with the RePneu© lung volume reduction coil.  
 
1.2 DEFINITION AND HISTORY OF EMPHYSEMA  
 
1.2.1 DEFINITION 
The term emphysema derives directly from the Greek word emphysēma, meaning 
inflation (from the verb emphysaein, to inflate, or blow in). It is defined as abnormal, 
permanent enlargement of air spaces distal to the terminal bronchioles, 
accompanied by the destruction of their walls and without obvious fibrosis. This 
destruction results in the loss of acinar structure, and a subsequent reduction in the 
area available for gas exchange (figure 1.1). The associated loss of elastic tissue leads 
to small airway collapse and the gas trapping that is often a prominent feature of the 
disease. Clinically, emphysema is part of the spectrum of disease encompassed by 
the term ‘‘chronic obstructive pulmonary disease’’ (COPD) that also covers chronic 
bronchitis, which is a chronic productive cough for 3 months during each of 2 
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consecutive years (other causes of cough being excluded). The cardinal feature of 
both emphysema and bronchitis is airflow obstruction. 
 
Frederick Ruysch (Ruysch 1691) provided the first recognized description of 
emphysema, and subsequent work by others such as Laennec (Laennec 1835) and 
Orsos (Orsos 1907) further characterized the disease, with the realization that 
disruption of the elastic fibres of the distal airways was the primary underlying 
pathology. 
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as ‘‘a 
preventable and treatable disease with some significant extrapulmonary effects that 
may contribute to the severity in individual patients. Its pulmonary component is 
characterized by airflow limitation that is not fully reversible. The airflow limitation is 
usually progressive and associated with an abnormal inflammatory response of the 
lung to noxious particles or gases.’’ This recognizes the permanent loss of lung 
function, as well as the often-neglected non-pulmonary components of the disease.  
 
Figure 1.1: Histology of a) normal lung tissue and b) emphysema (both x40). 
  
 (Courtesy of Augustine G. DiGiovanna, Salisbury University, Salisbury, MD; with permission. Copyright © 2004. All rights 
reserved.) 
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1.2.2 DIAGNOSIS 
1.2.2.1 Clinical measurements 
The diagnosis of COPD relies on spirometric measurements of forced vital capacity 
(FVC) and post-bronchodilator forced expiratory volume in 1 second (FEV1), the most 
widely used criteria being those defined by GOLD. The diagnosis requires an 
FEV1/FVC ratio of <0.7, and patients are then stratified into four categories from mild 
to very severe disease based on the severity of FEV1 impairment as set out in table 
1.1 below (Rabe 2007). The original GOLD publication separated moderate disease 
into stage IIa and IIb (Pauwels 2001), but the staging was later changed such that IIb 
has become III (severe) and stage IV (very severe) has been added. The National 
Institute for Health and Clinical Excellence (NICE) in the United Kingdom published its 
own guidelines in 2004, which differed slightly from the GOLD criteria (NICE 2004). 
While maintaining the need for an FEV1/FVC ratio of <0.7, it did away with the most 
mild category of disease all together, with an FEV1 of <80% predicted required to 
establish the diagnosis. A 2010 revision has now brought staging into line with GOLD 
staging (NICE 2010).  As the degree of airflow obstruction increases, so too, in 
general, does the degree of physical limitation and frequency of exacerbations, 
although there is considerable individual variation in symptom severity.  
 
Table 1.1: Chronic obstructive pulmonary disease staging by FEV1 
Stage 1: mild FEV1/FVC <70% 
FEV1 >80% predicted 
Stage2: moderate FEV1/FVC <70% 
FEV1 <80% predicted 
Stage3: severe FEV1/FVC <70% 
FEV1 <50% predicted 
Stage4: very severe FEV1/FVC <70% 
FEV1 <30% predicted or 
FEV1 <50% with chronic respiratory failure 
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1.2.2.2 Patterns of emphysema on histology and Imaging  
The recognition of different pathological patterns of emphysema first came about 
from the work of Gough and colleagues (Gough 1952; Leopold 1957) in Cardiff in the 
1950s, and can now be divided into three subtypes: centrilobular, panacinar, and 
paraseptal. Centrilobular emphysema is characterized by the loss of respiratory 
bronchioles with a degree of sparing of the distal alveoli, and predominantly affects 
the upper portions of the lung. This pattern is the one that is most commonly seen in 
smokers. Panacinar emphysema affects the entire acinus uniformly, is seen 
predominantly in the lower lobes, and is the pattern most associated with -1 
antitrypsin deficiency. Paraseptal (also known as distal acinar) emphysema is 
localized around the septae and pleurae, and affects the distal acinar structures. 
Although often co-existing with centrilobular emphysema in smokers, it can be an 
incidental finding in young patients and may lead to spontaneous pneumothorax, 
particularly in apical disease. Histological examination reveals a progressive 
inflammatory reaction within the small airways, with subsequent fibrosis and 
connective-tissue deposition (Cosio 1978), whilst the loss of lung elastic recoil 
pressure seen in emphysema seems to be attributable to microscopic enlargement 
of the air spaces rather than to grossly visible emphysema (Hogg 1994).   
 
Bullous emphysema develops from the local expansion of air spaces owing to air 
trapping and the relatively greater elastic recoil properties of surrounding healthier 
lung, and, in giant bullous disease, can cause significant loss of expansion of 
remaining lung tissue.  The distribution on imaging rather than the histologic pattern 
of disease has probably been more useful clinically, because lung volume reduction 
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surgery (LVRS) has been shown to benefit those with a predominance of upper lobe 
disease (Fishman, 2003), and endobronchial valve trials have been designed with this 
same patient group in mind (Strange 2007; Wood 2007).  However, as will be 
discussed in subsequent chapters, there is some evidence that different 
bronchoscopic lung volume reduction devices are most effective in different 
histological subtypes of emphysema rather than relying specifically on distribution. 
 
1.2.3 EPIDEMIOLOGY 
COPD is a common and under-diagnosed problem. The World Health Organization 
(WHO) estimates that 210 million people worldwide suffer from the disease, and 
that it led to over 3 million deaths globally in 2005 – 5% of all deaths (WHO 2008). It 
is thought that around half of all COPD cases in the developed world remain 
undiagnosed, and this proportion is likely to be higher still in the developing world. 
Data from NHANES III (Mannino 2000) indicated that, at the end of the 20th century, 
24 million Americans were living with impaired lung function, with 10 million of 
those reporting physician-diagnosed COPD. Eight million physician consultations, 1.5 
million emergency department attendances, and 726,000 hospital admissions were 
attributed to COPD, with 119,000 deaths. Similar data is available for England and 
Wales, and the most robust recent primary care data estimates 765,000 people with 
a General Practice diagnosis of COPD, although modelling suggests an expected 
prevalence of 3.58%, or just over 1.4 million (Nacul 2010). Over 100,000 admissions 
account for over 1 million bed-days, and the disease is thought to cost the National 
Health Service nearly £1.5 billion annually (NICE 2004), a huge strain on the public 
purse.   
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Bronchoscopic lung volume reduction techniques currently target those with stages 
III and IV COPD.  Whilst only accounting for 5.1% and 1.4% respectively of the total 
COPD population (Ekberg-Aronsson 2005), the absolute number of patients with at 
least severe COPD still totals approximately 60,000 people.  This population accounts 
for a hugely disproportionate amount of health care spending, with recent DH 
analysis estimating the direct cost per patient year associated with COPD by disease 
severity as follows (National Clinical Guideline Centre 2010): 
 
GOLD Stage I (FEV1 ≥ 80% predicted): £120 - £130 
GOLD Stage II (FEV1 50% to 79% predicted): £270 - £290 
GOLD Stage III (FEV1 30% to 49% predicted): £910 - £980 
GOLD Stage IV (FEV1 ≤ 30% predicted): £3,000 - £3,200 
 
Five year survival from a diagnosis of COPD is 78% in men and 72% in women with 
clinically mild disease defined as not requiring continuous drug therapy, but falls to 
30% in men and 24% in women with severe disease defined as requiring oxygen or 
nebulised therapy.  The mean age of death of patients with severe COPD is 74.2 
years compared with 77.2 years in patients with mild disease (National Clinical 
Guideline Centre 2010). 
 
The accumulation of tobacco smoking (or other risk factor exposure) required to 
cause destructive lung disease means that emphysema is predominantly a disease of 
middle and late adult life. Disease is often seen earlier in 1-antitrypsin deficiency, 
especially in those who also smoke, but isolated cases of early onset smoking-related 
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disease in the absence of 1-antitrypsin deficiency are occasionally seen (Gupta 
2007). Historically, COPD has been a male-dominated disease, but the increase in 
female smokers in the developed world and the increased risk of exposure to 
biomass fuels in developing countries has led to an equal distribution between the 
sexes. 90% of all deaths from COPD are thought to occur in the developing world 
(WHO 2008), where health care systems are absent or insufficient. This situation is 
mirrored to some extent in developed countries, were there is an association with 
lower social class. Many factors play a role here, and include smoking status, 
occupational history (manual labour and exposure to dusts and fumes), and poorer 
utilization of available health resources. 
 
1.2.4 AETIOLOGY 
1.2.4.1 Tobacco smoke 
Tobacco smoking is by far the single most important factor in the development of 
emphysema, and accounts for 80%–90% of cases in the developed world. The 
decline in FEV1 with smoking was shown by Fletcher and Peto in 1977 (Fletcher 
1977), but they had suggested that only a minority of smokers would go on to 
develop clinically significant airflow obstruction. This analysis led to the erroneous 
belief that there were effectively two populations of smokers: those who were 
resistant and those who were susceptible. Subsequent work over the years has 
shown that the amount of tobacco smoked is strongly correlated to the degree of 
emphysema and airflow obstruction, and it is now increasingly apparent that there is 
a continuum of susceptibility which is likely due to the interplay of a number of 
genetic and other environmental factors. The increasing use of cannabis has led to 
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the recognition of emphysematous lung disease, often bullous in nature, in some 
users. The degree to which lung destruction can be attributed to the cannabis itself is 
uncertain however, as studies are confounded by the mixing of the drug with 
tobacco when smoking, and the use of deeper inhalation and breath holding for 
maximal effect. 
 
1.2.4.2 Genetics  
The most well-known genetic association with emphysema is that of -1 antitrypsin 
deficiency, discovered in 1963 by Carl-Bertil Laurell (Laurell 1963). In addition to its 
importance in the field of emphysema, the discovery led to the identification of a 
new class of conformational protease inhibitors, the serpins, crucial in many biologic 
processes including coagulation and inflammation. The 1-antitrypsin gene is found 
on chromosome 14, and 1-antitrypsin is produced in the liver. Mutations of this 
gene lead to abnormal protein folding with altered secretion from hepatocytes, and 
subsequent low circulating blood levels. 1-antitrypsin is a wide-ranging 
antiprotease, but its most relevant activity in respect to the lungs is its action against 
neutrophil elastase, released from neutrophils at areas of inflammation and in 
response to tobacco smoke. A lack of 1-antitrypsin allows unopposed elastase 
activity and subsequent destruction of the lung architecture. Whilst previously 
thought to be largely a disease affecting those of European descent, it is now 
recognized that the disease affects a wide range of geographic and ethnic 
populations (de Serres, 2002). There are over 75 alleles of the 1-antitrypsin gene, 
designated Pi (Crystal 1989). The normal allele is PiM, with PiS and PiZ the two most 
common abnormal expressions. It appears that only one normal allele is required to 
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produce a normal phenotype, even though these individuals (PiMS, PiMZ) have lower 
serum 1-antitrypsin levels than PiMM individuals. Apart from very rare null alleles, 
PiZZ is associated with the most severe clinical picture, as not only are levels severely 
reduced, but the activity of the gene product is also diminished. The onset of clinical 
disease is variable, but it is usually evident by the fifth or sixth decade, and roughly 
20 years earlier in those who smoke (Janus 1985).  
 
Many other genes have been implicated in the pathogenesis of emphysema. Hersh 
and colleagues (Hersh 2006) have identified single nucleotide polymorphisms 
associated with different clinical features of advanced emphysema, including 
dyspnoea (transforming growth factor-beta1 [TGFB1]), exercise tolerance (latent 
transforming growth factor-beta binding protein-4 [LTBP4]) and gas transfer 
impairment (epoxyhydrolase 1 [EPHX1]), and gene polymorphisms in glutathione S-
transferase p1 (GSTP1), EPHX1, and matrix metalloproteinase 1 (MMP1) have 
recently been shown to correlate with upper-lobe predominant disease. This last 
finding is interesting, as altered function in these xenobiotic enzymes may alter 
detoxification of cigarette smoke metabolites (DeMeo 2007).  More recently, 
genome-wide association studies have identified numerous genes that influence lung 
function measures (Wilk 2007) or that may play a role in the susceptibility to (Kong 
2011) or pathogenesis of COPD/emphysema (Repapi 2010; Pillai 2010; Wan 2011).  
 
1.2.4.3 Early-life influences 
Although emphysema is traditionally thought of as an adult disease, there is 
mounting evidence that early-life events are important in the development of 
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disease in later life. Prenatal exposure to cigarette smoking is associated with 
measurable and significant declines in mid-expiratory flow rates (and to a lesser 
degree FEV1) in childhood (Moshammer 2006), but whether this leads to increased 
susceptibility to the effects of subsequent smoking is not known. There has also been 
interest in the role of childhood respiratory infections in the aetiology of 
emphysema. In 1994 the Medical Research Council (MRC) Environmental 
Epidemiology Unit published compelling data showing the relationship between 
childhood pneumonia and impaired FEV1 in adulthood (Shaheen 1994), although 
recently published data from the British 1958 Birth Cohort suggest that the rate of 
decline in lung function in mid-adult life is unaffected (Marossy 2007). 
Bronchopulmonary dysplasia, a disease of prematurity in neonates treated with 
oxygen and mechanical ventilation, leads to airflow obstruction, hyperinflation, and 
areas of emphysema on CT in those who survive to adulthood (Howling 2000). 
Although rare, it is likely to become an increasingly frequent cause of obstructive 
lung disease in the adult respiratory clinic. 
 
1.2.4.4 Industry 
A higher prevalence of emphysema is seen in workers in several occupations 
associated with exposure to fumes, chemicals, and dusts. The most extensively 
researched of these is the coal industry, with reports as far back as the late 1940s 
(Motley 1949; Leigh 1994). Exposure to respirable dust particles (p <.001) and -
quartz (p <.02) in Norwegian tunnel workers was shown to result in an excess decline 
in FEV1 of 25-38ml/yr in non-smoking workers (Ulvestad 2001), and studies in gold 
miners have demonstrated higher rates of emphysema at post-mortem in those with 
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long term exposure to underground mineral dust (Becklake 1987; Hnizdo 1991). 
Many such examples exist in the literature, and it is likely that any occupation in 
which workers are chronically exposed to a mixture of noxious fumes and airborne 
particles will confer an additional risk of emphysema on those workers, and this 
effect seems particularly prominent in those who also smoke.  
 
1.2.4.5 Biomass fuels 
Indoor exposure to smoke from biomass fuels (wood, crop residues, charcoal, and 
dung) used for cooking and heating is now recognized as a major cause of COPD 
worldwide (Salvi 2009; Salvi 2010), and causes widespread emphysema on computed 
tomography (CT) imaging (Ozbay 2001). It kills 1.6 million people every year of whom 
one million are children, and the WHO estimates that it is responsible for 22% of all 
cases of COPD (WHO 2002). The problem is disproportionately prevalent in women 
in the developing world, who can spend many hours a day around the cooking fire. A 
survey of over 20,000 citizens in southern China found an excess of COPD in those 
with poor ventilation in the kitchen and previous exposure to biomass fuels, with a 
degree of risk similar to a 15–30 pack year smoking history (Zhong 2007). More 
recently, a meta-analysis of 25 studies looking at respiratory disease in women and 
children in rural communities found that biomass fuel exposure was linked to chronic 
bronchitis (OR 2.52) and COPD (OR 2.40) in women, and respiratory infection (OR 
3.53) in children (Po 2011).  
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1.2.5 PATHOPHYSIOLOGY 
1.2.5.1 Clinical features 
The inhalation of noxious particles and fumes leads to a disruption of the mucocillary 
escalator, inflammation, and tissue damage resulting in airflow obstruction and a 
variable degree of chronic sputum production. Lung defences are altered, and there 
is a greater susceptibility to bacterial infection and colonization, exacerbations and 
perpetuation of the inflammatory process, and impaired quality of life (QoL). On 
pulmonary function testing, there are reductions in all spirometric lung volumes, and 
graphical representations of flow and volume are characteristic. There is a scalloping 
of the expiratory flow volume loop, with an increasingly severe and early pressure-
dependent small airway collapse and flow reduction as the disease progresses. In 
contrast, static lung volumes show hyperinflation with increases in total lung 
capacity (TLC) and residual volume (RV), and gas trapping is manifested as an 
elevated RV/TLC ratio. These features lead to the typical chest radiograph of large 
lung volumes, hyperlucent lung fields, and flattened diaphragms.  
 
As the lungs consist of multiple airways and airspaces (rather than a single airway 
with one distal airspace), there is the potential for different lung units to fill at 
different rates.  The rate of filling of each lung unit, known as the time constant (T), 
is determined by the product of airways resistance (Raw) and lung unit compliance 
(CL): 
 
RawCL=T 
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As airways resistance increases, flow decreases, and it takes longer to fill that lung 
unit. Similarly, as compliance increases at any given flow rate, the volume change 
generated by any change in pressure is greater than at lower compliances, and 
hence a longer filling time is required.  As both increased airways resistance and 
increased compliance co-exist in emphysematous lung, and the effects are multiplied 
rather than additive, the time constant is greatly increased.  If adjacent lung units 
have different time constants, then fast units will receive a larger proportion of the 
tidal volume than slow units.  Indeed, as fast units begin emptying as adjacent slow 
units are still filling, ventilation to slow units will consist partially of expired alveolar 
gas, exacerbating ventilation-perfusion (V/Q) mismatch. 
 
1.2.5.2 Hyperinflation 
The elastic recoil forces of the lung and the outward elastic forces of the chest wall 
are in equilibrium at functional residual capacity (FRC). With the slowly progressive 
destruction of lung tissue that underlies emphysema, the recoil forces of the lung 
become diminished, and FRC is shifted along the compliance curve of the lungs to 
the detriment of pulmonary mechanics, with an associated increase in the RV and a 
decrease in inspiratory capacity (IC).  
 
1.2.5.3 Hypercapnia 
The loss of distal airway structures reduces the effective surface area of the lung and 
hence the area available for gas exchange, and the associated disruption of the 
alveolar-capillary architecture over time leads to V/Q mismatch. As arterial carbon 
dioxide (CO2) levels are inversely correlated with alveolar ventilation, CO2 levels can 
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initially be maintained in the face of hypoxia by an increase in the minute volume. As 
the disease advances, there is an increase in physiologic dead-space secondary to 
under-perfused alveoli, and the subsequent impairment of CO2 clearance results in 
hypercapnic respiratory failure.  
 
1.2.5.4 Secondary pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH) may develop in any severe lung disease, and 
thus is seen in patients with advanced emphysema, exacerbating breathlessness and 
worsening exercise tolerance. There appears to be a subgroup of patients in whom 
there is a disproportionate degree of PAH (Thabut 2005), the mechanisms for which 
are not clear but may be genetic in origin (Eddahibi 2003), and who behave in a 
similar fashion to those with primary PAH. 
 
1.2.5.5 Non-pulmonary features 
Increasing recognition has been given to the non-pulmonary aspects of obstructive 
airways disease over recent years. Arguably the most important of these is 
peripheral muscle weakness, particularly of the quadriceps muscles, changes in 
which have been shown to contribute to exercise limitation (Gosselink 1996), impair 
health related QoL (Mostert 2000), and even predict mortality in moderate to severe 
COPD (Swallow 2007).  Similarly, pulmonary rehabilitation has been shown to 
improve both QoL and exercise capacity without changing lung function (Griffiths 
2000).  The aetiology of muscle weakness appears to be multifactorial, including 
disuse atrophy, the effects of systemic steroid therapy, and genetic factors. Work by 
Hopkinson and colleagues (Hopkinson 2004) has shown associations between 
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quadriceps strength and genotypes of the angiotensin converting enzyme and 
vitamin D receptors (Hopkinson 2008), potentially exciting targets for future 
therapies. 
 
1.2.6 NATURAL HISTORY 
COPD is recognized as a progressive disease, both in terms of symptoms and clinical 
measures of disease activity. Those with GOLD stage I disease usually have no 
symptoms or signs, in keeping with the very mild degree of airflow limitation. 
Symptoms then largely progress as outlined below, although there is considerable 
individual variation. 
 
Stage II 
No abnormal signs, have little or no breathlessness, and symptoms are limited to a ‘‘smoker’s 
cough’’. 
 
Stage III 
Onset of breathlessness with or without wheeze on moderate exertion, a productive cough, 
and abnormal signs such as a general reduction in breath sounds and the presence of wheeze. 
 
Stage IV 
Breathlessness on any exertion and even at rest, with prominent wheeze and cough, 
hyperinflation, and the eventual development of cyanosis, peripheral oedema and 
polycythaemia, especially during exacerbations. 
 
Never-smokers show a loss of FEV1 at approximately 40mls per year but almost 
never reach a level at which they are disabled by reduced airflow. Even in light 
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smokers, there is an additional accelerated decline, and a similar relationship almost 
certainly exists with exposure to any number of noxious stimuli, but a return to the 
usual age-related decline is seen on their withdrawal (Fletcher 1977). There may also 
be an accelerated loss with advancing age (Fletcher 1976). As lung function is already 
impaired on removal of any exposure, the subsequent natural fall results in 
development of worsening disability, as illustrated in figure 1.2. 
 
Figure 1.2: Decline in FEV1 with age 
 
 
Data from the Framingham Offspring Cohort has confirmed and clarified the above 
(Kohansal 2009).  The main findings of the study were: 
 
1. FEV1 in males peaked at age 23 years but not in females in the age range of the study.  
2. FEV1 in females (but not males) plateaus until about the age of 40 years.  
3. FEV1 decline for healthy never-smokers was 19.6ml/yr in males and 17.6ml/yr in females. 
4. Smoking reduced the maximal FEV1 value achieved in males, but not in females. 
5. Continuous smoking increased the rate of FEV1 decline to 38.2ml/yr in males and 
23.9ml/yr in females. 
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6. There is significant variability in the rate of FEV1 decline in continuous smokers, both in 
males (8 to 63ml/yr) and females (14 to 49ml/yr). 
 
As emphysema comes under the umbrella of COPD, there is limited information on 
the natural history of emphysema per se. The National Emphysema Treatment Trial 
(NETT) resulted in the collection of a large amount of follow-up data on this specific 
population of patients, with information regarding progression of lung function, 
symptoms, health status, exercise capacity, and mortality (Fishman 2003). The May 
2008 issue of the Proceedings of the American Thoracic Society published a series of 
articles analyzing this data, and these are summarised here and discussed in detail 
later.  COPD patients have an impaired QoL, which worsens with deterioration of 
lung function (Monzo 1998) and time (Spencer 2001), findings that were replicated 
in the NETT (Naunheim 2006). Those patients treated medically also had a 
progressive decline in exercise capacity as measured by cycle ergometry. Mortality 
was correlated with a number of clinical and physiologic measures: 
 
1. Higher RV and lower TLC – independently predictive in multivariate analysis  
2. FEV1 – significant on univariate analysis 
3. More homogenous disease 
4. Lower-lobe predominant emphysema  
5. Lower exercise tolerance  
6. Increasing age 
 
In keeping with a more multisystem approach to COPD, multifactorial scoring 
systems have been developed to provide a better indication to prognosis. The most 
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established of these is the BODE score, incorporating BMI, the degree of airflow 
Obstruction, Dyspnoea, and Exercise capacity (Celli 2004). The total score obtained 
correlates better than the FEV1 with all-cause and respiratory mortality, and analysis 
of the NETT data shows that the change in a modified BODE score is of short and 
intermediate term prognostic value (Martinez 2008).  Other scoring systems that 
have been developed include the ADO (Age, Dyspnoea, Obstruction) index (Puhan 
2009), shown to predict 3 year mortality across a variety of population groups, and 
the DOSE (Dyspnoea, Obstruction, Smoking status, Exacerbations) index, which 
predicts health status, risk of hospital admission or respiratory failure, and 
exacerbations in the subsequent year (Jones 2009). 
 
1.3 NON-SURGICAL TREATMENT OPTIONS IN COPD/EMPHYSEMA 
 
The medical treatment of COPD can be considered a stepwise process, much like the 
treatment of asthma, starting with short acting inhaled medication, moving on to 
long acting inhaled medication, possibly adding an inhaled steroid, and then the 
consideration of other oral medication as symptoms dictate.  Those with severe 
hypoxaemia may also benefit from oxygen (O2) therapy.  A brief outline of the 
medical management of COPD follows. 
 
1.3.1 BRONCHODILATORS 
Those with the mildest of symptoms require short-acting bronchodilator medication 
(such as the 2 receptor agonists salbutamol and terbutaline, and the anticholinergic 
ipratropium either alone or in combination) on an as-and-when basis (prn – pro re 
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nata, literally ‘for the thing born’).  Those who remain symptomatic should be trialed 
on long acting bronchodilators, for example the long acting 2 agonists salmeterol 
and formoterol.  The relatively new long acting anticholinergic drug tiotropium has 
been shown to improve symptoms, quality of life, and mortality over 4 years 
(Tashkin 2008; Celli 2009).  
 
1.3.2 INHALED STEROIDS 
Inhaled steroids are usually given to patients with an FEV1 <50% predicted who are 
taking long acting 2 agonists, often in combination inhalers.  Their use remains a 
heavily debated topic, however.  The Towards a Revolution in COPD Health (TORCH) 
study (Calverley 2007i) was a very large multicentre randomised trial of combination 
fluticasone and salmeterol vs salmeterol or fluticasone alone vs placebo.  Despite 
much fanfare, the results are contentious.  When comparing combination therapy 
with placebo, there was a statistically significant gain in QoL as measured by the St. 
George’s Respiratory Questionnaire (SGRQ), but the change did not meet clinical 
significance (i.e. a 4 point reduction in score).  Similarly, although the exacerbation 
rate was reduced, there was a significant increase in the risk of pneumonia, a finding 
seen in a recent systematic review (Rodrigo 2009).  There was a reduction in 
mortality, but this failed to reach the predetermined level of significance.  A 
Cochrane database review (Nannini 2007) concluded that ‘the superiority of 
combination inhalers should be viewed against the increased risk of side-effects, 
particularly pneumonia.’ 
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1.3.3 ORAL MEDICATION 
Short courses of high dose oral steroid medication are often used in the context of 
acute exacerbations of COPD for their anti-inflammatory properties.  The evidence, 
however, suggests that they are useful in reducing the chance of hospitalisation and 
improving quality of life in acute exacerbations, but not in improving the FEV1 over 
the first 72 hours when compared with placebo (Wood-Baker 2000). 
 
There is, however, no convincing evidence that doses of less than 10-15mg of oral 
prednisolone on a long-term basis provide any clinical benefit, although higher doses 
(≥30mg) do produce at least short-term improvements in lung function (Walters 
2005).  The side-effects of high dose corticosteroids would, however, mitigate 
against their use in most patients. 
 
A Cochrane review showed that theophylline has a modest effect on FEV1 and FVC 
and slightly improves arterial blood gas tensions in moderate to severe COPD. These 
benefits were seen in patients receiving a variety of different concomitant therapies 
(Ram 2002). There is also evidence that during exacerbations of COPD, low-dose 
theophylline improves the anti-inflammatory effects of steroids (Cosio 2009).  
However, a retrospective study which reviewed data from the Veterans Affairs 
health care system and analysed outcomes of 183,573 patients aged 45 years or 
older with a diagnosis of COPD concluded that patients receiving regimens that 
included theophylline had increased risks of mortality, COPD exacerbations, and 
COPD hospitalizations compared with patients receiving the same regimens without 
theophylline (Lee 2009). Side-effects often limit the use of methylxanthines in COPD, 
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but the new drug Doxofylline appears to be as efficacious as, but better tolerated 
than, theophylline (Santra 2008). 
 
Opiates (e.g. oral morphine liquid) work directly on the respiratory centre to 
diminish the sensation of breathlessness, and are used in those with persistent and 
distressing breathlessness, either on a regular or prn basis.  Similarly, dihydrocodeine 
has been shown to reduce breathlessness and increase exercise tolerance, with a 
reduction in ventilation at submaximal workloads (Woodcock 1981) in a select group 
of COPD patients, possibly by improving control of breathing. 
 
More recently, the long-acting phosphodiesterase (PDE) 4 inhibitor roflumilast has 
been licensed in the European Union for severe COPD associated with chronic 
bronchitis in those with a history of recurrent exacerbations as an add-on to 
bronchodilator therapy.  An oral therapy, it has anti-inflammatory effects and has 
been shown to reduce exacerbations and improve FEV1 in several clinical trials (Rabe 
2005; Calverley 2007ii; Calverley 2009; Fabbri 2009), but has a number of dose-
limiting side-effects, predominantly headache and gastrointestinal upset. 
 
1.3.4 LONG TERM OXYGEN THERAPY 
The beneficial effects of long term oxygen therapy (LTOT) on survival in subjects with 
COPD and severe resting hypoxemia were demonstrated in two randomized, 
controlled clinical trials: the Nocturnal Oxygen Treatment Trial (Nocturnal Oxygen 
Treatment Trial Group 1980) and the MRC study (MRC 1981). The NOTT 
demonstrated a survival benefit of continuous over nocturnal oxygen therapy, whilst 
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the MRC trial showed a survival benefit in those receiving O2 for at least 15 h/day 
over those receiving no O2. This did not, however, appear until after 500 days. The 
benefit was seen in those with an arterial blood partial pressure of oxygen (PaO2) on 
room air of <7.3 kiloPascals (kPa), or <8kPa in the presence of PAH, right ventricular 
impairment, or polycythaemia.  These trials demonstrated a relationship between 
survival and the average daily duration of O2 use.  Median survival in those using O2 
for 18 hours a day was approximately twice as long as those receiving no O2. 
 
1.3.5 PULMONARY REHABILITATION 
1.3.5.1 In stable disease 
It is now widely accepted that pulmonary rehabilitation (PR) is a mainstay of the 
treatment of stable COPD, and is defined in a joint European Respiratory Society 
(ERS)/American Thoracic Society (ATS) statement as “an evidence-based, multi-
disciplinary, and comprehensive intervention for patients with chronic respiratory 
diseases who are symptomatic and often have decreased daily life activities. 
Integrated into the individualized treatment of the patient, pulmonary rehabilitation 
is designed to reduce symptoms, optimize functional status, increase participation, 
and reduce health care costs through stabilizing or reversing systemic manifestations 
of the disease” (Nici 2006). 
 
The pulmonary rehabilitation team includes a Physiotherapist, an Occupational 
Therapist, a Clinical Nurse Specialist, a Dietician, and a Clinical Psychologist and is 
supported by the Respiratory Consultant.  Programs are run according to British 
Thoracic Society (BTS) guidelines, and consist of 12-16 sessions run over a period of 
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6-8 weeks (BTS 2001).  A Cochrane database review (Lacasse 2006) concluded that 
PR produces clinically significant improvements in dyspnoea and fatigue, improves 
emotional function and enhances patients’ sense of control over their condition.  
 
1.3.5.2 Following acute exacerbations 
There is now a body of evidence showing benefits from PR following hospital 
admissions for acute exacerbations of COPD, with clinically and statistically 
important improvements in exercise capacity and health status, with a reduction in 
readmissions and mortality (Man 2004; Puhan 2005; Seymour 2010). 
 
1.3.6 NON-INVASIVE VENTILATION 
1.3.6.1 In acute exacerbations 
Non-invasive ventilatory support (NIV) reduces mortality and morbidity associated 
with acute hypercapnic respiratory failure in COPD (Ram 2003).  Positive inspiratory 
pressure reduces the work of inspiration and provides enhanced tidal volumes, 
whilst expiratory pressure prevents distal airway collapse at end expiration, and 
overcomes intrinsic positive end expiratory pressure (PEEP; PEEPi; see 1.4.1.1).  
 
1.3.6.2 In chronic stable disease 
There is conflicting evidence as to the use of home nocturnal NIV in chronic, stable, 
COPD.  Early work has suggested a significant survival benefit (Budweiser 2007), but 
the AVCAL study (Australian trial of non-invasive Ventilation in Chronic Airflow 
Limitation, McEvoy 2009), a large randomised prospective study, showed that the 
survival benefit came at the cost of poorer QoL. 
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1.4 LUNG VOLUME REDUCTION 
 
1.4.1 PHYSIOLOGICAL AND ANATOMICAL CONSIDERATIONS 
1.4.1.1 Dynamic hyperinflation 
The hyperinflation seen in COPD/emphysema is exacerbated during exercise when 
ventilatory requirements are increased. Airflow obstruction and prolonged 
expiratory time mean that expiration cannot be completed before the urge to 
inspire, with inhalation triggered before FRC is reached. This leads to ‘‘stacking’’ of 
breaths and a gradual hyperinflation of the lungs, known as dynamic hyperinflation 
(DHI). Work of breathing is subsequently increased via two mechanisms. Firstly, the 
rightwards shift along the compliance curve requires a larger change in pressure (and 
hence effort) to generate a comparable tidal volume (VT). Secondly, the creation of 
an artificially high end-expiratory lung volume, or dynamic FRC, means that residual 
elastic recoil forces must be overcome before negative intrathoracic pressures are 
generated and inspiratory airflow can begin: intrinsic PEEP (PEEPi). These 
mechanisms are illustrated in figure 1.3. Capacity is further reduced because the 
inspiratory muscles are at a mechanical disadvantage owing to changes in the length-
tension relationship (Gauthier 1994). 
 
This dynamic impairment of ventilation can be reduced by bronchodilator therapy 
(Belman 1996; Tantucci 1998; Jorquera 2003; O’Donnell 2004), pulmonary 
rehabilitation (Porszasz 2005), surgical lung volume reduction procedures (O’Donnell 
1996; Martinez 1997), and work from our group has previously shown some success 
in this regard with endobronchial valve treatment (Hopkinson 2005). 
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Figure 1.3: Compliance curve of the lung 
 
 
1.4.1.2 Collateral ventilation 
First reported by Van Allen et al (Van Allen 1931), collateral ventilation is the 
ventilation of alveolar structures through passages or channels that bypass the 
normal airways, and occurs through interalveolar (pores of Kohn, who originally 
thought them pathological (Kohn 1893)), bronchioloalveolar (channels of Lambert 
(Lambert 1955)), and interbronchiolar (channels of Martin (Andersen 1980)) 
connections. These high-resistance channels are clinically unimportant and may be 
closed altogether in health (Bastacky 1992), but as airflow obstruction increases in 
the emphysematous lung, airways resistance approaches collateral resistance and 
collateral airflow increases (Terry 1978). This recruitment of collateral channels is 
assisted by hyperinflation, because there is an inverse relationship between 
resistance in collateral channels and lung volume (Cormier 1993). Analysis has also 
suggested that less than half of normal lungs have complete upper/lower lobe 
fissures, and that this number is diminished further in emphysematous lungs, with 
True FRC 
Dynamic FRC 
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substantial flow being demonstrated across the incomplete fissures (Hogg 1969).  
Parenchymal destruction in emphysema is also likely to create new, pathological, 
channels between lung units. One study of explanted lungs from patients with 
smoking related severe emphysema demonstrated that 66% of lungs had significant 
collateral interlobar ventilation (Higuchi 2006), which could account for the high 
non-response rate in endobronchial valve trials.  Interestingly, there was no 
relationship between the CT extent of fissuring and the presence of collateral 
ventilation in these ex-vivo lungs. 
 
With the advent of one-way endobronchial valve treatments for upper-lobe 
predominant heterogeneous emphysema, there has been a renewed interest in 
measurements of collateral ventilation. Results from the Valves for Emphysema 
palliatioN Trial (VENT, Sciurba 2010) showed that those with incomplete fissures on 
lung CT did not derive the same degree of benefit from valve placement as those 
with complete fissures, the inference being that collateral channels continued to 
aerate occluded segments thereby preventing volume loss. 
 
1.4.2 SURGERY  
The only cure for patients with COPD/emphysema is lung transplantation.  However, 
with strict eligibility criteria and an inadequate supply of donor organs, this is not a 
realistic option for many.  For those lucky enough to be called up for transplant, 90 
day mortality is 13%, with 22% dead at 1 year (Trulock 2007).  Owing to the shortage 
of donor organs, COPD patients tended to be offered a single lung transplant (SLT).  
More recently, the trend has been for double lung transplant (DLT) in COPD, with 
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five-year survival reported to be 66.7% for DLT recipients versus 44.9% for SLT 
recipients (Cassivi 2002).  Analysis of 20 years of lung transplants on the OPTN/UNOS 
database also reported improved five- and ten-year graft survival in DLT (Cai 2007).  
Furthermore, although a SLT may become available before a DLT, statistical 
modelling suggests that there is no benefit to patients from taking the SLT now 
rather than waiting for a DLT to become available (Wang 2011). 
 
Surgical procedures for the palliation of symptoms in emphysema have been 
attempted over many years, with widely varying procedures and, with the exception 
of bullectomy and LVRS, a universally disappointing (or disastrous) outcome. 
Artificial pneumoperitoneum, phrenic nerve dissection, thoracoplasty, 
costochondrectomy, and procedures to improve pulmonary blood flow were all cited 
as possible treatments, but were soon abandoned. 
 
LVRS was first reported in 1957 (Brantigan 1957), but not widely adopted owing to 
the high mortality rate of 18% and lack of objective measures of functional 
improvement.  Although a series published by Delarue and colleagues in 1977 
resulted in a 21% post-operative mortality, they did demonstrate functional benefits 
in 45% of survivors, suggesting that LVRS had something to offer the carefully 
selected patient (Delarue 1977). Even so, LVRS was not often performed until Joel 
Cooper perfected the technique of stapled resection and reported his case series of 
20 patients (Cooper 1995). All had bilateral volume reduction via median 
sternotomy, and at a mean of 6.4 months follow-up a mean increase in FEV1 of 82% 
was seen. Improvements in exercise capacity and QoL were also seen, and crucially 
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there were no deaths. A larger series of 150 consecutive patients published the 
following year demonstrated sustained benefits to 2 years and a low over all 
mortality of 4% at 90 days (Cooper 1996). 
 
With such encouraging results, there was widespread and enthusiastic uptake of 
LVRS, with several published series quoting mortality rates of up to 10% (Bingisser 
1996; Daniel 1996; Wisser 1997). However, the Centre for Medicare and Medicaid 
Services (CMS) published data in 1998 showing mortality rates of 14.4% at 3 months 
and 23% at 12 months from claims submitted between October 1995 and January 
1996, together with a high rate of rehospitalisation, and subsequently stopped 
reimbursements for the procedure (Health Care Financing Administration 1998).  
This led to the development of the National Emphysema Treatment Trial (NETT), a 
multi-centre, prospective, randomised trial designed to provide definitive evidence 
of benefit from LVRS, as well as the publication of several other controlled trials. 
 
1.4.2.1 Controlled LVRS trials 
The first randomised controlled trial of lung volume reduction surgery was published 
in 2000, and subsequently became known as the Brompton Trial (Geddes 2000).  
Potentially eligible patients were given intensive medical treatment and completed a 
smoking-cessation program and a six-week outpatient rehabilitation program before 
randomisation.  Forty eight patients were randomised in a 1:1 manner to receive 
either surgery or continued medical treatment.  At 6 months there was no significant 
difference in the rates of death between the 2 groups, but there were statistically 
significant improvements in the FEV1 (p=0.02) and shuttle walking distance (p=0.02) 
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in the surgical group over the medical group.  There was not universal benefit in the 
surgical arm, however, with 5 of the 19 surviving patients deriving no benefit from 
the treatment.  Medium-term follow-up (median 25 months) demonstrated that the 
immediate increase in FEV1 was not sustained, although beneficial changes in the 
FVC, RV, and RV/TLC ratio remained. There was also a gradual and sustained increase 
in transfer factor accompanied by improved oxygen saturations (Lim 2006). 
 
The Canadian Lung Volume Reduction (CLVR) study and the Overholt-Blue Cross 
Emphysema Surgery Trial (OBEST) were 2 similar, independently conceived and 
conducted, multicenter, randomized clinical trials of LVRS, but there results were 
published as a single (meta-) analysis (Miller 2005). Patients were required to have 
severe emphysema (FEV1 15-40% predicted), hyperinflation (TLC >120% predicted), 
and measurable dyspnoea. Optimal medical therapy included pulmonary 
rehabilitation in both arms of both studies. The CLVR study randomized 58 patients 
and the OBEST randomized 35 patients for a total of 93 patients. Of these, 54 
patients were randomized to undergo surgery, and 39 patients were randomized to 
receive medical treatment. Six month results were similar to the Brompton Trial, 
with no difference between arms in mortality, and significant beneficial changes in 
FEV1 (p=0.017), RV (p <0.001), TLC (p <0.001), and 6MWD (p=0.019). 
 
1.4.2.2 The National Emphysema Treatment Trial 
The NETT was funded by the CMS and the National Heart, Lung, and Blood Institute 
(NHLBI). The detailed trial design has been published elsewhere (National 
Emphysema Treatment Trial Research Group 1999), and is summarised here.  
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Seventeen designated centres in the United States of America enrolled patients into 
a prospective, randomised trial comparing best medical care with best medical care 
plus lung volume reduction surgery.  It aimed to answer 2 fundamental questions: 
 
 Could a sustained survival benefit be demonstrated? 
 Would LVRS improve measures of lung function, exercise capacity, and QoL? 
 
Entry criteria and outcome measures are shown in table 1.2.  Follow-up was at 6, 12, 
and 24 months. 3777 patients were evaluated for participation, and 1218 were 
randomised.  Subjects progressed as follows:  
  
Deemed eligible 
 
6-10 weeks of PR 
 
Randomisation 
                                
Best medical care (608 subjects) Best medical care + LVRS (610 subjects) 
       
8-9 weeks of further intense PR                  Bilateral stapled LVRS (20-35% each lung) 
         
Long-term maintenance PR              Resume PR as soon as possible 
 
Detailed results of the trial were published in 2003 (Fishman 2003).  Results out to 24 
months showed a higher early mortality in the surgical arm than the medical arm 
(2.2% vs 0.2% at 30 days; 5.1% vs 1.5% at 90 days), but no overall difference in 
mortality at 24 months. A greater proportion of patients in the surgical arm had an 
increase in exercise capacity at each time point (24% vs 4% at 6 months; 22% vs 5% 
at 12 months; 15% vs 3% at 24 months), as defined by an increase in maximum cycle 
ergometry workload of at least 10 watts.  There was also a greater chance of 
improvements in FEV1, 6 minute walking distance (6MWD), health related QoL 
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(improvement defined as an 8 point or greater fall in the SGRQ), and dyspnoea 
scores in the surgical arm.  Subsequent analysis also showed a reduction in 
exacerbation frequency, and an increase in time to first exacerbation (Washko 2008). 
 
As part of the trial, a safety monitoring board evaluated the data every 3 months, 
and it became clear that a high-risk group could be identified (National Emphysema 
Treatment Trial Research Group 2001).  These were patients with an FEV1 below 20% 
predicted and either homogeneous disease on CT or a total lung carbon monoxide 
uptake (TLCO) below 20% predicted.  Enrolment of patients in these categories was 
stopped in May 2001, by which time 140 had been recruited, 70 in each arm of the 
trial.  Of these, all had an FEV1 <20% predicted, 94% had homogeneous disease, and 
87% had a TLCO <20% predicted. Forty one patients met all 3 criteria.  Mortality in 
those who underwent surgery was 0.43 per person year, compared to 0.11 per 
person year in those treated medically.  Thirty day mortality was 16% and 0% 
respectively.  Poor outcome persisted to 2 years (Fishman 2003). 
 
Short-term safety analysis also identified that the only 2 statistically significant 
independent pre-operative factors that predicted mortality in the surgical arm were 
the presence or absence of upper lobe predominant disease on CT scanning, and 
baseline exercise tolerance (cut-off for low exercise capacity that determined risk of 
death was the 40th centile, 25 Watts in females and 45 Watts in males). When 
divided into 4 patient groups on the basis of these 2 parameters at 24 months, a 
clear stratification of benefit between groups could be seen, summarised in table 1.3 
and figure 1.4 (Fishman 2003). 
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Subject monitoring continued beyond the 24 month trial period, with 70% of 
survivors participating in extended follow-up.  Overall, a significant survival 
advantage in the LVRS group emerged at 5 years (0.11 deaths per patient year in the 
surgical arm vs 0.13 deaths per patient year in the medical arm; 283 vs 324 deaths 
respectively), with improvements in exercise capacity out to 3 years, and QoL out to 
5 years (Naunheim 2006).  High risk patients continued to demonstrate excessive 
mortality without functional benefit, whilst those in the upper lobe predominant, 
low exercise capacity group were consistently shown to benefit the most from 
surgery.  This improvement comes at considerable financial cost, however, with an 
estimated $190,000 per quality adjusted life year (QALY) in all-comers, and $98,000 
in those with upper lobe disease and low exercise tolerance (Ramsey 2008). 
 
Table 1.2: Entry criteria and outcome measures for the NETT 
Entry Criteria 
Bilateral emphysema 
Severe airflow obstruction 
Hyperinflation on chest x-ray 
Ability to do pulmonary rehabilitation 
Primary Outcome Measures 
Survival 
Maximal exercise capacity by cycle ergometry 
Secondary Outcome Measures 
Quality of life 
Cost effectiveness 
6 minute walking distance 
Lung function measures 
Oxygen usage 
Gas exchange 
Psychomotor function 
Cardiovascular measures 
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Table 1.3: NETT outcomes stratified by disease distribution and baseline exercise capacity 
 
Upper lobe 
predominant disease 
  
Non-upper lobe 
predominant disease 
Low baseline 
exercise capacity 
Survival                    
Quality of life          
Exercise capacity    
Survival                    
Quality of life          
Exercise capacity    
High baseline 
exercise capacity 
Survival                    
Quality of life          
Exercise capacity    
Survival                    
Quality of life          
Exercise capacity    
 
 
Figure 1.4: NETT survival curves stratified by risk, disease distribution, and exercise capacity 
 
 54 
1.4.3 BRONCHOSCOPIC LUNG VOLUME REDUCTION 
1.4.3.1 Endobronchial valves 
The NETT demonstrated that significant benefits in survival, exercise capacity, and 
QoL could be achieved in carefully selected patient groups.  The high short-term 
mortality, significant morbidity, and short-term costs have probably limited the 
widespread use of LVRS, however, along with the desire to find treatments for those 
deemed high risk, have led to the search for safer, semi-invasive, methods for 
achieving lung volume reduction. The most widely studied of such methods is the 
use of bronchoscopically deployed one-way valves, designed to occlude the airways 
of the most emphysematous areas of lung, preventing ventilation of those areas 
whilst still allowing expiratory airflow to occur with resultant atelectasis (see figure 
1.5).  Initial experience required general anaesthesia and an overnight stay in 
hospital, but insertion under conscious sedation on a day case basis is now favoured 
at our centre.  One other significant advantage of such devices over LVRS is the 
reversibility of the procedure, with valves removable via a flexible bronchoscope. 
Two commercially available valve systems exist, and a brief description of each 
follows. 
 
The earliest valves for human use were developed by Emphasys Medical (Redwood 
City, CA).  Similar in shape to a spigot, they consist of a framework of nitinol (a super-
elastic memory shape alloy) surrounding a silicone duck-billed valve in a stainless 
steel cylinder (figure 1.6a).  Air and secretions are able to pass through the valve 
from distal to proximal, but the valve acts as a plug to prevent movement of air in 
the opposite direction.  A more elegant second generation valve (the Zephyr valve) 
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was subsequently developed in order to reduce granulation tissue formation, with a 
framework of self-expanding nitinol and a latex one-way valve (figure 1.6b).  This is 
available in 2 sizes, a 4.0mm valve for airways of 4-7mm diameter, and a 5.5mm 
valve for airways from 5.5-8mm diameter. 
 
Figure 1.5: Radiological evidence of volume loss after valve insertion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following the completion of the VENT study, Emphasys Medical applied for a license 
from the FDA, but the scope of that application was too broad, they were turned 
down, and subsequently went into administration.  They were bought by a recently 
established medical device company, Pulmonx Corporation (Redwood City, CA), who 
have made the valves commercially available once more.  
Axial and sagittal scans of the thorax before (left) and after (right) 
endobronchial valve placement in the left upper lobe.  There is clear volume 
loss in the left upper lobe and re-expansion of the compressed lower lobe. 
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The second commercially available valve has been developed by Spiration 
Incorporated (now acquired by Olympus Medical). The Intrabronchial Valve© (IBV) 
consists of a nitinol frame covered by a latex membrane as shown in figure 1.6c. This 
‘umbrella valve’ has 5 distal anchors which penetrate approximately 1mm into the 
airway mucosa, and 6 proximal struts. These struts are flexible, conform to the shape 
of the airway during both inhalation and exhalation, and hold the latex membrane 
against the mucosa to prevent inspiratory airflow whilst allowing air and secretions 
to pass from distal to proximal. 5mm, 6mm, and 7mm valves are available, and are 
deployed via a 2.8mm or greater diameter working channel of a standard 
bronchoscope. 
 
Figure 1.6: Endobronchial valves 
                  
a) 1
st
 generation Emphasys valve       b) Zephyr valve                c) Spiration Intrabronchial Valve 
 
1.4.3.1.1 Early trials with Emphasys valves 
Early human studies confirmed the feasibility and safety of endobronchial valve 
placement, with improvements in lung function parameters, QoL, and exercise 
capacity (Toma 2003; Snell 2003; Yim 2004). On the back of these results, Emphasys 
Medical designed the VENT, intending it to be a pivotal prospective study, and this is 
discussed in more detail below.  
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Prior to the publication of the VENT (see below), the largest series reported in the 
literature was a retrospective analysis collating results using Emphasys valves from 
several centres and including 98 patients (Wan 2006). Treatment was not 
standardised, with both unilateral and bilateral treatments, some with complete 
lobar occlusion and some with only segmental occlusions. Overall, mean changes 
observed were as follows: RV decreased by 4.9% (p=0.025), FEV1 increased by 10.7% 
(p=0.007), FVC increased by 9.0% (p=0.024), and 6MWD increased by 23.0% 
(p=0.001). Those in whom lobar occlusion was attempted (70.4% of subjects) 
demonstrated the greatest response to treatment, and interestingly those treated 
unilaterally (65.3%) had greater improvements in measured parameters than those 
treated bilaterally (34.7%). 
 
Long-term survival data has recently been published (Hopkinson 2011), showing a 
survival benefit in patients in whom lobar collapse was achieved.  0/5 of those with 
atelectasis were dead at 6 years against 8/14 of those without atelectasis ( 2 
p=0.026). 
 
1.4.3.1.2 The Endobronchial Valves for Emphysema PalliatioN Trial (VENT) 
This trial was designed as a multi-centre, prospective, randomised, double blind, 
sham controlled trial in severe heterogeneous emphysema (FEV1 <45% predicted, 
TLC >100% predicted, RV >150% predicted).  It was set up to enrol 270 patients 
randomised 2:1 procedure to sham, with the aim of assessing the safety and efficacy 
of unilateral complete lobar occlusion. A co-primary endpoint of mean percent 
change in FEV1 and 6MWD at 180 days was used. Secondary end-points included 
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changes in health related QoL, dyspnoea scores, cycle ergometry, and total oxygen 
use per day (Strange 2007). 
 
Full results from the United States arm of the trial were finally published in 2010 
(Sciurba 2010), 3 years after they were first presented at the ERS 17th Annual 
Congress. Data on 171 European subjects are yet to be published.  Three hundred 
and twenty one patients were enrolled at centres in the United States, and 
randomised to endobronchial valve treatment (220 subjects; primary endpoint data 
on 179 subjects for FEV1 and 178 subjects for 6MWD) or standard medical care (101 
subjects; primary endpoint data on 75 subjects for FEV1 and 73 subjects for 6MWD).  
Statistically significant improvements in the treatment group were seen at 6 months 
when compared to changes in the control group with respect to both primary end 
points – FEV1 (p=0.005) and 6MWD (p=0.04).  There were significant improvements 
in the secondary endpoints of change in SGRQ and modified MRC dyspnoea scores. 
The change in maximum cycle ergometry workload just failed to reach significance, 
with a p value of 0.05. 
 
However, critics have argued that, whilst statistically significant, changes were 
modest and may not be clinically significant.  One example of this is the increase in 
6MWD in the treatment group, which at 20 metres (+9.3 metres in the treatment 
arm, -10.7 metres in the control arm) does not approach the 54 metres required for 
a clinically important change.  It is alleged that not all patients had their medical 
therapy optimised prior to randomisation, and it is unclear as to whether those in 
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whom therapy was optimised derived any additional benefit from valve insertion 
(Anzueto 2010). 
 
Subgroup analysis revealed subject characteristics that were associated with better 
outcomes.  A greater degree of heterogeneity on CT scanning between the upper 
and lower lobes was associated with greater positive changes in both FEV1 and 
6MWD.  The heterogeneity score was derived from the difference in the percentage 
of pixels below -910HU between the target lobe and the adjacent ipsilateral non-
target lobe.  Significant changes were seen above a heterogeneity score of 25% for 
both FEV1 (p=0.003) and 6MWD (p=0.009).  In subjects with complete lobar occlusion 
and anatomically isolated upper lobes (as determined by CT analysis of fissural 
integrity), FEV1 was increased by 16.2% relative to the control arm (p<0.001), a 
benefit that persisted out to 1 year of follow-up (17.9%; p<0.001).  Interestingly, 
however, this was not associated with a significant change in the 6MWD at either 
time point.   
 
The changes seen in these subgroups do seem to indicate a clinically as well as 
statistically meaningful change in the FEV1 with correct patient selection, but there is 
now a need for a trial specifically designed to look at this group of patients. 
 
1.4.3.1.3 Spiration valve trials 
A first-in-humans trial of 30 patients with upper lobe predominant heterogeneous 
emphysema treated with bilateral upper lobe valves demonstrated a clinically 
significant improvement - >4 point reduction (although >8 points was taken to be 
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significant in the NETT) - in the SGRQ in greater than 50% of participants, but no 
significant changes in any measured lung function parameters or exercise tolerance 
(Wood 2007).  The study was not blinded, so QoL changes need to be treated with 
caution. The study was expanded into an international multicentre pilot study, with a 
total recruitment of 98 patients.  There were no episodes of valve migration or 
erosion in 65 subjects re-scoped at 1 month, and no expectoration for the duration 
of follow-up (12 months). This again showed significant improvements in QoL (55.7% 
of subjects), but no changes in overall lung volumes (Springmeyer 2009).  When 
analysed with quantitative CT, there were significant changes in individual lobar 
volumes, with a mean reduction in upper lobe volume of 335mls, and an increase in 
lower lobe volumes of 374mls (Coxson 2008).  As the study was open label, changes 
in QoL must be treated with caution, although interestingly the degree of volume 
change correlated well with changes in the SGRQ (p <0.01 for non-upper lobe 
volume increase and SGRQ improvement).  
 
Atelectasis was documented in 9 subjects (9.2%) at 2 weeks, and 5 of these 
experienced a pneumothorax (1 fatal), and a significant association between 
atelectasis and pneumothorax was seen.  Three pneumothoraces occurred in those 
without atelectasis (89 subjects, 90.8%). One third of 18 patients who also had the 
lingula segments treated experienced a pneumothorax, leading to the 
discontinuation of lingular treatments after subject 65.  
 
The authors postulated that interlobar volume shift was the main mechanism for 
improvements in QoL seen in the pilot study, although 6-month analysis of 6 patients 
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who experienced atelectasis showed an additional clinically meaningful 
improvement in FEV1 (mean 140mls).  
 
Based on the pilot data, multicentre blinded, randomised, sham controlled trials 
were conducted in both the United States of America and Europe, and are discussed 
in chapter 3.  Taking into account the high rate of pneumothorax in those with 
atelectasis (55.6%), the protocols dictate bilateral incomplete occlusions of the 
upper lobes in order to minimise complications whilst achieving the maximum 
amount of interlobar volume shift. 
 
1.4.3.1.4 Other experimental uses for endobronchial valves 
A number of other novel uses for endobronchial valve technology have been 
reported in the literature.  Predominant among these is their use as a non-surgical 
treatment of persistent air leak in patients with pneumothoraces (Snell 2005; 
Ferguson 2006; Toma 2007; Abu-Hijeh 2010; Schweigert 2010).  The largest 
(retrospective) series to date collected data on 40 patients with a variety of 
underlying causes for their pneumothorax, the largest group being secondary 
spontaneous pneumothorax (n=21), with a median pre-valve air leak of 20 days 
duration (mean 119 days).  There was a complete resolution of air leak in 19 of the 
patients, with a reduction in 18 others.  The median and mean times to chest drain 
removal were 7.5 and 21 days respectively in those patients for whom complete data 
was available (n=28), suggesting that one-way valves represent a useful additional 
treatment option in these patients.  
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Two reports exist of their use in single lung transplant patients to treat native lung 
hyperinflation, both in the immediate post-operative period (Crespo 2007), and 
several years distant to the transplant (Pato 2010).  This thesis reports the first case 
series of the use of endobronchial valves in native lung hyperinflation. 
 
Sexton and colleagues have published an account of rapid recovery from gross type 2 
respiratory failure in a patient invasively ventilated for 4 days after the deployment 
of 2 endobronchial valves into an area of bullous disease in the left lower lobe, with 
extubation 8 hours post-treatment (Sexton 2010).  The patient continued to 
demonstrate incremental improvements in FEV1 up to 6 months following discharge 
from hospital. 
 
1.4.3.2 ‘Biologic’ lung volume reduction  
A fibrinogen biopharmaceutical suspension and thrombin solution that polymerize in 
situ to form a hydrogel (so called BioLVR) has been developed for deployment via a 
standard bronchoscope by Aeris Therapeutics Inc. (Woburn, MA).  It is intended to 
reduce lung volumes by tissue remodelling, and phase 2 results in heterogeneous 
upper-lobe emphysema (Criner 2009) and advanced homogeneous emphysema 
(Refaely 2010) have been encouraging.  Two treatment regimens were followed, 
with a high dose (HD) and a low dose (LD) group.   In heterogeneous subjects there 
was a reduction in the RV/TLC ratio at 12 weeks (LD mean -6.4%, p=0.002; HD mean -
5.5%, p=0.028).  Significant improvements in spirometric values were also seen at 6 
months, with mean changes of 15.6% (HD) and 6.7% (LD) in FEV1, and 9.1% (HD) in 
FVC. There was a non-significant increase in the FVC in the LD group.  Homogeneous 
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subjects also exhibited a better response to HD than LD therapy, with a significant 
reduction in gas trapping at 3 months in HD subjects. 
 
Refinements have led to the development of the AeriSeal system for lung volume 
reduction (LVR), a solution containing aminated polyvinyl alcohol and glutaraldehyde 
that creates a hydrogel foam when delivered to the distal airways.  As the air 
contained within the hydrogel foam diffuses out, it collapses leading to 
approximation of the tissues to which the surface of the hydrogel foam has attached. 
An open-label multi-centre exploratory clinical study is currently on-going in Europe, 
designed to evaluate the effects of different dosing regimens, number of sites 
treated, and distribution of emphysema on safety and efficacy.  The primary efficacy 
end-point is the change in RV/TLC at 12 weeks, with secondary outcomes being a 
number of other pulmonary function, exercise capacity, and QoL measures. 
 
The Medicines and Healthcare Products Regulatory Agency (MHRA) has objected to 
the use of the AeriSeal sysyem in the United Kingdom on the grounds of patient 
safety, owing to the presence of potentially toxic gluteraldehyde in the gel, and 2 
deaths in preliminary studies. 
 
1.5 SUMMARY 
 
The burden of disease attributable to emphysema is significant and growing, and is a 
leading cause of disability in middle and late life. There has traditionally been a 
rather nihilistic attitude toward emphysema and COPD, but with recent advances in 
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the understanding of aetiological, pathophysiological, and prognostic mechanisms, 
and the increase in treatment options, this approach is no longer appropriate. This 
thesis brings together a number of trials of new indications or techniques in 
bronchoscopic lung volume reduction, primarily looking at the benefits in patients 
with severe disease (GOLD stage III and IV) who either have been turned down for or 
do not want lung volume reduction surgery. 
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CHAPTER  2::   PROCEDURAL  METHODS  
  
2.1 ETHICAL APPROVAL 
 
All studies have received a favourable opinion from the Brompton, Harefield & NHLI 
Research Ethics Committee.  All enrolled subjects gave written informed consent to 
participate. 
 
2.2 EXHALED CARBON MONOXIDE 
 
A smoking history was obtained from all patients in each trial, and current smokers 
were excluded.  Smoking cessation was confirmed by measurements of exhaled 
breath carbon monoxide (CO) using a hand held device (Micro Medical Limited).   
 
The device is calibrated every 6 months to ensure accuracy. Table 2.1 illustrates the 
possible outcomes of exhaled breath CO monitoring.  A urinary cotinine level in the 
normal range for non-smokers supersedes the CO measurement in those with a CO 
value of 7-10 parts per million (ppm). 
 
Table 2.1: Interpretation of exhaled CO values 
Value (ppm) Suggested interpretation Action 
0-6 Non-smoker Include 
7-10 Light smoker Measure urinary cotinine 
11-20 Smoker Exclude 
>20 Heavy smoker Exclude 
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2.3 SYMPTOM AND HEALTH RELATED QUESTIONNAIRES 
 
2.3.1 ST. GEORGE’S RESPIRATORY QUESTIONNAIRE 
The St. George’s Respiratory Questionnaire (Jones 1991) is a validated self-
completed questionnaire for assessing disease-specific QoL in patients with 
respiratory disease.  Patients complete the questionnaire themselves, and whilst 
investigators are allowed to clarify the meaning of questions, there is no external 
help given with answers.  Individual questionnaires are scored from 0 to 100, with a 
higher score indicating a worse QoL.  Three component scores are generated, 
measuring symptoms, activity, and disease impact, with a total score calculated from 
these.  A reduction in the total score indicates an improvement in QoL, and an 
overall 4 point change has been identified as being the minimal clinically important 
change (Jones 2002).  
 
 It has been validated in COPD, and scores correlate with MRC dyspnoea score, 
wheeze, exercise capacity (Jones 1992), FEV1 (Ferrer 1997) and PaO2 (Okubadejo 
1996).  Higher scores are also associated with increased mortality following acute 
exacerbations of COPD (Almagro 2002), in those with chronic respiratory failure 
(Carone 2001), and in stable disease independent of lung function (Domingo-Salvany 
2002). 
 
Subjects were asked to complete a questionnaire at each visit to assess longitudinal 
changes in QoL over the course of each study. 
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2.3.2 MRC DYSPNOEA SCORE 
The MRC dyspnoea score is a simple five point (1-5) scoring system for the subjective 
assessment of breathlessness. In those with MRC grades 3-5 breathlessness, there is 
a significant association between MRC grade and measures of exercise performance, 
QoL, and mood, but not air flow obstruction as measured by the FEV1 (Bestall 1999).  
A modified MRC scale (mMRC) with gradings from 0-4 as in table 2.2 was used for 
studies reported in this thesis. 
 
Table 2.2: mMRC dyspnoea scale 
mMRC Description 
0 I only get breathless with strenuous activity 
1 I get breathless when hurrying on the level or up a slight hill 
2 I walk slower than other people of the same age on the level because of 
breathlessness or have to stop for breath when walking at my own pace on the 
level 
3 I stop for breath after walking 100 metres or after a few minutes on the level 
4 I am too breathless to leave the house 
 
2.4 ARTERIAL BLOOD GASES 
 
Arterial blood gas (ABG) analysis was performed at each study visit.  A 1ml sample of 
arterial blood was taken from the radial artery and analysed for pH, and for partial 
pressures of O2 and CO2 (Rapidlab 348, Bayer, Germany).  The blood gas analyser 
performs an automatic 2-point calibration every 30 minutes, and a manual 
calibration using tonometered bovine haemoglobin solution is performed if 
automatic calibration results are out of range. 
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2.5 EXERCISE TESTING 
 
Tests used for studies in this thesis were the 6 minute walking test (6MWT), and 
cycle ergometer testing with measures of ventilatory function and oxygen uptake. 
 
2.5.1 BORG SCORES 
Borg developed 2 scoring systems of use in exercise testing, a rating of perceived 
exertion (RPE) from 6 to 20 (Borg 1970) and a category scale with ratio properties 
from 0 to 10 for breathlessness (Borg 1982).  Both are reliable and reproducible 
(Silverman 1988; Muza 1990; Mahler 1991). When asked, subjects pointed to charts 
to indicate their level of symptoms (figures 2.1 and 2.2).  Scores were obtained 
before and immediately after all exercise tests. 
 
Figure 2.1: Borg’s scale of breathlessness      Figure 2.2: Borg’s rating of perceived exertion 
Figure 2.2: Borg’s rating of perceived exertion 
0 No breathlessness at all  6 No exertion at all 
0.5 Just noticeable 7 Extremely light 
1 Very slight 8  
2 Slight 9 Very light 
3 Moderate 10  
4 Somewhat severe 11 Light 
5 Severe 12  
6  13 Somewhat hard 
7 Very severe 14  
8  15 Hard 
9 Very very severe 16  
10 Maximal 17 Very hard 
 18  
19 Extremely hard 
20 Maximum exertion 
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2.5.2 CYCLE ERGOMETRY 
Although a less typical activity, cycle ergometry has several advantages over exercise 
tests performed using a treadmill in those with COPD.  It is easier to calculate the 
true workload, is potentially safer (ATS/ACCP 2003), there is less exercise induced 
hypoxaemia (Christensen 2004; Hsia 2009), and the patient is able to fix the upper 
limbs in order to enable the use of accessory muscles of respiration. 
 
Subjects exercised on a magnetically braked cycle ergometer (Jaeger Ergoline 800), 
breathing through a mouthpiece and wearing a noseclip. Oxygen saturations and 12-
lead ECG were continuously monitored throughout all tests.  The metabolic analysis 
system used (Oxycon device, Jaeger Systems, Germany) measures respiratory 
parameters on a breath by breath basis, allowing instantaneous and continuous 
measurements of respiratory samples. Ventilation is measured using a turbine unit 
based on an electronic sensor detecting the rotation of a vane inside the turbine 
unit.  The number of pulses recorded per unit time is proportional to flow. Oxygen 
uptake is measured using a paramagnetic analyser.  Oxygen is unique among 
respiratory gases in being paramagnetic, and changes in magnetic field which occur 
when different concentrations of oxygen are passed through the analyser can be 
used to assess the O2 content of inhaled and exhaled air.  Carbon dioxide output is 
measured using an infra red CO2 analyser.  The system was calibrated for volume and 
gas analysis prior to each test, and adjustments were made for humidity and room 
temperature. Biological controls are exercised for 10 minutes on a weekly basis.   
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Accurate measurements of the amount of oxygen consumed during exercise (VO2) 
requires measurements of arterial (CaO2) and central venous (CvO2) blood oxygen 
content and cardiac output (Q) using the Fick principle (VO2=Q(CaO2-CvO2).  
However, this is impractical for most purposes, and a good estimate of VO2 can be 
derived using inspired and expired air gas volumes as such: 
 
VO2 = (VI x FIO2) – (VE x FEO2) 
 
VI = Volume of Inspired Air FIO2 = Percent Oxygen in Inspired Air 
VE = Volume of Expired Air  FEO2 = Percent Oxygen in Expired Air 
 
VO2 measurements are usually displayed in litres/minute, but can be corrected for 
body mass to give a value in terms of mls/kg/min. 
 
By varying the resistance, workload remained constant independent of the cadence, 
and subjects were asked to maintain a cadence of 60-70 revolutions a minute.  A 
digital cadence meter was visible to the patients throughout. During exercise, the 
data from every eight breaths were averaged (i.e. breaths 1-8, 2-9, 3-10 etc.) and the 
data recorded and printed.  Information averaged from the last 30 seconds of each 
minute during the test was also collected, and these values were used to determine 
patients’ maximum oxygen utilisation (VO2peak) and minute ventilation (VEmax).  
Borg scores of breathlessness and RPE were recorded before commencement of 
each test and at maximal exertion. 
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2.5.2.1 Incremental cycle 
Standardised incremental cycle ergometry was performed according to the protocol 
below.  Encouragement was given by me during this test to ensure that subjects gave 
their best performance, as results from the incremental cycle test were used to 
determine workloads on endurance cycle ergometry.  Results from the incremental 
test per se do not constitute study data. 
 
2 minutes rest (10 minutes rest for studies in chapter 5) 
↓ 
1 minute unloaded cycling 
↓ 
5W additional workload applied every minute 
↓ 
Patient cycles until exhaustion (Tlim) 
↓ 
Reason for cessation of exercise recorded 
 
2.5.2.2 Endurance cycle 
Endurance cycle ergometry was performed at a constant workload set to 75% of the 
maximum workload achieved for at least 30 seconds during the incremental cycle 
test.  Pre-exercise bronchodilator treatment was standardised (consisting of a 
patient’s usual medication). The protocol was as follows: 
 
2 minutes rest (10 minutes rest for studies in chapter 5) 
↓ 
1 minute unloaded cycling 
↓ 
Constant workload applied 
↓ 
Tlim calculated as time from when workload applied until exhaustion 
↓ 
Reason for cessation of exercise recorded 
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Where both incremental and endurance tests were performed on the same day, the 
second test was performed at least 1 hour after the first to allow adequate recovery. 
 
2.5.2.3 Dynamic hyperinflation and inspiratory capacity measurements 
DHI during exercise has been shown to impair exercise capacity in COPD (O’Donnell 
2001).  In contrast to healthy subjects, where end expiratory lung volumes (EELV) fall 
on exercise as tidal volume increases, subjects with COPD can experience a rise in 
EELV.  Airflow obstruction prevents completed expiration before the urge to inspire, 
which, together with some loss of breathing control, results in a gradual increase in 
gas trapping, and hence EELV.  Assessments were made of all patients at baseline 
and at 6 months post-procedure.  Measurements of lung volumes were taken with 
the patient sat on the cycle ergometer at rest and every minute during exercise.  
End-expiratory lung volumes were calculated by measuring the inspiratory capacity 
and subtracting this from the resting total lung capacity as measured by 
plethysmography before ergometry.  The degree of DHI in millilitres was determined 
as EELVmax – EELVrest.  Total lung capacity is known not to change on exercise, so 
repeated measures are not required (Stubbing 1980). 
 
2.5.3 THE 6 MINUTE WALKING TEST 
The 6 minute walking test is the most widely used test for assessing exercise capacity 
in COPD.  All tests were performed according to American Thoracic Society 
guidelines (ATS 2002). The patient is instructed to walk as far as they can in 6 
minutes along a 30 metre corridor, completing as many out-and-back laps as 
possible.  Subjects can stop as often as they like, and for as long as they like, but the 
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timer does not stop.  The distance walked at 6 minutes is then recorded.  Borg scores 
are obtained pre-test at rest and immediately post-test. Standardised instructions 
are given during the test, as encouragement can affect performance (Guyatt 1984). 
 
The minimum important difference in the distance walked in a 6MWT is usually 
taken to be 54 metres in clinical practice (Redelmeier 1997), although a more recent 
estimate suggests a much lower figure of 26 metres (Puhan 2011). However, COPD 
patients who walk a very short distance (often less than 200 metres) in their 6MWT 
may still gain a meaningful benefit from shorter improvement distances.  In such 
cases, it may be more reasonable to evaluate efficacy based on the percent change, 
and a change of 10% has been suggested as clinically important in COPD (Puhan 
2008). 
 
2.6 PULMONARY FUNCTION TESTING 
 
To ensure consistency and accuracy of results, all pulmonary function testing was 
performed by highly trained Specialist Clinical Physiologists at the Royal Brompton 
Hospital (Compact Master lab system, Jaeger, Germany) and not by me.  Reference 
values are those of the European Community for Steel and Coal (Quanjer 1993). 
 
2.6.1 DYNAMIC LUNG VOLUMES 
Spirometers are calibrated prior to any patient measurement using a 2 litre 
calibration syringe. Ambient temperature, humidity and barometric pressure are 
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measured and taken into account for correction of volume. A member of staff who 
has stable lung function performs a manoeuvre on the spirometer at least once a 
day, effectively acting as a biological control. 
 
With the patient sitting and wearing a nose clip, they are asked to place a 
mouthpiece in their mouth. They are then instructed to breathe in to TLC and exhale 
as hard and as fast as they possibly can until they reach RV. At this point they are 
instructed to inhale as hard and as fast as possible until they are back to TLC.  
 
2.6.2 BRONCHODILATOR REVERSIBILITY TESTING 
Bronchodilator reversibility is determined by spirometry before and at least 15 
minutes after 400mcg salbutamol administered via a volumatic spacer device. 
Reversibility has been defined for the purposes of chapters 5 and 6 as a rise in FEV1 
of 20% after the administration of salbutamol. 
 
2.6.3 STATIC LUNG VOLUMES 
Static lung volumes are measured via body plethysmography.  The plethysmograph 
 (‘body box’) works on the principle of Boyle’s law, which states that the volume of a 
given mass of gas is inversely proportional to its pressure at constant temperature. 
 
PV = K or P1V1 = P2V2. 
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Figure 2.3: Graphical representation of lung volumes 
 
 
Taken from free media repository at http://commons.wikimedia.org/wiki/File:Lungvolumes.svg 
 
Calibrations are automatically driven by the computer software associated with the 
equipment, is performed at least twice daily, and biological controls are put through 
the box on a daily basis.  
 
The Jaeger system calculates TLC by measuring the intrathoracic gas volume (ITGV; 
equivalent to FRC in figure 2.3) and the expiratory reserve volume (ERV). The ERV is 
subtracted from the ITGV to give the RV. An inspiratory vital capacity is then added 
to the RV to give the TLC. 
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2.6.4 GAS TRANSFER 
Gas transfer was measured via a single breath technique.  The gas analysers are 
calibrated a minimum of 4 times a day using a standard helium (He) calibration gas.  
The pneumotachograph is calibrated using a 2 litre syringe prior to testing each 
patient. A member of staff acts as a biological control on every piece of equipment 
every day. 
 
Using the inspiratory and expiratory concentrations, breath holding time, inspiratory 
volumes and ambient conditions, a calculation of the gas transfer (TLCO) is made. This 
measurement is performed as many times as necessary to ensure reproducible 
results.  The corrected TLCO (TLCOc) is calculated using the measured haemoglobin, 
and is corrected to haemoglobin concentrations of 14.6 g/dl for adult males and 
13.5g/dl for adult females.   
 
2.7 MUSCLE STUDIES 
 
2.7.1 RESPIRATORY MUSCLE STRENGTH TESTS 
All pressures were measured relative to atmospheric pressure.  A Bio-Tek hand held 
pressure meter was used to perform a 2-point calibration (0cmH2O and 
approximately negative 200cmH2O) of the recording equipment prior to each test. 
The calibration was performed using a 5ml syringe attached to a closed system 
linking the pressure transducer (Validyne MP45; Validyne, Northridge, CA) and the 
calibration meter.  All measurements were recorded using a computer running 
Labview software (National Instruments). 
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2.7.1.1 Sniff nasal pressure 
The sniff nasal pressure (SNIP) is a good non-invasive tool for assessing the 
contractile strength of the diaphragm (Koulouris 1989).  Subjects occlude one nostril 
with a plastic bung and are asked perform a short, sharp sniff. The nasal bung 
contains a central channel and is connected to a pressure transducer via a 
polyethylene catheter.  Several attempts are made with the bung in each nostril, 
until there is no further increase in the pressure generated with each attempt. 
 
2.7.1.2 Mouth pressures 
Mouth pressures are a non-invasive method for assessing global respiratory muscle 
strength.  Manoeuvres are performed at TLC (maximum expiratory pressure; MEP) or 
at RV (maximum inspiratory pressure; MIP).  Owing to hyperinflation and the effects 
of PEEPi, MIP measurements in patients with COPD may be under estimates of the 
true force generating capacity of the inspiratory muscles.  Any changes in lung 
volumes and compliance following bronchoscopic LVR are therefore expected to 
have an influence on MIP measurements. 
 
A hollow rigid tube with an occludable valve is attached to a pressure transducer, 
and held in the subject’s mouth with a rubber mouth piece (Wilson 1984).  Wearing 
a nose clip and forming a tight seal with the mouth around the mouth piece, the 
subject breathes in to TLC or out to RV prior to making a maximal respiratory effort 
against the closed valve.  A small hole is present in the rigid tube to allow a small air 
leak to occur during manoeuvres, preventing glottic closure on inspiration and buccal 
recruitment on expiration. 
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The maximum sustained pressure over 1 second is recorded, and subjects perform a 
minimum of 3 tests, or as many as are needed to reach a performance plateau.  
Adequate time for recovery (as determined by the subject) is given between efforts.  
 
2.7.2 QUADRICEPS FUNCTION 
2.7.2.1 Maximal voluntary contraction 
Volitional measurements of quadriceps maximum voluntary contraction (MVC) can 
be made with the patient lying back at 45 degrees on a specially designed couch.  
With the knees bent to 90 degrees over the end, the dominant leg is held at the 
ankle by an inextensible restraining strap. This in turn is connected to a linear strain 
gauge from which a signal is passed to an appropriate amplifier.  Calibration of the 
system was undertaken prior to testing in each subject using a weight suspended 
from the strain gauge. Subjects’ position was maintained consistent, as changes in 
posture influence the length–tension relationship of the muscle. Subjects performed 
5 sustained maximal isometric quadriceps contractions of 5–10-s duration, with a 
gap of approximately 30 seconds (or longer if requested by the subject) between 
each contraction. Values were recorded using using LabView 4 software (National 
Instruments, Austin, Texas), and the best effort taken to represent the MVC. 
 
2.7.2.2 Femoral nerve magnetic stimulation 
Quadriceps MVC relies on patient effort.  To overcome this, femoral nerve magnetic 
stimulation was used to gain an assessment of non-volitional quadriceps strength 
(twitch quadriceps strength (TwQ)), based on the technique of Polkey and co-
workers (Polkey 1996), using a 70mm figure-of eight coil powered by a Magstim 200 
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Stimulator.  Force was measured using the same equipment and subject positioning 
as for quadriceps MVC, except that the subject rested for 20 minutes prior to testing 
to depotentiate the quadriceps muscles. 
 
The coil head is positioned firmly high in the femoral triangle, just lateral to the 
femoral artery, and the best position is determined by measuring the force achieved 
with minor positional adjustments.  In order to ensure a supramaximal stimulus is 
delivered, tests at intensities less than 100% were delivered to establish that a 
maximum response had been obtained prior to formal testing. 
 
A protocol of 16 varying intensity stimuli ranging from 90% to 100% was 
administered in a random order unknown to the subject, at least 30 seconds apart, 
with the average of the best 5 responses at 100% intensity being recorded. 
 
2.8 CT SCANNING PROTOCOLS 
 
Computed tomography was the first radiographic technique for allowing detailed 
imaging of internal structures (Ambrose 1973; Hounsfield 1973), and current 
technology allows for three dimensional reconstructions to be visualised.  The 
Hounsfield Unit (HU), named after Sir Godfrey Newbold Hounsfield, Nobel Prize 
winner and one of the principal developers of CT technology, is the standard 
measure of tissue density used to distinguish structures on CT imaging, on a scale 
where water has a value of 0HU and air -1000HU. 
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Each trial involved cross-sectional imaging using high resolution CT (HRCT) scanning 
at baseline and at the primary endpoint data collection visit.  All scans were 
performed on a Seimens Sensation 64, a 32 detector scanner with a flying focal spot 
allowing identical performance to a 64 slice machine. The rapid rotation time (0.33 
seconds) means that breathing artefact is minimised and image quality exceptionally 
well preserved.  The scanning protocol and image reconstruction algorithms below 
were used for all trials in this thesis.   
 
 Volumetric spiral acquisition with contiguous slices (no gaps in the scan) 
 120 kVp and 90 mAs 
 Scan in craniocaudal direction at full suspended inspiration 
 Smallest field of view that includes both lungs 
 Image reconstruction algorithms: 
 High spatial frequency: Siemens – b50f medium 
 Low spatial frequency: Siemens – b30f medium smooth 
 
Image reconstructions did vary between trials in terms of slice reconstruction 
thickness.  In order to obtain the most high definition images of emphysema 
distribution and severity, overlapping 0.6mm slices every 0.5mm were used for work 
in chapters 3, 4, and 7.  Scans undertaken on patients in chapter 5, which was a 
retrospective analysis of clinical data, were determined by the usual clinical HRCT 
scanning protocol performed at the relevant hospital at the time of the scan.  
Chapter 6 used 1mm thick reconstructions.  This was the non-contrast thin section 
CT thorax protocol used in clinical practice at both sites involved in this trial.  All 
patients considered for the trial would have had a CT scan prior to consideration for 
the trial, and it was felt that there was little justification for additional radiation for 
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this small pilot study, as 0.6mm slices were likely to add little to the primary analysis. 
Chapter 8 used 6mm thick overlapping reconstructions every 3mm, as these 
provided optimum images for analysis by the lung density software used in that trial 
(see section 2.10).   
 
2.9 CT LUNG VOLUME ANALYSIS 
 
CT lung volume analysis was carried out using Myrian™ XP-Lung (Intrasense, Paris, 
France).  This software detects the lungs in CT volume scans by using automatic 
tissue detection algorithms.  The software then reconstructs an interactive three 
dimensional model of the chest and derives the volume of each lung.  A function 
allowing a modifiable, smoothed cutting surface to be identified can isolate areas of 
lung, meaning that individual lobes can be delineated by mapping the cutting surface 
to the interlobar fissure(s), and the software then calculates the volume of that lobe. 
 
Figure 2.4: CT lobar volume assessments using Myrian 
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The ability to view images in axial, sagittal, and coronal planes simultaneously allows 
very accurate fissure mapping, with good interobserver variability (see chapter 3). 
 
2.10 CT LUNG DENSITY ANALYSIS 
 
CT lung density analysis was carried out using Pulmo-CMS software (Medis Specials, 
Leiden, the Netherlands).  The software automatically detects the lungs in CT volume 
scans and analyses the density distribution of the lungs. Image densities are rescaled 
after calibrating for blood (using the descending aorta) and air outside the patient, 
and the lung fields are then automatically detected by the software, after the user 
has selected a tracheal seed point. The lung parenchyma is defined by excluding the 
septae, trachea and large vessels from the initial segmentation, resulting in a high 
degree of reproducibility.  
 
Figure 2.5: CT density mapping and graphical output of quantitative results using Pulmo-CMS 
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Quantitative densitometry was performed by calculating the Relative Area (RA) of 
pixel values below -950HU in 12 axial partitions of equal volume in each lung. The 
top and bottom partitions were excluded to prevent influence by partial volume 
effects, and the heterogeneity of each lung was then characterized by its RA slope, 
defined as the slope in the plot of RAs against partitions.   
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CHAPTER  3::   THE  EFFIICACY  OF  IINTRABRONCHIIAL  VALVES  
IIN  PATIIENTS  WIITH  NON--UPPER  LOBE  PREDOMII NANT  
EMPHYSEMA  
 
Based on the pilot studies discussed in chapter 1, this trial was designed to assess the 
potential benefits of intrabronchial valve treatment in patients with non-upper lobe 
heterogeneous emphysema.  To do this, a comparator group consisting of upper 
lobe predominant emphysema patients was also recruited.  The NETT showed that 
those with non-upper lobe predominant emphysema did not perform as well as 
those with upper-lobe predominant disease (Fishman 2003).  However, if the 
operative risk and subsequent morbidity is removed, as would be the case with 
intrabronchial valve treatment, these patients may derive some benefit.   
 
This was a consecutive case series.  Suitable subjects who gave informed consent 
were classified into one of two study arms based on disease pattern:  upper lobe 
predominant or non-upper lobe predominant.  Analysis evaluated the mean change 
from baseline to 6 months in a variety of endpoints. The trial design allowed for 
those with 1-antitrypsin deficiency to be enrolled, as this greatly increased the 
potential pool of lower lobe predominant patients, and there is some evidence in the 
literature of a benefit from LVRS in these patients (Donahue 2009). 
 
3.1 ENDPOINTS 
 
All endpoints assessed the difference between study arms in the changes in 
measured parameters from baseline to 6 months. 
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Primary Endpoint 
1. To estimate the difference between study arms (upper lobe predominant, non-
upper lobe predominant) in percent change in volume of the treated lobe(s) by 
CT scan 
 
Secondary Endpoints 
1. To measure the difference between study arms in percent change in volume of 
the non-treated lobes by CT scan  
2. To measure the difference between study arms in the change in FEV1  
3. To measure the difference between study arms in the change in RV 
4. To measure the difference between study arms in the change in gas transfer  
5. To measure the difference between study arms in the change in modified MRC 
dyspnoea score 
6. To measure the difference between study arms in the change in the SGRQ 
7. To measure the difference between study arms in the change in the 6 minute 
walk test 
8. To measure the difference between study arms in changes in respiratory and 
quadriceps muscle strength 
9. To measure the difference between study arms in the change in endurance cycle 
ergometry time 
10. To measure the difference between study arms in dynamic hyperinflation during 
cycle ergometry 
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3.2 DETERMINATION OF SAMPLE SIZES 
 
This study is designed as a non-inferiority trial, and as such rather than selecting a 
sample size to achieve a certain power to reject a hypothesis, this study is designed 
to estimate a confidence interval with a pre-specified width.  Since a subject’s 
emphysema pattern cannot be randomly assigned, the ratio of subjects in the two 
study arms is unknown, so an assumption of a 2:1 (upper lobe:non-upper lobe) ratio 
was made.  Based on data on 34 subjects at 3 months in the Spiration Pilot Study, a 
conservative estimate for the standard deviation for percent change in the treated 
lobe(s) volume is 12%.    Assuming the data are normally distributed, and using a 95% 
confidence width of at most 15%, the number of subjects required is 16 and 32 in the 
two study arms.  Allowing for 10% of subjects to be lost to follow-up or have 
unusable data, this study aimed to enrol 54 subjects.  The maximum allowable 
enrolment into any one arm was 36 subjects. 
 
3.3 METHODS 
 
3.3.1 PATIENT SELECTION CRITERIA 
Patients were predominantly recruited from the COPD clinics at the Royal Brompton 
Hospital, but referrals from outside hospitals via Dr. Shah’s practice were also 
considered for enrolment. Inclusion and exclusion criteria are detailed in tables 3.1 
and 3.2.  
 
 87 
CT scans were scrutinised by a Consultant Radiologist to determine heterogeneity.  If 
there was any doubt or disagreement between the Radiologist and the study team as 
to the degree of heterogeneity, the patient was excluded from enrolment.  A pattern 
of upper or non-upper lobe predominant disease was ascribed to the patient, and 
they were offered entry into the appropriate arm of the study. 
 
Table 3.1: Inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Exclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion Criteria 
 Age 18-80 years 
 Ex-smoker with smoking cessation confirmed by exhaled CO levels 
 Heterogeneous emphysema on CT scanning 
 Moderate to severe airflow obstruction FEV1 <50% Predicted 
 Severe dyspnoea – mMRC  ≥2 
 Hyperinflation – TLC ≥100% predicted, RV ≥150% predicted 
 6MWT ≥75 metres 
 Optimum COPD treatment for at least 6 weeks 
 No COPD exacerbation for at least 30 days 
 Fewer than 4 admissions for exacerbation in the preceding 12 months 
 
Exclusion Criteria 
 Patient unable to provide informed consent 
 Patient without clear targets for airflow re-distribution 
 TLCO <15% predicted and FEV1 <15% predicted 
 pO2 on air <6.0kPa 
 pCO2 on air >8.0kPa 
 Neurological, rheumatological or other cause of exercise limitation 
 Other major medical illness that will limit participation 
 Production of purulent sputum more than 50% of days 
 Clinically significant bronchiectasis 
 Large bulla more than 1/3 of hemithorax volume on CT scan 
 Arrhythmia or cardiovascular disease posing risk during procedure or exercise 
 Prednisolone dose greater than 15mg a day 
 Significant pulmonary hypertension – RVSP ≥65mmHg 
 Left ventricular failure – left ventricular ejection fraction <40%  
 Prior LVRS or lobectomy 
 Lung nodule requiring surgery 
 Pulmonary rehabilitation within 3 months of enrolment 
 Female of childbearing age with positive pregnancy test 
 Participated in a study of investigational drug or device in prior 30 days 
 Taking clopidogrel/anticoagulants and unable to stop for 5 days pre-procedure 
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3.3.2 TESTING SCHEDULE 
All consented patients underwent screening and baseline testing to assess eligibility 
and to provide values against which testing at 3 and 6 months post-procedure could 
be compared.  Table 3.3 outlines the schedule of events for this study. 
 
Table 3.3: Event schedule for the upper vs lower lobe intrabroncial valve trial 
 
 Screening Baseline Procedure 3 months 6 months 
Echocardiogram X     
Clinical History X X  X X 
Examination X X  X X 
CXR    X  
ABG X   X X 
Full Lung Function X   X X 
6MWT X   X X 
Dyspnoea Score X   X X 
SGRQ   X  X X 
CT scan X    X 
Cycle ergometry  X   X 
BMI  X  X X 
Bronchoscopy  X    
Measurement of 
quadriceps MVC 
 X  X X 
Measurement of 
respiratory muscle 
strength 
 X  X X 
Valve insertion    X   
 
Screening and baseline tests could (and usually were) combined in 1 visit if this was 
easier for the patient and study team. 
 
3.3.3 PULMONARY FUNCTION TESTING 
Full pulmonary function testing including static and dynamic lung volumes and gas 
transfer measurements were performed at baseline, and again at 3 and 6 months 
using a Compact Master Lab system (Jaeger, Germany). 
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3.3.4 RADIOLOGICAL ASSESSMENTS 
High resolution volume scans of the chest were performed before the procedure and 
again at 6 months.  All scans were reconstructed to provide overlapping 0.6mm thick 
slices for in depth analysis.  An assessment of volume changes within each lobe was 
made using Myrian™ XP-Lung, a validated commercially available lobar volume 
assessment software package (Intrasense, Paris, France).  CT-derived lung volumes 
were calculated for the treated lobe and a combination of all non-treated lobes as 
follows: 
 
Upper lobe disease subjects:   a) upper lobes 
     b) lower and middle lobes together 
      
Non-upper lobe disease subjects: a) lower lobes (no middle lobe subjects enrolled) 
     b) upper and middle lobes together 
 
3.3.5 QUALITY OF LIFE 
Quality of life was assessed at baseline using the SGRQ, and re-assessed for changes 
at the 3 and 6 month follow-up visits.  The mMRC scale was also used to obtain a 
subjective assessment of breathlessness at each visit. 
 
3.3.6 EXERCISE TESTING 
3.3.6.1 Cycle ergometry 
Incremental and endurance cycle ergometry were performed at baseline using a 
magnetically braked cycle ergometer (Jaeger Ergoline 800).  Subjects wore a nose 
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clip, and gas analysis equipment was attached to a lightweight rubber mouthpiece.  
Subjects cycled until they could carry on no longer, with measures of inspiratory 
capacity made every minute at rest, during exercise, and for 2 minutes post testing.  
A workload of 75% of the maximum workload achieved for at least 30 seconds on 
the incremental protocol was used for the endurance protocol.  A gap of at least 1 
hour was left between the 2 tests to allow adequate recovery.  Endurance ergometry 
was repeated at 6 months, using the same workload determined at baseline.  Pre- 
and post-exercise Borg scores for breathlessness and RPE were recorded. 
 
3.3.6.2 The 6 minute walking test 
A 6MWT using standard protocols was performed at each visit, and the distance 
walked recorded.  Pre- and post-exercise Borg scores for breathlessness and RPE 
were recorded, along with blood pressure, pulse, and blood oxygen saturation (using 
an infrared finger probe). 
 
3.3.7 MUSCLE STRENGTH TESTING 
All muscle strength tests were assessed at each visit (baseline, 3 and 6 months). 
 
3.3.7.1 Respiratory muscle strength tests 
Non-invasive respiratory muscle testing was undertaken.  A nasal bung was used to 
measure the pressure generated during sniffing (SNIP), and a pressure transducer 
attached to an occludable rigid tube was used to measure overall inspiratory (MIP) 
and expiratory (MEP) muscle strength. 
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3.3.7.2 Quadriceps muscle strength tests 
Quadriceps muscle testing was used as a surrogate marker of increased activity in 
the community secondary to improvements in lung function. Maximum isometric 
quadriceps force (MVC) was measured.  The maximum force generated during a 
minimum of 5 maximum voluntary contractions with vigorous encouragement was 
recorded.  Non-volitional strength testing by femoral nerve magnetic stimulation 
(TwQ) was also undertaken at each visit. 
 
3.3.8 EQUIPMENT USED AND PRE-PROCEDURE CALIBRATIONS 
3.3.8.1 Calibration balloon 
A catheter with an inflatable balloon on the distal end (Olympus Medical Systems 
Corporation) was used to measure the diameter of target airways prior to valve 
deployment (see figure 3.1). The catheter is designed to be used down the working 
channel of the bronchoscope, and the balloon is inflated with 0.9% saline solution 
injected via a port at the proximal end of the catheter. 
 
Prior to airway measurement commencing, the balloon had to be calibrated to 
ensure accurate valve size selection.  This required firstly that all the air was 
removed from the catheter using a 10mls syringe attached via a 3-way tap to create 
a vacuum, followed by balloon inflation with saline.  This was repeated until the 
bubble of air seen in the inflated balloon was smaller than the diameter of the 
catheter.   
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A 500 l glass measuring syringe was attached to the proximal end of the catheter 
and was used to obtain accurate measurements of the amount of saline injected into 
the distal balloon.  A calibration gauge containing standard sized circular holes was 
then used to calibrate measurements for each of the valve sizes, as well as hole sizes 
both smaller and larger than available valves. 
 
3.3.8.2 Deployment catheter 
Valves are loaded into the distal end of a deployment catheter by a dedicated 
loading device.  Once loaded, the folded valve sits at the very distal end of the 
deployment catheter, which is used down the working channel of the bronchoscope.  
This is illustrated in figure 3.2.  Once the bronchoscope had been manoeuvred to the 
desired location, the valve was deployed by depressing a plunger at the proximal end 
of the catheter.  The valve opens out automatically and immediately, and is held in 
place in the airway by anchoring struts.  
 
Figure 3.1: Inflated balloon catheter      Figure 3.2: Intrabronchial valve loaded in deployment catheter 
Figure 3.2: Intrabronchial valve loaded in deployment catheter 
                      
 
 
3.3.8.3 Valves 
These have been described in chapter 1 (1.4.3.1).  The Intrabronchial Valve© (IBV) 
consists of a nitinol frame covered by a polymer membrane as shown in figure 1.4c. 
Valves are available in 5mm, 6mm, and 7mm diameters in order to fit a range of 
airway sizes, and the procedure for deployment is identical regardless of valve size. 
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3.3.9 ARTERIAL BLOOD GASES 
Arterial blood gas tensions were measured at baseline, 3 and 6 months, via a radial 
arterial sample (Rapidlab 348, Bayer, Germany). 
 
3.3.10 BRONCHOSCOPIC PROCEDURES 
Suitable patients are treated according to their pattern of emphysema as follows: 
 
Predominant upper lobe emphysema: had valves placed in both upper lobes but 
excluding the lingula segments of the left upper lobe, and one segment or sub-
segment of the right upper lobe.  Incomplete occlusions were performed to reduce 
the incidence of potentially fatal pneumothorax. 
 
Predominant in lobes other than upper: had valves placed in no more than 2 lobes 
and in each of those lobes, with at least one segment or sub-segment left open in 
each lobe.  
 
Procedures were performed under conscious sedation using intravenous midazolam 
and alfentanyl, with oxygen delivered via a nasal cannula. After bronchoscopic 
examination of the airways, the calibrated balloon catheter connected to the glass 
syringe was inserted through the working channel of the bronchoscope and used to 
measure each of the airways where valves were placed.  Airway sizing determines 
the valve size and number of valves that need to be used, and takes up to 20 
minutes, depending on the airway sizes and number of subsegments measured.   
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When all the airways had been sized, the appropriate valves were loaded (one at a 
time) into the deployment catheter.  The catheter was then introduced into the 
working channel of the bronchoscope and advanced to the target location.  Once 
deployed, the open valve occluded the lumen of the targeted airway. Total 
procedure times varied from 26 to 84 minutes (mean 43mins, standard deviation 
(SD) 12mins).  When incorrect deployment or delivery catheter failure resulted in the 
need for a valve to be removed, this was done using bronchoscopic forceps that 
were used to grasp and remove the valve. 
 
Patients were observed for a minimum of 2 hours post procedure, and were 
discharged if a post-procedure x-ray did not reveal a pneumothorax.  
 
Valve removal was offered to patients with persistent deteriorations in symptoms 
and lung function, or with any serious or chronic sequelae that, in the opinion of the 
investigators, warranted removal of one or more of the valves. 
 
3.4 SUBSEQUENT TREATMENTS 
 
All patients who completed the study without deriving significant benefit from the 
procedure in lung function, exercise capacity, or degree of dyspnoea were offered 4 
choices: 
 
1. Do nothing further and leave the valves in place 
2. Remove all the valves 
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3. Proceed directly to LVRS without valve removal after agreement with surgical 
team 
4. Proceed to unilateral complete lobar occlusion (side determined by CT scan 
analysis), after consideration of clinical need and risks 
 
A separate chapter (chapter 4) deals with additional follow-up data from those 
patients who elected to undergo complete lobar occlusion after study completion. 
 
3.5 RESULTS 
 
3.5.1 BASELINE DATA 
Twenty six subjects were recruited to the upper lobe arm and 6 to the lower lobe 
arm of the trial.  Baseline data are represented in table 3.4, with values presented as 
Mean (SD).  All p values are for unpaired t-tests except the mMRC score and number 
of valves, for which the Mann-Whitney U test was used, presented as Median 
(Range), and sex, for which the chi squared test was used. 
 
Non-upper lobe predominant subjects had a greater number of valves placed per 
patient than upper lobe predominant subjects owing to the greater number of 
bronchopulmonary segments in the lower lobes, although the difference failed to 
reach statistical significance (p=0.07). This did, however, lead to significantly longer 
procedure times (p=0.004; unpaired t-test). 
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Table 3.4: Baseline data 
 
 Upper Lobe Non-upper Lobe p value 
Number 26 6 - 
Age (y) 59.1 (10.5) 58.8 (14.2) 0.96 
Male 53.8% 66.7% 0.57 
Body Mass Index (BMI) 24.7 (3.5) 21.7 (3.0) 0.06 
FEV1 % predicted 31.6 (9.5) 25.4 (5.9) 0.14 
FVC % predicted 88.9 (17.2) 81.4 (18.5) 0.35 
RV % predicted 227.3 (43.0) 240.3 (70.6) 0.56 
RV/TLC 60.91 (8.02) 62.90 (12.64) 0.63 
FRC % predicted 191.7 (25.0) 198.8 (48.2) 0.61 
TLco % predicted 33.8 (12.1) 30.2 (8.4) 0.50 
mMRC 2 (2-3) 3 (2-4) 0.02 
SGRQ 57.8 (11.5) 64.0 (15.9) 0.27 
6MWD (m) 298.9 (97.4) 283.2 (130.9) 0.74 
Cycle time (s) 199.3 (119.5) 160.8 (15.3) 0.44 
Procedure time (min) 40.4 (9.7) 56.0 (15.8) 0.004 
Number of valves 6 (3-10) 8.5 (4-14) 0.06 
 
3.5.2 PRIMARY ENDPOINT 
One subject in the upper lobe arm of the trial withdrew owing to worsening of 
symptoms, requesting valve removal at 6 weeks post-treatment, and 1 subject in the 
non-upper lobe arm of the trial died between the 3 and 6 month visits.  Figure 3.3 
shows subject numbers remaining in the trial at each data collection time point.  
Twenty five upper lobe subjects and 5 non-upper lobe subjects were available at the 
6 month primary endpoint visit, and paired CT scans for these 30 subjects were 
available for lobar volume assessments.  Owing to unilateral lower lobe disease, the 
right lower lobe alone was treated in 1 non-upper lobe disease subject (N1). 
 
Raw data for individual lobar volumes can be found in appendix 2.  Lobar volume 
changes from baseline to 6 months are shown in tables 3.5, with percentage changes 
from baseline in table 3.6.  Upper lobe treatment subjects are denoted by the prefix 
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‘U’, and non-upper lobe treatment subjects by the prefix ‘N’.  Values for treated 
lobes are highlighted in bold.   
 
Figure 3.3: Subjects available for assessment at each follow-up time point 
 
 
 
 
The mean change in volume of the treated lobes reached statistical significance in 
both the upper lobe predominant subjects (p=0.0002) and non-upper lobe 
predominant subjects (p=0.02).  A mean change of -265.6mls was seen in the upper 
lobe arm and –288.2mls in the non-upper lobe arm.  This equated to mean 
percentage changes of -6.8% in the upper lobe arm and -11.7% in the non-upper 
lobe arm.  Significance was achieved in the lower lobe group even though only 5 
subjects completed the 6 month follow-up.  The difference between the 2 arms in 
the magnitude of change in treated lobar volumes (4.5%) did not reach statistical 
significance (p=0.19), but the number of subjects recruited did not reach that 
required by the power calculation.  Figure 3.4 shows graphical representations of the 
data, plotted as mean +/- SD. 
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Table 3.5: Volume changes in millilitres at six months 
 
 Volume change at 6 months (mls) Totals 
Subject LUL LLL RUL RLL T Non-T 
U1 179 392 -107 112 72 504 
U2 -349 207 -707 459 -1056 666 
U3 -103 248 -137 218 -240 466 
U4 -164 60 -56 57 -220 117 
U5 -256 233 -411 177 -667 410 
U6 -95 -156 -17 -81 -112 -237 
U7 17 191 44 529 61 720 
U8 79 -52 51 -17 130 -69 
U9 -253 189 -103 210 -356 399 
U10 23 173 -388 385 -365 558 
U11 -139 -271 -35 -89 -174 -360 
U12 11 68 44 120 55 188 
U13 -105 175 -392 230 -497 405 
U14 -121 93 19 65 -102 158 
U15 -57 -58 -129 279 -186 221 
U16 -39 3 -191 -109 -230 -106 
U17 -1 78 49 170 48 248 
U18 16 157 -48 101 -32 258 
U19 -107 123 -90 58 -197 181 
U20 -207 211 -21 109 -228 320 
U21 -54 209 -321 338 -375 547 
U22 -312 -65 -149 -22 -461 -87 
U23 -95 -31 -76 -8 -171 -39 
U24 -22 94 -960 231 -982 325 
U25 -243 12 -113 34 -356 46 
Mean -95.9 91.3 -169.8 142.2 -265.6 233.6 
SD 125.9 145.1 244.7 167.3 299.0 279.6 
 
N1 289 -327 70 131 -327 490 
N2 -239 96 -181 -240 -144 -420 
N3 -208 -71 -136 -5 -76 -344 
N4 360 -149 252 -343 -492 612 
N5 -25 -214 56 -188 -402 31 
Mean 35.4 -133.0 12.2 -129.0 -288.2 73.8 
SD 277.4 158.7 174.7 190.1 174.5 469.9 
  LUL: change in left upper lobe volume LLL: change in left lower lobe volume  
  RUL: change in right upper lobe volume RLL: change in right lower lobe volume    
  T: change in treated lobes   Non-T: change in non-treated lobes 
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Table 3.6: Percentage changes in volumes at 6 months  
 
 Percentage change at 6 months Totals 
Subject LUL LLL RUL RLL T Non-T 
U1 6.7 30.1 -2.7 11.2 1.1 21.9 
U2 -15.5 11.0 -30.9 19.5 -23.3 15.7 
U3 -4.4 20.2 -6.5 13.3 -5.4 16.3 
U4 -12.3 5.1 -3.6 3.7 -7.6 4.3 
U5 -12.7 12.1 -28.2 6.4 -19.2 8.7 
U6 -4.0 -10.3 -0.8 -4.5 -2.4 -7.1 
U7 0.7 13.0 1.7 27.5 1.2 21.2 
U8 3.3 -2.3 3.3 -0.7 3.3 -1.5 
U9 -17.8 18.2 -6.6 18.2 -11.9 18.2 
U10 1.1 11.1 -21.7 20.7 -9.5 16.3 
U11 -6.2 -13.0 -1.9 -3.4 -4.3 -7.7 
U12 0.6 6.9 2.5 7.5 1.5 7.3 
U13 -6.7 13.0 -19.7 16.0 -13.9 14.6 
U14 -7.9 7.8 1.1 4.7 -3.2 6.1 
U15 -1.6 -3.9 -3.6 14.8 -2.6 6.6 
U16 -2.0 0.2 -9.8 -5.4 -5.8 -3.1 
U17 0.0 6.7 3.3 8.7 1.4 8.0 
U18 1.0 12.3 -2.4 5.2 -0.9 8.0 
U19 -5.3 8.9 -4.4 3.0 -4.9 5.4 
U20 -14.9 19.5 -1.3 7.6 -7.7 12.7 
U21 -2.9 13.6 -19.4 15.2 10.8 14.6 
U22 -16.4 -7.5 -8.5 -2.0 -12.6 -4.4 
U23 -6.5 -2.5 -6.4 -0.5 -6.5 -1.3 
U24 -0.9 4.5 -29.9 7.7 -17.4 6.4 
U25 -12.7 0.8 -6.2 1.6 -9.6 1.3 
Mean -5.5 7.0 -8.1 7.8 -6.8 7.5 
SD 6.8 10.2 10.5 8.7 6.9 8.6 
 
N1 22.8 -25.9 4.1 9.7 -25.9 11.3 
N2 -14.8 7.1 -9.4 -15.8 -5.0 -11.9 
N3 -9.6 -1.8 -4.1 -0.2 -1.3 -6.2 
N4 17.2 -7.7 9.4 -16.5 -12.2 12.8 
N5 -1.7 -18.3 3.9 -11.0 -13.9 1.1 
Mean 2.8 -9.3 0.8 -6.8 -11.7 1.4 
SD 16.5 13.1 7.5 11.3 9.5 10.7 
  LUL: % change in left upper lobe volume LLL: % change in left lower lobe volume  
  RUL: % change in right upper lobe volume RLL: % change in right lower lobe volume    
  T: % change in treated lobes  Non-T: % change in non-treated lobes 
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Figure 3.4: Changes in treatment and non-treatment lobes at 6 months 
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3.5.3 SECONDARY ENDPOINTS 
3.5.3.1 Volumes of untreated lobes 
A highly significant increase in the mean volume of non-treated lobes was seen in 
the upper lobe treatment groups (233.6mls; p=0.0003), similar to the magnitude of 
reduction in volume in treated lobar volumes (233.6(279.6)mls vs -265.6(299.0)mls).  
Although there was a small increase in the volume of non-treated lobes in the non-
upper lobe group, the standard deviation was very large and the change failed to 
reach statistical significance (73.8mls; p=0.74).  All data are detailed above in tables 
3.5 and 3.6, and represented graphically in figure 3.4. 
 
3.5.3.2 Lung function measures 
No significant changes in airflow obstruction (as measured by FEV1; pUL=0.56, 
pNUL=0.89), hyperinflation (RV; pUL=0.72, pNUL=0.73), or oxygen uptake (TLco; 
pUL=0.14, pNUL=0.66) were seen in either arm of the trial, and there was no difference 
between arms in the change in these endpoints (although numbers in the non-upper 
lobe arm may not be sufficient to detect a true difference).  Indeed, no changes were 
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seen in any other measured, non-endpoint, lung function parameter (FVC, TLC, 
RV/TLC).  At the earlier 3 month visit, however, there were statistically significant 
deteriorations in the upper lobe treatment group in the FEV1 (p=0.04), FVC (p=0.01), 
RV (p=0.03), and RV/TLC ratio (p=0.001), indicating an acute worsening of respiratory 
function following valve insertion.  Average values for these 4 parameters had not 
returned to baseline by the 6 month visit, although they were no longer statistically 
significantly worse than at baseline.  Values for each parameter are shown in table 
3.7 as Mean(SD), with graphical representation of endpoint data in figures 3.5 and 
3.6. 
 
Table 3.7: Lung function parameters - a) upper lobe, b) non-upper lobe, c) changes UL v NUL 
 
a) Baseline 3 months p value 6 months p value 
FEV1 0.88(0.37) 0.83(0.40) 0.04
† 0.86(0.41) 0.56 
RV 4.76(1.02) 4.94(1.05) 0.03† 4.81(0.82) 0.72 
TLco 2.83(1.20) 2.93(1.19) 0.25 2.98(0.96) 0.14 
FVC 3.05(0.94) 2.86(0.92) 0.01† 2.93(0.89) 0.23 
TLC 7.90(1.40) 7.83(1.39) 0.24 7.85(1.35) 0.61 
RV/TLC 60.61(8.04) 63.40(8.18) 0.001†† 62.04(7.28) 0.21 
         † p<0.05; †† p<0.01 
 
b) Baseline 3 months p value 6 months p value 
FEV1 0.75(0.26) 0.74(0.24) 0.82 0.77(0.26) 0.89 
RV 5.15(1.75) 5.21(1.84) 0.85 5.57(2.10) 0.73 
TLco 2.72(0.92) 2.58(0.63) 0.40 2.51(0.51) 0.66 
FVC 3.11(1.39) 2.73(1.01) 0.09 2.88(1.08) 0.43 
TLC 8.24(2.18) 8.14(2.30) 0.54 8.44(2.62) 0.90 
RV/TLC 62.90(12.64) 63.72(8.70) 0.82 65.76(9.87) 0.74 
 
c) % UL 3m % NUL 3m p value % UL 6m NUL 6m p value 
FEV1 -6.69(11.34) -0.21(14.08) 0.24 -2.03(18.31) 2.41(13.08) 0.61 
RV 3.93(8.17) 2.29(19.06) 0.74 2.32(12.27) 4.63(24.95) 0.75 
TLco 4.26(14.10) -1.48(15.78) 0.85 10.28(20.76) 1.90(27.20) 0.44 
FVC -6.37(11.59) -8.73(13.93) 0.67 -2.74(16.67) -1.34(20.03) 0.87 
TLC -0.83(4.12) -1.63(5.92) 0.70 -0.41(5.68) -1.07(9.15) 0.83 
RV/TLC* 2.79(3.83) 0.81(8.23) 0.38 1.42(5.57) 1.49(9.46) 0.74 
          *absolute value 
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Figure 3.5: Secondary endpoint lung function parameters - a) upper lobe, b) non-upper lobe 
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Figure 3.6: Comparison of changes in lung function parameters 
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3.5.3.3 Symptom scores 
Changes in SGRQ and mMRC within and between groups were both clinically and 
statistically unimportant at the 6 month follow-up visit.  There was clinically 
meaningful (-8.1 points), but not statistically significant (p=0.30), change in the 
average SGRQ in the non-upper lobe group at 3 months.  This should be interpreted 
with caution given the small numbers and non-blinded trial design, and this change 
was not significantly different to that seen in upper lobe subjects.  Data are shown in 
*p<0.05 
a) 
b) 
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table 3.8 and figures 3.7 and 3.8 as Median(Range) for mMRC and Mean(SD) for 
SGRQ, and for all changes between groups.  
 
Table 3.8: Symptom scores - a) upper lobe, b) non-upper lobe, c) changes UL v NUL 
 
a) Baseline 3 months p value 6 months p value 
mMRC 2(2-3) 2(1-3) 0.23 2(1-4) 0.51 
SGRQ 57.25(11.42) 56.5(13.46) 0.72 54.95(13.2) 0.30 
 
b) Baseline 3 months p value 6 months p value 
mMRC 3(2-4) 2(2-3) 0.09 3(2-4) 1.00 
SGRQ 63.96(15.91) 55.84(6.28) 0.30 58.04(5.39) 0.85 
 
c) UL 3m NUL 3m p value UL 6m NUL 6m p value 
mMRC 0(-2-1) -1(-2-1) 0.08 0(-2-2) 0(-1-1) 0.87 
SGRQ -0.75(10.59) -8.12(17.37) 0.19 -2.31(10.87) -1.20(13.91) 0.84 
 
Figure 3.7: Symptom scores - a) upper lobe, b) non-upper lobe 
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a) 
b) 
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Figure 3.8: Comparison of changes in symptom scores 
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3.5.3.4 Measures of exercise performance 
There were no differences in the changes in measures of exercise performance 
between the 2 groups at 6 months, and no differences at 3 months in 6MWD.  
Similarly, no intra-group differences were seen in either performance measure at 
any assessment point. Values for each parameter are shown in table 3.9 as 
Mean(SD), and represented graphically in figure 3.9. 
 
Table 3.9: Exercise capacity - a) upper lobe, b) non-upper lobe, c) changes UL v NUL 
 
a) Baseline 3 months p value 6 months p value 
6MWD 303.4(96.7) 296.4(108.4) 0.52 294.5(107.3) 0.51 
Cycle time 204.5(118.9) - - 192.8(142.9) 0.73 
 
b) Baseline 3 months p value 6 months p value 
6MWD 283.2(130.9) 293.2(105.0) 0.70 255.2(107.9) 0.51 
Cycle time 165.2(12.3) - - 155.6(141.4) 0.89 
 
c) UL 6m NUL 6m p value 
6MWD -1.5(22.9) -4.7(44.7) 0.82 
Cycle time 7.9(87.9) -3.1(90.0) 0.80 
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Figure 3.9: Exercise performance - a) 6MWD, b) Cycle time 
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3.5.3.5 Muscle strength 
One upper lobe treatment subject declined to undergo quadriceps muscle testing 
owing to shin pain.  Data at 3 and 6 months was not available in 1 further upper lobe 
subject (back pain), and one declined testing at 6 months, leaving 23 data points at 3 
months follow-up and 22 endpoint data points.    There were no significant changes 
in any measure of respiratory (MIP, MEP, SNIP) or quadriceps (MVC, TwQ) muscle 
strength within or between groups.  Data are presented as Mean(SD) in table 3.10, 
and graphically in figure 3.10. 
 
 
 
a) 
b) 
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Table 3.10: Muscle strength - a) upper lobe, b) non-upper lobe, c) changes UL v NUL 
 
a) Baseline 3 months p value 6 months p value 
SNIP 64.52(16.25) 65.01(14.23) 0.86 64.26(14.97) 0.94 
MIP 67.62(15.41) 71.02(17.87) 0.24 68.18(14.99) 0.87 
MEP 92.64(25.47) 95.44(26.29) 0.48 94.80(24.05) 0.56 
MVC 30.45(9.58) 31.10(10.40) 0.87 29.19(7.15) 0.14 
TwQ 11.63(4.64) 11.55(3.91) 0.70 11.09(4.05) 0.82 
 
b) Baseline 3 months p value 6 months p value 
SNIP 58.50(19.18) 61.05(20.98) 0.40 64.06(25.23) 0.90 
MIP 64.48(18.37) 68.73(29.30) 0.40 71.88(35.97) 0.62 
MEP 104.28(28.70) 100.52(35.25) 0.63 100.64(37.52) 0.40 
MVC 27.08(11.11) 27.52(11.02) 0.81 28.22(16.84) 0.98 
TwQ 10.08(5.07) 10.33(537) 0.69 9.22(3.25) 0.80 
 
c) UL 3m NUL 3m p value UL 6m NUL 6m p value 
SNIP 3.55(22.72) 4.95(12.49) 0.89 3.59(29.42) -0.26(23.19) 0.79 
MIP 6.86(22.19) 6.27(25.52) 0.95 4.02(26.73) 6.78(27.57) 0.84 
MEP 4.27(20.99) -4.03(13.78) 0.37 4.46(21.63) -8.51(22.52) 0.23 
MVC 0.94(23.62) 1.85(16.80) 0.93 -3.19(21.11) -5.12(16.63) 0.85 
TwQ 6.53(27.64) 1.78(24.51) 0.71 1.99(33.03) 14.15(39.19) 0.48 
 
Figure 3.10: Changes in muscle strength - a) 3 months, b) 6months 
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3.5.3.6 Dynamic hyperinflation 
Paired data were available for all patients reaching the 6 month visit.  End-expiratory 
lung volumes (EELV) were calculated by measuring the IC and subtracting this from 
the resting TLC as measured by plethysmography prior to ergometry.  
 
b) a) 
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Isotime EELV values were compared.  Isotime was defined as the final 30 second 
period achieved on the shortest test.  Data for each group were analysed using 
paired t-tests, and for comparison of changes between the 2 arms an unpaired t-test 
was used.  No difference was seen in baseline EELV between the two groups 
(p=0.34). There were no statistically significant changes in EELV at 6 months in either 
upper lobe (p=0.69) or non-upper lobe (p=0.84) treatment groups, and moreover 
there was no difference in the changes between the groups (p=0.90).  Individual 
patient data is located in appendix 2.  Figure 3.11 shows graphical representations of 
all data with means and 95% confidence intervals. 
 
Figure 3.11: Isotime end expiratory lung volumes on cycle ergometry  
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3.5.4 ADVERSE EVENT PROFILE 
A log of all adverse events (AEs) up to the final 6 month follow-up was kept for all 32 
subjects.  Figures are represented in table 3.11 as total (mean; SD).  The most 
commonly occurring AE in both arms was acute exacerbation of COPD, accounting 
for over half of all AEs (63.8% upper lobe, 50.0% non-upper lobe). One 
pneumothorax occurred in each arm of the trial.  The upper lobe treatment subject 
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who experienced a pneumothorax required a thoracotomy for repair of a persistent 
middle lobe air leak.  When all respiratory AEs were grouped, these accounted for 
72.5% of upper lobe AEs and 64.3% of non-upper lobe AEs.  There was 1 death in the 
non-upper lobe cohort.  This subject missed his 6 month follow-up owing to a 
general deterioration in health, and subsequently died 1 week later (cause of death 
COPD), still within the acceptable window for follow-up.  The death was not thought 
to relate to valve treatment. There were no significant differences between the 2 
groups in the number of AEs or COPD exacerbations, but the number of serious 
adverse events (SAEs) was statistically significantly greater in the non-upper lobe 
arm (owing to the fact that all the numbers in one group were identical – 1 SAE for 
each non-upper lobe subject - a t-test cannot be performed, so the Mann-Whitney U 
test was used). 
 
Table 3.11: Adverse events by treatment arm 
 
 Upper lobe Non-upper lobe p value 
AEs 69 (2.65;1.70) 14 (2.33;1.37) 0.67 
SAEs 
COPD 
10 (0.38;0.57) 
44 (1.69;1.59) 
6 (1.00;0.00) 
7 (1.17;1.17) 
<0.01 
0.45 
 
3.6 DISCUSSION 
 
This study remains to our knowledge the largest single centre series of IBVs in the 
literature.   Nonetheless, the trial failed to recruit to target, and in fact was halted 
after 32 subjects had been recruited.  By this stage it had become apparent that very 
few patients were reporting any improvement with the treatment, several were 
expressly stating that they wished they had never entered the trial, and many 
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subjects’ 3 month results were worse than at baseline.  A decision was made to 
continue with trial follow-ups but to halt further recruitment to the trial until all 
those so far recruited had reached the full 6 months of follow-up and an interim data 
analysis had been performed.  Although this has implications for the statistical 
validity of a trial, it was felt that this was justified on safety grounds, and that this 
over-ruled scientific curiosity.  The data presented in this thesis represents that 
interim analysis, the results of which, together with increasing evidence for benefit 
from complete lobar occlusions, led the study team to terminate the trial as it was 
felt we could not justify putting subjects at risk of significant harm for a procedure 
which all the evidence was beginning to suggest was unlikely to benefit them. 
 
One other important aspect of this trial when compared to most other trials in this 
field was the deliberate exclusion of subjects who were taking part in or had taken 
part in a formal programme of pulmonary rehabilitation in the preceding 3 months.  
The trial was commercially sponsored, and whilst the protocol was developed in 
partnership to some extent with the study team, there were some points on which 
Olympus Medical were not prepared to compromise.  The rationale provided was 
that subjects who had recently completed rehabilitation would see a drop-off in 
measures of exercise performance over the 6 months of the trial as the benefits of 
rehabilitation diminished with time, and that this may affect trial results.  A better 
way to ensure that any changes in exercise performance were real procedure-related 
changes would have been to have mandated an immediate pre-trial period of formal 
rehabilitation followed by a further period following the procedure, or otherwise 
some form of on-going exercise programme.   
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The magnitude of change in treated lobe volumes in the 2 groups was not 
statistically significantly different, but the numbers recruited did not meet that 
deemed necessary by the power calculation.  A larger multicentre trial would be 
needed in order to recruit enough patients in a timely fashion to this arm of the trial 
to achieve the necessary power.  It is similarly not possible to comment on the 
difference between arms in any of the multiple measures of pulmonary and extra-
pulmonary function.  However, given that neither group demonstrated 
improvements in any measure, it is difficult to claim success in either group from this 
trial, and in particular we cannot say that a strategy of bilateral incomplete 
occlusions in non-upper lobe heterogeneous emphysema provides benefits to 
patients.  If anything a deterioration in lung function at the end of the trial was seen 
in the larger upper lobe group (e.g. FEV1 -2.03%, RV +2.32%), and several measures 
of lung function at 3 months were statistically significantly worse. 
 
It is probably best in this situation to analyse all the data as one group to see if there 
are any correlations between the change in lobar volumes and any of the parameters 
measured in this trial. Overall, there was a very significant reduction in the volume of 
treated lobes, together with a significant rise in the volume of untreated lobes 
(figure 3.12).  There were still no significant improvements in lung function, exercise 
performance, symptoms, or muscle strength (figure 3.12), however, which raises the 
question as to whether the beneficial effects of volume loss in treated lobes is 
negated by further (hyper)expansion of already overinflated, emphysematous, non-
treated lobes.   
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Figure 3.12: Pooled outcomes 
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Working on the premise that non-treatment lobes represent ‘better’ lung than 
treatment lobes, one might still expect an increase in the TLco and a decrease in DHI, 
but neither of these were the case.  Furthermore, there were no correlations 
between the change in treated lobe volumes and any other measure (table 3.12).  
 
In cases where there is genuine lung compression, one would expect the expansion 
of non-treated lung to result in an improvement in pulmonary function, for example 
following surgical excision of giant bullae.  However, in our subjects with widespread, 
albeit heterogeneous, emphysema, further expansion of the relatively good, but still 
anatomically and functionally sub-normal, untreated lung could actually lead to an 
effective increase in the severity of the emphysema in that untreated area.  This may 
account for the lack of benefit seen in this trial. 
 
Table 3.12: Correlations between volume changes and other measured parameters 
 
 FEV1 FVC RV TLC TLco Walk Cycle SNIP MIP MEP MVC TwQ MRC SGRQ 
r
2
 0.007 0.033 0.009 0.000 0.010 0.013 0.034 0.098 0.086 0.005 0.030 0.017 0.013 0.015 
P 0.70 0.38 0.65 0.98 0.64 0.30 0.82 0.13 0.15 0.73 0.44 0.57 0.58 0.56 
 
There are 2 potential problems with CT measured lung volumes as performed in this 
trial.  The first variable, and one over which it is difficult to have complete control, is 
the degree to which subjects fully inspired prior to CT scanning.  Measured lobar 
volumes are directly affected by completeness of inspiration, and differences 
between the 2 visits could account for the magnitude of some of the changes.  
However, the consistency of the change in volumes (reduction in treated lobes, rise 
in untreated lobes) argues against this being a significant factor – one would expect 
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changes related to inspiratory variations to be randomly distributed in both 
directions – and every effort was made by the radiographers to ensure maximum 
inspiration for all CT scans, with encouragement provided to all subjects.  One way to 
combat this is to present the data for each lobe as percentages of whole lung volume 
(as measured by CT), and to see whether there is still a significant volume shift.   This 
makes the bold assumption that airway compliance is equal throughout all lung 
units, and hence ventilation to each alveolus occurs at the same rate, but still 
provides some degree of correction for variable inspiration during CT. The 
relationship between treated lobes and volume shift remains, even after this crude 
correction (figure 3.13), with an average 3.4% of total lung volume (as opposed to 
the lobar volume percentages documented above) moving away from the treated 
lobes (p<0.0001). 
 
 
 
Figure 3.13: Volume shift as a percentage of total lung volume 
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The second factor is the accuracy of lobar volume measurements made by a single 
operator (SK).  Training was provided by the software company, and a number of 
test CT scans were analysed to gain familiarity with the software prior to analysing 
any study CT scans.  For quality control, a second operator (ZZ) was asked to perform 
an independent analysis of all scans, and a comparison of results made.   Taking all 
analyses across both the baseline and 6 month visits, scatter (figure 3.14) and Bland-
Altman (figure 3.15) plots were constructed.  The data show a highly significant 
Pearson correlation co-efficient of 0.983 (r2=0.966; p<0.0001), with a Bland-Altman 
bias of -0.148 and 95% limits of agreement of -3.355 to 3.060.  A paired t-test 
showed no overall difference in the change in values between the 2 analyses (figure 
3.16). 
 
 
 
Figure 3.14: Correlation between lung volume measurements by SK and ZZ 
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With respect to the Bland-Altman plot in figure 3.15, a single point on the plot 
identifies the percentage of an individual lung that was measured as being 
attributable to the upper lobe, and takes the average of measurements from SK and 
ZZ, represented on the x-axis.  The difference between the 2 measurements is then 
represented on the y-axis, in this case as %UL SK minus %UL ZZ. 
 
Figure 3.15: Bland-Altman plot of lung volume measurements by SK and ZZ 
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Figure 3.16: Graph of measurements of changes in lung volume by SK and ZZ 
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One important marker of success in any clinical trial is what the subjects chose to do 
at the end of that trial.  This particular trial gave subjects several options on trial 
completion (section 3.4), and outcome trees for both groups and all subjects 
together are shown below (figure 3.17). 
 
Figure 3.17: Outcome trees - a) upper lobe, b) non-upper lobe, c) all subjects 
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lobe drop-out) felt that they had deteriorated enough that they requested valve 
removal and would not consider the option of unilateral complete occlusion, for 
which the evidence of benefit is more robust (Sciurba 2010; Hopkinson 2011), with 
one further subject opting instead to go straight for LVRS.  The 16 subjects who 
elected for further valves are discussed in chapter 4. 
 
The European multicentre randomised, blinded, sham controlled trial of bilateral 
upper lobe IBV treatments (incomplete occlusions; 73 patients in 7 centres) in 
heterogeneous emphysema (Ninane 2012) demonstrated similar shifts in lobar 
volume at 3 months to those seen at 6 months in the upper lobe treatment arm of 
this trial (-7.3±9.0% vs -6.8±6.9%), with the control group, unsurprisingly, showing no 
shift in volumes.  Six month CT analysis showed a reduction in the amount of volume 
loss in the upper lobes to -5.3±7.8, comparing unfavourably with the results reported 
in this chapter. A responder analysis was conducted, with a responder being a 
subject with a 7.5% decrease in treated lobar volumes and a ≥4 point fall in the SGRQ 
at 3 months.    The treatment group had a 24% responder rate, against 0% in the 
control group.  This result was used by the authors to suggest a beneficial treatment 
effect of bilateral incomplete lobar occlusions with the IBV.  However, there was no 
overall difference in the change in SGRQ between groups and no difference in SGRQ 
‘responders’, and changes in SGRQ were not reported to correlate with volume 
shifts.   This suggests that changes in SGRQ were randomly distributed across both 
groups, and were independent of any treatment effects. Moreover, there were no 
differences in changes in lung function parameters, breathlessness as measure by 
the mMRC, or 6MWD between the 2 groups.  The authors suggest that the change in 
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SGRQ in the control subjects (-3.6±10.7) was a combination of placebo effect and 
Hawthorne effect (improvements in the course of clinical trials owing to closer 
monitoring of disease), but simultaneously put a similar magnitude change in the 
treatment arm (-4.3±16.3; p=0.835) down to a real effect from volume shift, ignoring 
the fact that a similar degree of artifactual change should occur in both arms of a 
blinded trial. Using a combined endpoint in which one of the measures of success 
appears to bear no relation to the underlying treatment and is randomly distributed 
throughout both treatment and non-treatment subjects together with a measure 
that could not reasonably be expected to happen in one arm of the trial would be 
considered by some to be floored statistics.  The trial demonstrated that IBV 
treatments reduce treated lobar volumes without any physiological benefit, and 
claims of benefits in quality of life should be treated with extreme caution.  In 
general, both the European study and the study reported here gave very similar 
results, but the interpretation of those results by the respective authors is very 
different. 
 
Results from the VENT (Sciurba 2010) illustrated that a successful outcome was 
dependent on the presence or absence of collateral ventilation between lobes, the 
heterogeneity of the disease, and the achievement of complete lobar occlusion by 
correct valve placement (collateral ventilation between lobar segments in 
emphysema is likely to be substantial in many cases).  Patients with lobar atelectasis 
benefit the most.  By the very nature of the strategy used in this trial, lobar occlusion 
was not achieved in our subjects, and no formal assessment of collateral ventilation 
was made.  These 2 factors made complete lobar atelectasis impossible.  All scans 
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were discussed in a COPD multi-disciplinary team meeting with Radiologist review to 
ensure that only patients with heterogeneous disease were recruited, but no formal 
scoring system was used.    
 
A number of our subjects had bronchoscopic examination of their airways 
subsequent to exiting the trial, either for clinical reasons or for additional valve 
placement.  The design of the IBV allows for expired air and secretions to pass 
around the outside of the valve along the airway wall, in contrast to the other 
commercially available valve system (Zephyr valve, Pulmonx Corporation, Redwood, 
CA) which vents air via a duck-billed mechanism mounted in the middle of the valve 
(Figure 3.18).  The function of the IBV is therefore dependent on the interface 
between the valve umbrella and the airway wall being clean and clear.  We noted in 
a number of subjects that some valves had ceased to function as valves, rather acting 
as spigots.  The causes of this were twofold.  Firstly, thick secretions were pooled 
around the valve-wall interface, effectively gluing the umbrella to the surrounding 
mucosa.  Owing to the diminished airflow in those segments that had IBVs in situ, 
subjects were not able to adequately clear this mucus, and we saw this particularly in 
those with lower lobe valves, where substantial pools of mucus were seen in 2 
individuals (upper lobe treatment subjects had the benefit of gravity to assist with 
clearance from occluded segments).  Secondly, in some subjects the valves caused a 
significant granulation reaction at the point where the umbrella struts rested against 
the airway wall, again effectively closing the pathway for air and secretions to move 
from distal to proximal.  Assurances were given by the manufacturers that airway 
hypertrophy but not granulation occurred in some subjects (private 
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correspondence), but areas of airway mucosa with the visual appearance of 
granulation tissue were still present in some subjects several months after valve 
extraction. 
 
Figure 3.18: Comparison of airflow in the Zephyr valve and IBV 
 
 
Could the valve design have contributed to the excess of SAEs seen in the non-upper 
lobe arm of the trial (of which 5 out of 6 were respiratory problems, with 4 being 
infection/exacerbation)?  Pooling of mucus and secretions around the valves is more 
likely to occur in the lower lobes than the upper lobes owing to the orientation of 
the airways and the effects of gravity, and it is not difficult to imagine lower lobe 
valves in airways whose proximal portions lie superior to their distal portions being 
swamped with mucus that cannot be cleared, owing to the lack of airflow in those 
airways (this was in fact the case when we removed valves from one of the non-
upper lobe subject).  This situation effectively mimics bronchiectasis, with a perfect 
culture medium for recurrent bacterial infections.  Whilst the overall number of 
respiratory related AEs was not greater in this arm of the trial, perhaps the inability 
to clear secretions adequately led to a greater chance of any infection being more 
difficult to treat, and hence becoming an SAE. 
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3.7 CONCLUSION 
 
Significant reductions in the volumes of treatment lobes were seen in both arms of 
the trial, and these changes were similar in magnitude.  Owing to poor recruitment 
to the non-upper lobe arm of the trial, it is not possible to state categorically that the 
patients with non-upper lobe predominant emphysema derive the same benefit in 
terms of volume change as upper-lobe predominant patients, but the figures 
presented here are if anything more impressive in non-upper treatments (both 
absolute and percentage volume changes).   No meaningful changes were seen in 
any other endpoint in either arm of the trial, and moreover there was no correlation 
between the degree of lobar volume shift and change in any measured parameter, 
suggesting that lobar volume shift is neither a useful nor relevant measure of success 
with IBV placement.  It is not possible on the basis of this data to recommend 
bilateral incomplete lobar occlusions for the treatment of heterogeneous 
emphysema. 
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CHAPTER  4::   STAGED  IINTRABRONCHIIAL  VALVE  
TREATMENT  IIN  SEVERE  HETEROGENEOUS  EMPHYSEMA  
 
During the course of the upper versus non-upper lobe intrabronchial valve trial, data 
were increasingly being presented showing the benefits of lobar atelectasis resulting 
from endobronchial valve treatment (Hopkinson 2011; Sciurba 2010).  Our bilateral 
incomplete occlusion trial was designed to avoid atelectasis and the attendant risk of 
pneumothorax, and the results indirectly back up the assertion that atelectasis 
should be the goal of treatment.  Therefore, subjects from that trial without 
improvements in lung function and symptoms were offered the opportunity to 
undergo further valve implantation with the aim of achieving complete unilateral 
lobar occlusion and atelectasis. 
  
4.1 ENDPOINTS 
 
Endpoints chosen for analysis of the data obtained from the patients in this series 
were the changes in FEV1 and 6MWD, specifically to be in line with endpoints in the 
VENT study (Sciurba 2010).  Secondary endpoints are listed below, and relate to 
changes in lung volumes (a measure of improvements in the biomechanics of 
respiration) and symptom scores. All endpoints assessed the changes in measured 
parameters from baseline to 3 month (although the VENT assessed changes at 6 
months). 
 
Primary Endpoints 
1. To measure the change in FEV1 from baseline to 3 months 
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2. To measure the change in 6 minute walking distance from baseline to 3 
months 
 
Secondary Endpoints 
1. To measure the change in FVC from baseline to 3 months 
2. To measure the change in RV from baseline to 3 months 
3. To measure the change in RV/TLC from baseline to 3 months 
4. To measure the change in the SGRQ from baseline to 3 months 
5. To measure the change in mMRC dyspnoea score from baseline to 3 months 
 
4.2 METHODS 
 
4.2.1 PATIENT SELECTION CRITERIA 
Patients discussed in this chapter had all participated in the trial described in the 
previous chapter.  That is to say, the patients had IBVs deployed to achieve bilateral 
incomplete occlusions.  No other patient data are presented here.  Patients would 
have been excluded from further IBV treatment if they met any of the exclusion 
criteria in table 4.2.  However, no patients considered for complete occlusion met 
any of the exclusion criteria. 
 
Table 4.1: Inclusion criteria 
 
 
 
 
 
 
 
 
Inclusion Criteria 
 Previous participation in the upper versus lower lobe intrabronchial valve trial 
 Assessed as having clinical need for further procedures 
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Table 4.2: Exclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 TESTING SCHEDULE 
For the purposes of this chapter, ‘baseline’ refers to the values obtained at the 6 
month follow-up visit from the study reported in chapter 3.  All tests were 
performed at baseline and again at 3 months post-procedure.  Table 4.3 outlines the 
testing schedule. 
 
Table 4.3: Event schedule for complete occlusion patients 
 
 Baseline Procedure 3 months 
Clinical History X  X 
Examination X  X 
ABG X  X 
Full Lung Function X  X 
6MWT X  X 
Dyspnoea Score X  X 
SGRQ  X  X 
CT scan X  X 
Valve insertion   X  
 
4.2.3 PULMONARY FUNCTION TESTING 
Full pulmonary function testing including static and dynamic lung volumes and gas 
transfer measurements were performed at baseline, and again at 3 months using a 
Compact Master Lab system (Jaeger, Germany). 
Exclusion Criteria 
 pO2 on air <6.0kPa 
 pCO2 on air >8.0kPa 
 Neurological, rheumatological or other cause of exercise limitation 
 Other major medical illness that will limit participation 
 Arrhythmia or cardiovascular disease posing risk during procedure or exercise 
 Prednisolone dose greater than 15mg a day 
 Lung nodule requiring surgery 
 Female of childbearing age with positive pregnancy test 
 Subject taking clopiogrel or anticoagulants and unable to abstain for 5 days pre-
procedure 
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4.2.4 RADIOLOGICAL ASSESSMENTS 
High resolution volume scans of the chest were performed at 3 months after 
complete occlusion was attempted.  All scans were reconstructed to provide 
overlapping 0.6mm thick slices for in depth analysis, and were assessed for the 
presence of atelectasis in the treated (complete occlusion) lobe. 
 
4.2.5 QUALITY OF LIFE 
Quality of life was assessed at baseline and 3 months using the SGRQ.  The mMRC 
scale was also used to obtain a subjective assessment of breathlessness at each visit. 
 
4.2.6 THE 6 MINUTE WALKING TEST 
A 6MWT using standard protocols was performed at both visits, and the distance 
walked recorded.  Pre- and post-exercise Borg scores for breathlessness and RPE 
were recorded, along with blood pressure, pulse, and blood oxygen saturation (using 
an infrared finger probe). 
 
4.2.7 EQUIPMENT USED AND PRE-PROCEDURE CALIBRATIONS 
4.2.7.1 Calibration balloon 
Balloon calibration occurred as described in section 3.3.8.1. 
 
4.2.7.2 Deployment catheter 
Valves were loaded into the end of a deployment catheter by a dedicated loading 
device.  The procedure for valve deployment was identical to that described in 
section 3.3.8.2.   
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4.2.7.3 Valves 
These have been described in sections 1.4.3.1 and 3.3.8.3, and shown in figure 1.4c.  
 
4.2.8 ARTERIAL BLOOD GASES 
Arterial blood gas tensions were measured at baseline and 3 months, via a radial 
arterial sample (Rapidlab 348, Bayer, Germany). 
 
4.2.9 BRONCHOSCOPIC PROCEDURES 
All patients undergoing complete unilateral lobar occlusion had participated in the 
trial described in chapter 3.  As such, all had bilateral IBV placement and required a 
limited procedure to effect complete occlusion of one of the previously treated 
lobes.  Pre-procedure scans were analysed by the clinical team within the MDT 
setting to determine which side it was thought would benefit most from further 
valve placement, based on the presence of intact fissures, degree of anatomical 
destruction, and degree of hyperinflation (see figure 4.1). 
 
Procedures were performed under conscious sedation using intravenous midazolam 
and alfentanyl, with oxygen delivered via a nasal cannula. Inspection of previously 
placed valves was made prior to further deployment, in order to ensure that there 
were no displaced or otherwise abnormal valves (for example crumpling of the latex 
membrane, preventing airway occlusion), and any such valves replaced.  The 
bronchoscope was then passed into the segment or subsegment previously left 
unoccluded, the airway measured, and 1 or more valves deployed to achieve 
complete lobar occlusion using the technique described in section 3.3.10.  Procedure 
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times were available for 10/16 procedures, and varied from 3 to 24 minutes (Mean 
11.1(6.8)).  Incorrect deployment of valves or delivery catheter failure resulting in 
the need for a valve to be removed did not occur in this series. 
 
Patients were observed for a minimum of 2 hours post procedure, and were 
discharged if a post-procedure x-ray did not reveal a pneumothorax.  A course of 
antibiotics and prednisolone (30mg od) were given after the procedure to reduce the 
risk of post-procedure COPD exacerbations.  
 
Figure 4.1 Decision tree for determining additional treatment lobe 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mediastinal 
reflection to R 
Treat side with 
greatest destruction 
Mediastinal 
reflection to L 
Treat side with intact 
fissure 
Treat L lung Treat R lung 
Parenchymal 
destruction R>L or L>R 
CT reviewed with 
Radiologist 
1 intact major 
fissure 
0 or 2 intact 
major fissures 
Parenchymal 
destruction R=L 
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Valve removal was offered to patients with persistent deteriorations in symptoms 
and lung function, or with any serious or chronic sequelae that, in the opinion of the 
clinical team, warranted removal of one or more of the valves. 
 
4.3 STATISTICAL ANALYSIS 
Values for measured parameters at 3 months and at baseline were compared using 
paired t-tests, except for mMRC scores, where the Mann-Whitney U test was used.   
 
4.4 RESULTS 
 
4.4.1 PRIMARY ENDPOINTS 
 
Of the 16 patients treated with additional valves to achieve lobar occlusion, 15 were 
available for follow-up at 3 months.  One subject died from advanced COPD, and no 
connection with valve placement was apparent.  Figure 4.2 shows the number of 
patients available at each stage of the process.   
 
Figure 4.2: Subjects available for assessment at each follow-up time point 
 
 
30 bilateral IBVs 
16 consents 
16 TREATMENTS 
15 subjects 
1 death 
14 no further action Enrolled 
3 months 
Eligible 
 129 
 
There was a non-significant increase in the FEV1 (+0.16L, +15.0%; p=0.24) and a 
marginal fall in the 6MWD (-5.4m, -0.7%; p=0.78) at 3 months post-procedure.   
 
If the patients with any degree of atelectasis at 3 months are analysed, there are 
greater (although still statistically insignificant) changes in both primary endpoints.  A 
17.4% increase in the FEV1 (p=0.23) and an 11.5% increase in the 6MWD (p=0.49) 
were seen, but when considering in isolation the 2 patients in this series in whom 
complete lobar atelectasis was achieved, these values rise to 45.6% (+0.29L) and 
33.6% (+71.0m) respectively.  Both of these changes represent clinically significant 
changes, although it is obviously difficult to draw firm conclusions from such a small 
dataset.  
 
Data presented as Mean(SD), except for mMRC where data are presented as 
Median(range), can be found in table 4.4a for all patients, 4.4b for those with any 
atelectasis, and 4.4c for those with complete lobar collapse. 
 
4.4.2 SECONDARY ENDPOINTS 
 
There were no significant changes in any secondary endpoint at 3 months.  There 
were effectively no changes at all in measures of lung volumes (FVC -0.6%; RV +0.2%; 
RV/TLC +0.52), and no change in the median mMRC score.  There was, however, a 
5.2 point rise in the mean SGRQ, a change that is clinically if not statistically 
significantly worse than at baseline. 
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As with the primary endpoints, lung volume values are seen to move in the direction 
of improvement in the group with atelectasis, with a mean 420ml fall in RV (p=0.11) 
and a 330ml increase in FVC (p=0.23), representing important clinical change.  There 
was still no change in the mMRC score, and the SGRQ continued to suggest a worse 
QoL (although no longer reaching clinical significance).  The 2 patients with complete 
atelectasis demonstrated marked falls in lung volumes, with an 830ml fall in RV, 
880ml rise in FVC, and a fall in the RV/TLC from 66.8% to 56.6%.  These patients also 
reported a clinically important improvement in the SGRQ.  
 
Table 4.4: Data from a) all patients; b) those with any atelectasis; c) complete lobar atelectasis 
 
a) Baseline 3 months 3m % 3m p value 
FEV1 0.83(0.38) 0.99(0.67) 0.16(0.49) 15.0(48.8) 0.24 
6MWT 287.7(70.1) 282.3(73.6) -5.4(69.0) -0.7(26.1) 0.78 
FVC 2.86(0.84) 2.82(0.85) -0.04(0.47) -0.6(20.7) 0.71 
RV 4.82(1.28) 4.87(1.36) 0.05(0.44) 1.2(9.8) 0.65 
RV/TLC 62.36(6.23) 62.88(5.83) 0.52(5.44) - 0.71 
SGRQ 53.3(17.1) 58.6(13.6) 5.2(17.5) - 0.27 
mMRC 2(2-3) 2(0-4) 0(-2-4) - 0.67 
 
b) Baseline 3 months 3m % 3m p value 
FEV1 0.68(0.09) 0.80(0.20) 0.12(0.18) 17.4(29.1) 0.23 
6MWT 258.6(58.6) 284.6(86.1) 26.0(73.2) 11.5(33.7) 0.47 
FVC 2.36(0.46) 2.69(0.57) 0.33(0.52) 15.7(25.9) 0.23 
RV 4.45(0.49) 4.03(0.42) -0.42(0.46) -8.9(10.2) 0.11 
RV/TLC 64.10(4.59) 59.60(4.40) -4.50(6.54) - 0.20 
SGRQ 63.1(4.8) 66.5(13.7) 3.4(15.7) - 0.65 
mMRC 2(2-2) 2(0-4) 0(-2-2) - 1.00 
 
c) Baseline 3 months 3m % 3m 
FEV1 0.65 0.94 0.29 45.6 
6MWT 206.5 277.5 71.0 33.6 
FVC 2.24 3.12 0.88 41.8 
RV 4.78 3.95 -0.83 -17.4 
RV/TLC 66.83 56.62 -10.21 - 
SGRQ 63.8 58.0 -5.8 - 
mMRC 2(2-2) 1(0-2) -1(-2-0) - 
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Figure 4.3: Graphical representations of changes in measured parameters at 3 months 
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Figure 4.4: Serial chest radiographs of a subject a) pre- b) post-bilateral incomplete and c) post 
complete unilateral occlusions 
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Figure 4.5: Axial CT image corresponding to figure 4.4c 
 
 
 
 
4.5 DISCUSSION 
 
The results presented here are largely in line with those in the VENT (Sciurba 2010), 
in that only small benefits were achieved in the group as a whole, but in those with 
atelectasis an enhanced response was seen.  Although the numbers are not large, 
there is certainly the impression from the graphical representations of the data that 
a progression in the degree of benefit is seen with increasing degrees of atelectasis. 
 
The 160ml, 15% change in FEV1 from 0.83L to 0.99L in our patients probably 
represents a clinically important change (Donohue 2005), and compares favourably 
to results from the VENT (a 4.3% mean increase (Sciurba 2010)).  However, numbers 
here are small and hence do not achieve statistical significance.  The 6MWD did not 
change, and this is in line with the lack of change in the RV/TLC ratio (62.4% at 
baseline to 62.9% at 3 months), a marker of hyperinflation.  Hyperinflation plays a 
Collapsed LUL with 
mediastinal shift 
 
IBVs in situ 
 133 
dominant role in exercise limitation (O’Donnell 1993), and therefore it is not entirely 
unexpected that a change in FEV1 alone might not cause a change in exercise 
capacity. 
 
Some degree of atelectasis was seen in 33% (5/15) of our subjects, a number similar 
to the 26.3% (5/19) seen in the original patients of Hopkinson and co-workers 
(Hopkinson 2011).  In 2 patients (13.3%), sustained complete lobar atelectasis was 
achieved, something that was not seen in many early studies (Snell 2003; Toma 
2003; Yim 2004; de Olivera 2006), but has become the holy grail of endobronchial 
valve treatment. 
 
We did not specifically divide data into those with and those without a complete 
fissure, rather into those with and without a degree of atelectasis after complete 
lobar occlusion.  The reason for this was to show that it seems to be the 
achievement of atelectasis that predicts good outcomes, rather than to highlight the 
mechanism behind that good response, as the technique used in chapter 3 was 
designed specifically to avoid atelectasis (the likely reason for the poor results). 
 
There is now enough evidence in the literature to conclude that achieving atelectasis 
with endobronchial valve treatment leads to better outcomes (Toma 2003; Yim 
2004; de Olivera 2006; Hopkinson 2011; Sciurba 2010).  This can only realistically be 
achieved with complete lobar occlusion, but even then not all treatments result in 
significant atelectasis.  Being able to predict those patients who will develop 
significant atelectasis will allow targeting of this expensive and potentially hazardous 
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treatment at those who have the most to gain, and much work is on-going looking 
into strategies to achieve this.  Correct valve placement is essential to ensure that all 
airways within a treated lobe are distal to any implanted valves, but collateral 
ventilation is clearly also of paramount importance.  Collateral ventilation can either 
be measured directly, or be inferred from surrogate markers.   
 
Direct measurement was until recently a time consuming and awkward process, 
requiring the detection of inhaled helium within an adjacent lobe isolated using a 
bronchial occlusion catheter (Morrell 1994), or imaging techniques such as 
hyperpolarised helium magnetic resonance imaging (Marshall 2012).  The CHARTIS® 
system (Pulmonx Corporation, Redwood, CA) provides a more straight forward 
method of directly assessing collateral ventilation, and is discussed in detail below.  
Some idea of the degree of interlobar collateral ventilation can be gained from the 
CT appearances of the interlobar fissure, with a greater degree of continuity and 
completeness of the fissure indicating a lower likelihood of translobar ventilation.  In 
the VENT (Sciurba 2010), those with a complete fissure on CT had a greater FEV1 
response to treatment relative to the control group at 6 months than the treatment 
group as a whole (16.2% vs 2.0%), and also achieved greater volume loss in the 
targeted lobe (712.5mls vs 378.4mls).  Nonetheless, this is an imperfect method of 
collateral ventilation assessment, and we know that communications exist between 
lobes even in healthy lungs when there are apparent complete fissures (Higuchi 
2006).  An MRC trial is currently recruiting to determine whether completeness of 
the interlobar fissure is an adequate marker of lobar exclusion to permit valve 
deployment without further collateral ventilation measurements. 
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A simple catheter based system has been developed which measures airway 
pressures and flows within lobar airways, calculating airway resistance in vivo to 
derive a measure of collateral ventilation (Aljuri 2009), and is now commercially 
available as the CHARTIS® system (figure 4.6).  A graphical display on the CHARTIS 
monitor allows the operator to determine if collateral ventilation exists in significant 
amounts (figure 4.7).  This method aids in endobronchial valve treatment planning, 
and predicts response in 90% of analysable cases (Gomplemann 2010; Vortuba 
2011).  Those with low collateral ventilation (so-called CV- patients) achieve 
significant changes in lung function, symptom scores, and exercise tolerance when 
compared to those with substantial collateral ventilation, or CV+ patients 
(Gomplemann 2011). 
 
Figure 4.6: The CHARTIS system for measuring collateral ventilation 
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Figure 4.7: CHARTIS graphical display: fall in flow rate to zero indicating no collateral ventilation 
 
 
 
Further studies specifically looking at the use of collateral ventilation measures are 
ongoing to determine the best planning strategy for endobronchial valve insertion, 
as it now seems certain that atelectasis should be the goal of treatment. 
 
One weakness of this small follow-on study was the lack of a control group with 
which to compare outcome data.  Further treatments attempting to achieve 
atelectasis in these patients were deemed appropriate on clinical grounds after 
discussion in the COPD MDT at the Royal Brompton Hospital, and as such all data 
represents clinical follow-up data.  Exclusion criteria were specifically those things 
that would make the procedures unsafe or unwise in a clinical setting (or situations 
in which a more appropriate clinical course was apparent, such as a potentially 
malignant lung nodule).  A number of subjects had elected to have their valves 
removed or undergo formal lung volume reduction surgery, and in fact only 8 
subjects kept their valves and did not progress to further treatments.  Subjects 
recruited for the bilateral intrabronchial valve trial were referred from around the 
country, including subjects from Scotland, and as such were not under routine clinic 
follow-up at our institute.  These two factors made the collection of useful quantities 
of robust follow-up data impossible.  That the magnitude of changes in outcomes 
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mirrored changes seen on cross-sectional imaging suggests that benefits 
documented in these patients were real changes rather than placebo effect, 
although this cannot, from the data presented here, be proven. 
 
4.6 CONCLUSION 
 
The clinical data presented here suggest that patients with lobar atelectasis achieve 
greater benefits from IBV treatment than those with partial atelectasis, who in turn 
do better than those without radiological response, although small numbers prevent 
definitive statistical proof.  Nonetheless, the findings are in line with other studies 
showing maximal benefit in this group of patients, and the aim of endobronchial 
valve treatment should be lobar atelectasis.  There appears to be no value in staging 
treatment with incomplete occlusions in the first instance, and suitable patients 
should be put forward for unilateral complete occlusion at the outset.  The challenge 
now is to find a simple, cost efficient way to predict treatment response. 
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CHAPTER  5::   THE  ROLE  OF  ENDOBRONCHIIAL  VALVES  IIN  
PATIIENTS  WIITH  LUNG  TRANSPLANTATIION    
 
Native lung hyperinflation (NLH) is a unique condition seen in emphysema patients 
following single lung transplant (SLT), and results in impaired graft function.  One 
proposed mechanism of action is that the reduced elastic recoil of the native lung 
together with the difference in compliance between the native and donor lungs 
creates progressive hyper-expansion of the native lung and compression of the 
donor lung, at the expense of donor lung function.  Resulting falls in forced vital 
capacity and the forced expiratory volume in one second, together with a rise in 
residual volume, lead to reduced exercise tolerance, increased breathlessness, and 
potential reductions in quality of life.  Dynamic hyperinflation of the native lung on 
exercise further impairs exercise tolerance. 
 
NLH has been treated with surgical lung volume reduction (LVRS), with 
improvements in both symptoms and physiological measures (Anderson 1997).  
Surgery does, however, bring with it the risks of major morbidity and even mortality.  
The risk of infection during or after surgery is increased in those who are heavily 
immunosuppressed, and some anti-rejection medication seriously impairs wound 
healing.  Endobronchial valves provide an opportunity for lung volume reduction 
without the need for major surgery (Toma 2003; Sciurba 2010). 
 
Endobronchial valves therefore seem an extremely attractive treatment option in 
these patients.  The literature on endobronchial valve use in NLH is restricted to a 
single case report in acute NLH in the immediate post-operative period by Crespo 
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and colleagues from the University of Pittsburgh (Crespo 2007).  This patient was 
ventilator dependent owing to native hyperinflation compressing the transplanted 
lung.  The risk of LVRS was deemed excessive, and therefore valves were placed in all 
segments of the native lung.  The resulting atelectasis of the native lung allowed 
volume expansion of the allograft, and the subsequent improvement in pulmonary 
mechanics allowed the withdrawal of invasive ventilation.   
 
To date there are no published data on the use of endobronchial valves in chronic 
NLH.  Here we report retrospectively gathered data from four patients in whom we 
have used this technique on a compassionate basis. 
 
5.1 METHODS 
 
Patients are under long-term follow-up in our lung transplant clinics having 
undergone SLTs, one left and three right.  Three of these were for emphysema, 
whilst one patient had a primary diagnosis of lymphangioleiomyomatosis (LAM). All 
patients had a slowly progressive decline in lung function prior to valve insertion, 
and reasons for decreasing spirometric values other than NLH were ruled out by high 
resolution CT scanning, transbronchial biopsies, and bronchial lavage for 
microbiological analysis.  Under conscious sedation, Zephyr® valves (Pulmonx, USA) 
were inserted via a flexible bronchoscope to fully occlude the target lobe(s). 
Procedures were undertaken as day-cases, without complications, and patients were 
followed-up in the out-patient setting, with interval measurements of FEV1 and FVC 
as per standard protocols.  Interval scans, where available, were assessed for volume 
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loss in the target lobes.  Although formal testing was not undertaken in all patients, 
verbal reports of exercise tolerance were given during consultations. Each patient is 
discussed individually below, in chronological order, and all data is shown in tables 
5.1-5.5. 
 
5.1.1 PATIENT 1 
A female who underwent right SLT for LAM at 46 years of age.  The post-operative 
period was complicated by chylous effusions secondary to a torn thoracic duct and 
she underwent a bilateral talc pleurodesis.  Her lung function peaked 5 months later 
(FEV1 1.66L, FVC 2.84L), and she was able to take part in ‘strenuous outdoor hiking’, 
but there was a subsequent gradual and relentless decline in lung function.  On 
review 18 months post-transplant, a CT scan showed extensive pleural thickening 
around the transplant causing a restrictive defect.  She was deemed inappropriate 
for LVRS as it was felt she was unlikely to get any transplant lung expansion.  By this 
stage, her exercise tolerance was ‘a few minutes’, and DHI on exercise was 
demonstrated.  By then her FEV1/FVC had fallen to 1.20L/2.08L, and a decision to use 
endobronchial valves was made in a final attempt at palliation.  Three valves were 
placed to occlude the left upper lobe and lingula. The patient never experienced any 
subjective change in breathlessness, consistent with her post-valve spirometry.  At 
one month the FEV1 and FVC had risen by 9.2% and 3.4% respectively. By three 
months, however, the FEV1 had returned to baseline and the FVC was measured at 
only 91.2% of baseline.  This loss of lung function had progressed by the 6 month 
follow-up, with only 81.7% and 73.6% of baseline FEV1 and FVC respectively 
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remaining. Exercise tolerance and lung function have continued to slowly decline 
since. 
 
Figure 5.1: Changes in FEV1 and FVC for patient 1 
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5.1.2 PATIENT 2 
A female given a left SLT at the age of 63 years for severe emphysema.  Other than 
CMV infection in the first year post-transplant, she remained free of infections and 
rejection episodes, but nonetheless experienced a steady decline in graft function 
from two and a half years post-transplant.  Three years later she was back on long-
term oxygen therapy (LTOT), and CT scanning revealed compression of the graft by 
right lung hyperinflation.  A decision to attempt bronchoscopic lung volume 
reduction (BLVR) was made later that year, and three valves were used to achieve 
complete occlusion of the right lower lobe.   Rises of 16.7% in FEV1 and 21.9% in FVC 
from baseline were seen at first follow-up, with these gains largely sustained out to 
32 months (16.7% and 18.8% respectively).  Along with these improvements, the 6 
minute walking distance rose by 50% from 180 metres to 270 metres (although this 
had fallen to 230 metres at 32 months), and the modified MRC dyspnoea score fell 
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from 5/5 at baseline to 4/5 at one month, and then further to 3/5 at 3 months where 
it has remained.   
 
Figure 5.2: Changes in FEV1 and FVC for patient 2. 
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5.1.3 PATIENT 3 
A female given a right SLT at 59 years of age for severe homogenous emphysema.  
Her post-operative course was complicated by recurrent pneumothoraces, but these 
resolved with intercostal tube drainage without the need for pleurodesis.  Her lung 
function peaked at 5½ months post-operatively with a FEV1/FVC of 1.65L/2.64L, and 
remained stable for the next 18 months, when a steady decline in lung function over 
several years began without evidence of infection or rejection.  This was associated 
with progressive breathlessness to the point where she was unable to lie down in the 
bath, and exercise tolerance was impaired such that she could not carry shopping.  A 
referral was made to the Thoracic Surgeons for LVRS, but she declined this after a 
discussion of the risks involved.  Therefore BLVR was performed 7½ years after 
transplantation, with 2 valves inserted to completely occlude the left upper lobe and 
lingula.  Oxygen saturations on air rose from 96% to 99% on the day of the 
procedure, with gains of 7.3% and 3.8% in FEV1 and FVC respectively at one month.  
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Spirometry continued to show additional improvements at each visit, with 16.4% and 
25.3% gains in FEV1 and FVC respectively by 6 months of follow-up.  Over this time, 
she went from using a stair-lift to regular participation in aerobics and ‘aquafit’ 
classes.  Figure 5.5 shows slices from both a pre-procedure CT scan and a repeat scan 
at 7 months in patient 3, and clearly demonstrates the presence of partial collapse 
and volume loss in the left upper lobe, consistent with successful valve placement.  
By one year, her exercise tolerance remained stable at 30 minutes on the flat, but 
she was using her stair lift owing to pain in the hips.  Interestingly, her exercise 
capacity was maintained in spite of falls in both FEV1 and FVC back to baseline values 
(both 102.7% of baseline).  Similar values for the FEV1 were obtained at 18 and 20 
months (103.6% and 100%). However, there was a subsequent gradual slide in the 
FVC, falling to 97.6% then 93.4% of baseline, although still without any subjective 
deterioration in exercise capacity or breathlessness, although a CT scan at this time 
showed moderate patchy air trapping consistent with obliterative bronchiolitis (OB) 
in the transplanted lung.  
 
Figure 5.3: Changes in FEV1 and FVC for patient 3 
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5.1.4 PATIENT 4 
A 63 year old male with severe emphysema and bilateral upper lobe bullous disease.  
Prior to transplantation, he had suffered a pneumothorax requiring intercostal tube 
drainage and transfer to the Intensive Care Unit, but not pleurodesis.  He underwent 
right SLT without complication, with improvement in lung function over the first 6 
months of the post-operative period, at which time his FEV1/FVC was 2.06L/3.40L.  
Over the next 18 months there was a progressive deterioration in function, resulting 
in NYHA class III breathlessness and spirometry of 1.47L/3.11L.  LVRS to the native 
lung (LUL) was performed via full thoracotomy with excellent results, with a 
subsequent rise in FEV1/FVC to 2.15L/3.55L with NYHA class I breathlessness.  
Unfortunately, all benefit was lost at 1 year (lung function and symptoms), and redo 
LVRS was discounted owing to the patient’s weight and adhesions from the previous 
thoracotomy.   BLVR was performed 3 years and 3 months after transplantation (1 
year and 2 months following LVRS), and total occlusion of the lingula and remainder 
of the LUL was achieved with 3 valves, with improvements in spirometry at eight 
weeks (FEV1 up 11.5%, FVC up 11.7%).  Although he was symptomatically less 
breathless, his self-reported exercise tolerance was largely unchanged owing to a 
lower respiratory tract infection and recent brachytherapy for carcinoma of the 
prostate.  Subsequently, his spirometry has fluctuated considerably, although the 
dips at 5 and 18 months co-incided with respiratory tract infections.  A repeat CT 
scan 6 weeks post-BLVR revealed a faint background mosaic attenuation pattern in 
the transplanted lung on expiratory phase images which had not been present 1 year 
previously, again suggesting the onset of air trapping, and this is likely to have 
contributed to what appears nonetheless to be a trend towards gradual decline. 
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Figure 5.4: Changes in FEV1 and FVC for patient 4 
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Table 5.1: Patient Demographics 
  1 2 3 4 
Sex Female Female Male Female 
Age at transplantation (yrs) 46 63 63 59 
Underlying Disease LAM* Emphysema Emphysema Emphysema 
Side transplanted Right Left Right Right 
Time from SLT to EBVs 18 months 73 months 39 months 90 months 
Treated lobe LUL + lingula RLL LUL + lingula LUL + lingula 
 
* lymphangioleiomyomatosis    
 
Table 5.2: Baseline and follow-up FEV1 
  1 2 3 4 
FEV1 1 month 9.2 16.7 11.5 7.3 
FEV1 3 months 0.0 15.0 - 9.1 
FEV1 6 months -18.3 20.0 0.0 16.4** 
FEV1 12 months -19.2 - 9.0 2.7 
FEV1 long-term -22.5 16.7 -0.6 3.6 
 
** 9 months   
- not recorded 
 
Table 5.3: Baseline and follow-up FVC 
  1 2 3 4 
FVC 1 month 3.4 21.9 11.7 3.8 
FVC 3 months -8.7 2.7 - 18.1 
FVC 6 months -26.4 23.1 -12.3 25.3** 
FVC 12 months -26.4 - 6.0 2.7 
FVC long-term -36.7 18.8 -14.7 -2.2 
 
** 9 months   
- not recorded 
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Table 5.4: Baseline and follow-up dyspnoea data 
  1 2 3 4 
Breathlessness baseline MRC 3/5 MRC 5/5 MRC 4/5 'Can't lie flat' 
Breathlessness 1 month MRC 3/5 MRC 4/5 MRC 3/5 Climbing stairs 
Breathlessness 3 months MRC 3/5 MRC 3/5 - - 
Breathlessness 6 months MRC 4/5 MRC 3/5 MRC 4/5 Sustained 
Breathlessness 12 months MRC 4/5 - MRC 4/5 Sustained 
Breathlessness long-term MRC 4/5 MRC 3/5 MRC 4/5 Sustained 
 
- not recorded 
 
Table 5.5: Baseline and follow-up exercise data 
  1 2 3 4 
Exercise tolerance baseline Few mins on flat 6MWD 180m - Stairlift 
Exercise tolerance 1 month Unchanged 6MWD 270m - Climbing stairs 
Exercise tolerance 3months - - 'No better' - 
Exercise tolerance 6 months Declining - 'No better' Aquafit classes 
Exercise tolerance 12 months Declining - 'No better' 30mins on flat 
Exercise tolerance long-term Declining 6MWD 230m - 30mins on flat 
 
- not recorded 
6MWD – 6 minute walking distance 
 
5.2 DISCUSSION 
 
Finding a method for palliating the symptoms of native lung hyperinflation without 
recourse to surgery should not only reduce peri-procedure morbidity and mortality, 
but could also provide cost benefits.  The cost of surgical lung volume reduction and 
subsequent in-patient care is estimated at £7,700, with an additional £331 for each 
in-patient day beyond 41 days (Department of Health 2008).  This is similar to the 
cost of bronchoscopic valve insertion, with costs of around £1500-£2000 per valve 
inserted, although BLVR has the advantage that it can be performed as a day case 
procedure using local anaesthetic and light sedation, and with reduced morbidity.  
The results in patients 2 to 4 suggest that lung function benefits comparable to those 
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seen with surgical LVR can be achieved in selected patients, although there are 
clearly factors as yet unidentified which influence the chances of initial and on-going 
success.  Unfortunately, BLVR was not a success in patient 1.  The small increases in 
FEV1 (9.2%) and FVC (3.4%) seen at 1 month were within the accepted variability of 
these tests, with a return to progressive loss of lung function after one month.   
 
A technique to determine the relative contributions of NLH and OB to deteriorations 
in lung function following SLT for COPD has been demonstrated by Moore and 
colleagues (Moore 2009).  This required the patient to undergo general anaesthetic 
with intubation and mechanical ventilation using a double lumen tube, and 
measurements of individual lung inspiratory airflow resistance were made.  They 
were able to determine that 6 of 8 patients suspected of having developed 
significant OB in fact had extrinsic compression of the transplanted lung by NLH as 
the cause of their deteriorating lung function, with the other 2 having a combination 
of NLH and OB.  The presence of significant OB in the transplanted lung is highly 
likely to attenuate any benefit from procedures designed to reduce hyperinflation in 
the remaining COPD lung, and it would have been very useful in the cases presented 
here to have had measurements of individual lung airflow resistances.  The test 
described by Moore is not routinely available in clinical practice, and the 
retrospective, clinical, nature of this report means that it is not possible to gather the 
necessary information. 
 
There has been renewed interest in the concept of collateral ventilation since the 
advent of bronchoscopic LVR.  Results from the Endobronchial Valve for Emphysema 
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Palliation Trial (VENT) suggest that those with an incomplete fissure on the side of 
valve placement, as measured by high resolution CT scanning, had an attenuated 
response to therapy (Sciurba 2010).  It is impossible to say whether collateral 
ventilation played a role in the varying fortunes of our patients, but what soft CT 
evidence we do have supports the VENT findings. Owing to a lack of contiguous thin 
slice HRCT images, comprehensive radiological assessment of fissural integrity in the 
native lung was not possible, however, it is interesting to note that the major fissure 
was difficult to identify with any certainty in patient 1, providing a suggestion that 
there may have been a greater degree of collateral ventilation in the native lung at 
the time of valve insertion than in the other patients.  This is backed up to some 
extent by the finding of partial left upper lobe collapse 7 months post-procedure in 
patient 3 (figure 5.5), in whom the oblique fissure was easy to identify on CT imaging 
and is clearly seen to have moved after treatment. The development of significant 
pleural disease around the transplanted lung in patient 1 is likely to have been 
another confounding factor in the lack of success in this patient. 
 
 
One could argue that collateral ventilation is less of a concern in this group of 
patients than in those with 2 emphysematous native lungs.  If inter-lobar collateral 
ventilation is known to exist, then it is possible to occlude all segments of all lobes in 
the non-transplant lung (as in the Crespo case) without adversely affecting gas 
exchange.  Hypoxic vasoconstriction would potentially redirect pulmonary blood 
flow to the transplant lung, restoring V/Q matching.  This is not an option in those 
with 2 emphysematous lungs, as it is unlikely that the untreated lung alone would be 
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able to provide adequate gas exchange.  Whether the previous pleurodeses in 
patient 1 prevented volume changes in either or both lungs is uncertain (although 
this was predicted pre-procedure), but could well have been an important factor in 
the lack of response to valve insertion.   
 
Patient 3 demonstrated progressive improvements in FEV1 and FVC at each 
appointment up to and including 9 months post-procedure.  At her 12 month follow-
up, however, there was a sudden and unexpected fall in values back to baseline, this 
decline being slowly progressive out to her 20 month follow-up.   At neither of these 
was there any apparent infection or other reason for decline, and interestingly the 
patient’s self reported (and hence subjective) exercise tolerance and degree of 
breathlessness were unchanged.  The OB on the most recent CT scan would account 
for this deterioration in spirometry, and indeed may also account for the loss of 
benefit in patient 4 (albeit much sooner after BLVR).  This fall in lung function does 
not reflect the role of endobronchial valves in reducing DHI on exercise (Hopkinson 
2005), and it may be this effect that has maintained the benefits in exercise 
tolerance and breathlessness in this case. 
 
Figure 5.5: Pre- and post-treatment CT images for patient 3 with arrow indicating oblique fissure 
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5.3 CONCLUSION 
 
The retrospective nature of this data means that some desirable, objective, 
measurements were not possible in all the patients, including formal assessments of 
exercise tolerance and quality of life, changes in static lung volumes (the primary 
measure of graft function in our transplant patients is the FEV1), and CT measured 
lobar volumes.  An assessment of the relative contributions of NLH and OB would 
also have been useful, but this was not performed in any of the patients reported 
here.  Nonetheless, the impressive increases in spirometric values seen, at least 
initially, in patients 2 to 4 testify to the potential of this technique in appropriately 
selected patients, and the challenge now is to determine how best to identify them. 
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CHAPTER  6::   AUTOLOGOUS  BLOOD  LUNG  VOLUME  
REDUCTIION  
 
Current bronchoscopic LVR technology requires the deposition of implants in the 
airways, or of the use of biological gels and sclerosants to effect the desired volume 
reduction.  These techniques have the disadvantage of leaving foreign material in the 
patients’ lungs, with the risk of infection, implant migration, and device failure, and 
treatment for a single patient can cost many thousands of pounds.  One novel 
approach that has been put forward is the use of autologous blood to achieve 
volume reduction.  A recent case report showed significant reductions in static lung 
volumes and dyspnoea in a 59 year old man with emphysema in the right upper lobe 
with infusion of blood and fibrinogen into a large bulla (Kanoh 2008).  This group has 
also published encouraging results in patients with lymphangioleiomyomatosis and 
advanced emphysema (Kanoh 2009; Kobayashi 2009).  A further open label series of 
12 patients presented at the World Bronchology Conference, Tokyo 2008, reported 
improvements in lung function with no significant complications (unpublished data, 
Soichiro Kanoh).  
 
One other significant and important advantage that this technique is likely to have 
over endobronchial valves is the circumventing of problems with device failure 
secondary to collateral ventilation.  The fibrosis and contraction of the upper lobe 
expected to occur with blood LVR will be irreversible, and re-expansion will not occur 
even in the presence of collateral channels.  One unanswered question with this 
technique, however, is how much of its action can be attributed to the blood 
component of the mixture. The published biologic LVR data (see section 1.4.3.3.1) 
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suggests that fibrinogen solutions can induce changes on cross-sectional imaging in 
keeping with volume loss.  Whole autologous blood itself will contain clotting 
products, and blood is an airway irritant, so if it can be shown that blood alone can 
induce beneficial changes in lung volumes then the potential cost savings would be 
huge.    
 
This trial was designed as a pilot study, run in a randomised, double blind, placebo 
controlled fashion where the response in patients treated with blood LVR would be 
compared to patients treated with a sham procedure (control group). Blinded 
analysis of scarring by a senior Radiologist with experience in cross-sectional thoracic 
imaging was undertaken to determine whether any anatomical changes had 
occurred between baseline and follow-up CTs in the two study arms based on 
subjects’ blinded bronchoscopic intervention. 
 
6.1 ENDPOINTS 
 
Primary Endpoint 
1. Evidence of new scarring in target lobe on 6 week post-procedure CT scan 
 
Secondary Endpoints 
1. To ensure no significant deteriorations in lung function (FEV1, RV/TLC, TLco) 
at 6 weeks post-procedure 
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2. To ensure no significant deteriorations in arterial blood gas tensions at 6 
weeks post-procedure  
3. To assess changes in exercise capacity at 6 weeks post-procedure 
4. To assess changes in the SGRQ between subject groups 
5. To assess changes in the modified MRC dyspnoea score 
 
6.2 METHODS 
 
6.2.1 PATIENT SELECTION CRITERIA 
Patients were recruited from the Respiratory clinics at the Royal Brompton Hospital 
and the Chelsea and Westminster Hospital, after discussion in an appropriate 
multidisciplinary meeting. The trial recruited patients with severe airflow 
obstruction, significant hyperinflation (and hence the potential to benefit from a 
reduction in lobar volumes), and limiting breathlessness, without any clinical 
features which would present an unacceptable risk during the procedure.  There was 
no requirement for smoking cessation in this study, as it was felt that any smoking-
related deterioration would be insignificant over the 6 week course of the trial.  
Inclusion and exclusion criteria are detailed in tables 6.1 and 6.2. 
 
Table 6.1: Inclusion criteria 
 
 
 
 
 
 
 
 
Inclusion Criteria 
 Age 18-80 years 
 Severe airflow obstruction FEV1 <50% Predicted 
 Severe dyspnoea – mMRC  ≥2 
 Hyperinflation – TLC ≥100% predicted, RV  ≥150% predicted 
 Optimum COPD treatment for at least 6 weeks 
 No COPD exacerbation for at least 30 days 
 Fewer than 3 admissions for exacerbation in the preceding 12 months 
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Table 6.2: Exclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.2 BLINDING 
Following the signing of the informed consent form and initial assessments, subjects 
were randomised to either the blood LVR arm or the sham arm.  This was done by 
the selection of a sealed envelope immediately prior to bronchoscopy, in the 
absence of the patient, and by a member of staff who was not part of the study 
team.  The blood and saline mixtures were referred to as ‘the study solution’ at all 
times to prevent unblinding, and syringes were covered with strapping tape to 
prevent the patient from seeing the solution at the time of injection. Documentation 
of the procedure did not specify which solution was administered, except in the 
subject’s study file. 
 
All 6 week assessments were performed by persons blinded as to which arm of the 
study a subject was in.  Lung function department staff and radiographers had no 
knowledge of which solution was administered, questionnaires were self-completed, 
and the history and examination were performed by a blinded member of the 
research team. 
Exclusion Criteria 
 Patient unable to provide informed consent 
 TLCO <15% predicted and FEV1 <15% predicted 
 pO2 on air <6.0kPa or pCO2 on air >8.0kPa 
 Other major medical illness that will limit participation 
 Clinically significant bronchiectasis 
 Large bulla more than 1/3 of hemithorax volume on CT scan 
 Maintenance oral steroids greater than 10mg prednisolone a day 
 Prior LVRS or lobectomy 
 Lung nodule requiring surgery 
 Female of childbearing age with positive pregnancy test 
 Participated in a study of investigational drug or device in prior 30 days 
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6.2.3 TESTING SCHEDULE 
All consented patients underwent baseline testing to assess eligibility and to provide 
values against which testing at 6 weeks post-procedure could be compared. 
Assessment at 6 weeks was undertaken by a blinded assessment team as detailed in 
section 6.2.2 in order to remove expectation and subjectivity from the assessment.  
Table 6.3 outlines the schedule of events for this study. 
 
Table 6.3: Event schedule for the autologous blood LVR trial 
 Baseline 6 weeks 
Clinical History X X 
Examination X X 
Full Lung Function X X 
Dyspnoea Score X X 
SGRQ  X X 
HRCT scan X X 
6MWT X X 
Arterial Blood Gas X X 
Bronchoscopy X  
Unblinding  X 
 
Subjects were made aware that the process is expected to be irreversible.  Any 
problems during the bronchoscopy (for example worsening hypoxia) would have 
prompted the procedure to have been abandoned as soon as it was safe to do so, 
although this did not occur in any of our trial subjects.  A log of adverse and serious 
adverse events for each patient was kept as part of the safety monitoring of the trial. 
 
6.2.4 PULMONARY FUNCTION TESTING 
Full pulmonary function testing including static and dynamic lung volumes and gas 
transfer measurements were performed at baseline and again at 6 weeks using a 
Compact Master Lab system (Jaeger, Germany). 
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6.2.5 RADIOLOGICAL ASSESSMENTS 
High resolution volume scans of the chest were performed before the procedure and 
again at 6 weeks.  All scans were reconstructed to provide 1mm thick slices for in- 
depth analysis.  Scans were directly compared by an experienced Radiologist blinded 
to the study procedure to assess for the presence of new scarring in the treated 
lobes. 
 
6.2.6 QUALITY OF LIFE 
Quality of life was assessed at baseline using the SGRQ, and re-assessed for changes 
at the 6 week follow-up visit.  A clinically important change is defined as a 4 points or 
greater fall in the SGRQ score from baseline to 6 weeks.  The mMRC scale was also 
used to get a subjective assessment of breathlessness at each visit. 
 
6.2.7 THE 6 MINUTE WALKING TEST 
A 6MWT using standard protocols (ATS 2002) was performed along a 30m corridor at 
the baseline and 6 weeks post-procedure visits, and the distance walked recorded.  
Pre- and post-exercise Borg scores for breathlessness and RPE were recorded, along 
with blood pressure, pulse, and blood oxygen saturation (using an infrared finger 
probe). 
 
6.2.8 ARTERIAL BLOOD GASES 
Arterial blood gas tensions were measured at baseline and again at the 6 weeks 
follow-up visit, via a radial arterial sample (Rapidlab 348, Bayer, Germany). 
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6.2.9 BRONCHOSCOPIC PROCEDURES 
Procedures in all patients were carried out under conscious sedation using 
intravenous midazolam and alfentanyl. After bronchoscopic examination of the 
airways, an endoscopic retrograde cholangiopancreatography (ERCP) balloon 
catheter (ExtractorTM RX, Boston Scientific) was inserted into a target sub-segment, 
and the balloon inflated. Fifty millilitres of blood were taken from the patient’s arm 
via an intravenous cannula using a masked syringe, and taken out of sight of the 
patient.  The randomised treatment solution – either autologous blood or 0.9% 
saline – was then injected into the airways via the central lumen of the catheter.  The 
balloon remained inflated for 2 minutes after instillation of the treatment solution in 
order to minimise the risk of overspill into other areas of the lung. The balloon 
catheter was then repositioned in the next sub-segment of the target lobe of the 
lung and the process repeated until 3 subsegments had been treated. 
 
Both the treatment and placebo arms involved an identical protocol, except that in 
the placebo arm injections of 50mls of 0.9% saline replaced the injections of blood.   
After each sham procedure, 2-3mls of blood were injected into the trachea via the 
extended working channel to ensure that patients from both arms of the trial had 
the potential for post-procedure haemoptysis.  The rest of the blood retrieved during 
the procedure was discarded in accordance with infection control policies.  
 
ERCP balloon catheters are extremely long (200cm) with a narrow central lumen 
(0.89mm), and as such the resistance to flow of both blood and 0.9% saline was very 
high, resulting in an injection time of up to 3 minutes per sub-segment, and then 
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only if considerable force was used to depress the syringe plunger.  After 7 
procedures (3 treatments, 4 shams), the method for solution instillation was 
simplified.  A simple extended working channel was inserted 4cm beyond the origin 
of the bronchial segment and the solution injected without airway occlusion.  The 
reduced length (105cm) and wider internal diameter (2.55mm) meant that 
resistance to flow was 122.8 times lower, and instillation times fell to around 5 
seconds for both blood and 0.9% saline, and neither solution was seen to reflux from 
the airways during the procedure.   
 
Figure 6.1: Bronchoscope a) with ERCP balloon catheter inserted through working channel and 
inflated and b) with extended working channel 
 
 
 
6.2.10 STATISTICAL ANALYSIS 
This is a pilot study, with the intention of using data to estimate sample sizes for a 
larger, definitive, trial.  For the primary endpoint, we conducted a responder 
analysis, with those shown to have radiological volume loss defined as ‘responders’.   
Secondary endpoints are analysed using t-tests of changes between groups. 
B A 
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6.3 RESULTS 
 
6.3.1 BASELINE DATA 
Of the 10 subjects enrolled, 5 were randomized to the procedure arm and 5 to the 
sham arm of the trial.  Baseline data are represented in table 6.4, with values 
presented as Mean (SD).  All p values are for unpaired t-tests except for sex, for 
which the chi squared test was used. 
 
Table 6.4: Baseline data 
 Treatment Sham p value 
Number 5 5 - 
Male 4 5 0.29 
Age (y) 64.9 (4.0) 68.0 (6.9) 0.41 
BMI 24.2 (4.9) 22.1 (5.3) 0.54 
FEV1 % predicted 26.7 (6.2) 23.7 (10.0) 0.59 
FVC % predicted 81.0 (8.7) 68.6 (16.9) 0.18 
RV % predicted 237.4 (31.3) 228.7 (55.8) 0.77 
RV/TLC 65.15 (5.52) 66.68 (10.65) 0.78 
TLco % predicted 31.9 (16.4) 26.0 (6.8) 0.48 
mMRC 2.60 (0.55) 2.80 (0.45) 0.54 
SGRQ 51.04 (13.67) 60.31 (8.87) 0.24 
6MWD (m) 268.8 (90.8) 205.2 (67.9) 0.25 
Procedure time (min) 25.2 (4.4) 24.6 (7.5) 0.88 
 
There were no differences in the treatment areas between arms, with the left upper 
lobe treated in 3 patients in each arm, and the right upper lobe in 2.  
 
6.3.2 PRIMARY ENDPOINT 
There were no drop-outs, and no patients were unblinded prior to the completion of 
all their assessments over the course of the study.  Figure 6.2 shows the flow of 
 160 
subjects through the trial.  Full data sets at baseline and 6 weeks post-procedure 
were available for all patients. 
 
Figure 6.2: Subjects available for assessment at each follow-up time point 
 
 
Using an intention to treat analysis, 0/5 (0%) procedures and 0/5 (0%) shams met the 
‘responder’ criteria.  One new inflammatory lesion was seen in the left lower lobe of 
a sham patient, but otherwise the radiologist was unable to identify any changes 
indicative of a treatment response.  The null hypothesis is therefore accepted. 
 
6.3.3 SECONDARY ENDPOINTS 
Paired t-tests were performed on data at the 6 week visit against baseline data 
within both groups, with unpaired t-tests performed on the difference in changes 
between the two groups.  Two-tailed tests were used for all paired t-tests, and for 
the unpaired t-tests on the endpoints of 6MWT, SGRQ, and mMRC.  As we were 
specifically looking for deterioration (or lack thereof) in lung function parameters 
and arterial gas tensions between groups at 6 weeks, one-tailed unpaired t-tests 
12 screenings 
10 randomisations 
2 failed screenings 
5 TREATMENTS 5 SHAMS 
5 subjects 5 subjects 
 
 
  
Procedure 
6 weeks 
 161 
were used for inter-group analysis of these endpoints. Graphical representations of 
the data are shown in figures 6.3 and 6.4 as mean with error bars representing 
standard deviations, and statistically significant differences in changes are marked 
where they occur (*p<0.05; **p<0.01).  Individual patient data and p values for all t-
tests are located in appendix 4. 
 
There were no statistically significant differences between baseline and 6 week data 
in any measured parameters within either group. However, when comparing 
changes between groups, significant differences to the detriment of the treatment 
arm subjects were seen in the FVC, RV, RV/TLC ratio, and pO2, but not in any other 
measured parameters.  There were no significant differences in subjective measures 
of symptoms or in the 6MWD. 
 
Figure 6.3: Outcome lung function data for treatment and sham arms 
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Figure 6.4: Non-lung function data for treatment and sham arms 
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6.4 DISCUSSION 
 
The change in the bronchoscopy procedural method was not considered to have 
altered potential outcomes in the 3 patients treated via the extended working 
channel.  Treatment solutions were delivered to the airways at an equivalent 
distance from the end of the bronchoscope with both the ERCP catheter and the 
extended working channel, and there was, perhaps surprisingly, no reflux of either 
solution seen in procedures undertaken without balloon occlusion of the treated 
airway.  In all other respects the procedure was identical, except for the potential to 
reduce overall procedure time.   
 
There was no difference in the primary outcome measure (scarring on CT) between 
the 2 arms of the trial.  Indeed, no scarring was seen in any patient, suggesting no 
treatment effect of intrabronchial blood injection.  Two possibilities present 
themselves to explain this.  The first and most obviously conclusion to draw is that 
autologous blood does not cause a fibrotic/scarring response in the lungs.  This is 
consistent with the clinical findings in those with diffuse alveolar haemorrhage, 
where subsequent fibrosis is not seen, although the milieu in damaged and inflamed 
lung parenchyma in the vasculitides and interstitial lung diseases is different to that 
in stable COPD.  Similarly, in cases of large volume haemoptysis or severe bleeding 
following bronchoscopic interventions where there is a significant volume of blood 
present in the bronchial tree, one does not see post-event atelectasis developing.  It 
is without doubt that blood reaches the smaller airways in these situations (after all 
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deaths in such circumstances are usually caused by effective drowning rather than 
from blood loss per se), which should result in volume changes in the affected areas 
if the hypothesis behind this study is correct.  Secondly, the injected blood did not 
penetrate deeply enough into the bronchial tree to reach bronchiolar and alveolar 
levels, where any inflammatory response may be expected to produce contraction of 
lung volumes (rather than bronchiectasis that might be expected if the proximal 
airways were damaged).  As it was not possible to see more than 1 or 2 centimetres 
distal to the bronchoscope, it is not possible to comment on the distribution of the 
blood beyond the segmental level, although the lack of reflux of blood suggests good 
penetration into the bronchial tree, likely to the level of the alveolus.   
 
Significant changes were seen in several lung function parameters related to gas 
trapping (RV, RV/TLC, FVC).  As TLC = RV + FVC, these values are not independent.  
Given that there was no difference in the change in TLC between groups, it follows 
that a change in RV (0.64 ± 0.83 litres) would necessarily be accompanied by a change 
in FVC (-0.50 ± 0.61 litres), and similarly a change in the RV/TLC ratio.  These 
deteriorations in lung function did not, however, impact on exercise tolerance or 
quality of life as measured by the SGRQ, with higher scores in both arms of the trial 
(treatment 3.90 ± 5.79; sham 3.03 ± 4.02) at 6 weeks.  These changes were neither 
statistically nor clinically significant.  Interestingly, there was no change in the degree 
of airflow obstruction in spite of the increase in gas trapping. 
 
We postulate that the deteriorations seen in the treatment group with respect to the 
sham group can be explained by subtle parenchymal inflammation in the treated 
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lobes, and that 6 weeks of follow-up is too short a time for the subjects to recover or 
improve from the initial insult of intra-airway blood.  Similar findings were seen in 
the BioLVR study, where a number of early adverse events presumed secondary to 
an acute inflammatory response were seen (Criner 2009).  There is some 
circumstantial evidence to support this.  One treatment subject who is followed-up 
regularly in our COPD clinic has recently had respiratory function tests 7.5 months 
post-procedure for clinical reasons, with a substantial improvement seen.  Table 5.5 
contains values for pre-, 6 weeks post-, and 7.5 months post-procedure.  He has not 
to date had repeat cross-sectional imaging, so it is not possible to confidently 
comment on any parenchymal scarring in the treated lobe, but he has undergone no 
other interventions or change in medication since exiting the trial. 
 
Table 6.5: Serial lung function data for subject 09 
 Baseline 6 weeks 7.5 months Change % Change 
FEV1 (L) 1.04 0.83 1.58 0.54 51.9 
FVC (L) 3.46 2.70 4.09 0.63 18.2 
RV (L) 5.34 5.78 4.85 -0.49 -9.2 
TLC (L) 9.03 8.94 9.07 0.04 0.4 
RV/TLC 59.16% 64.73% 53.41% -5.75% N/A 
TLco (mmol/min/kPa) 5.17 4.75 5.52 0.35 6.8 
Raw ex 0.71 1.05 0.49 -0.22 -31.0 
 
One significant weakness with this trial is the very small numbers included.  Although 
there were significant (detrimental) changes in some measures of lung function, the 
sample size makes drawing firm conclusions very difficult indeed.   Follow-up time 
was short, and probably too short to allow adequate recovery from any initial lung 
insult induced by the procedure, and a further set of tests at 3 or 6 months would 
have been useful. 
 165 
6.5 CONCLUSIONS 
 
The data presented from this small study would suggest that intrabronchial 
autologous blood does not induce treatment lobe scarring or produce beneficial 
changes in lung volumes in patients with severe COPD.  Whether this relates to the 
omission of the clotting products used in the Japanese series or the short duration of 
follow-up is still not clear.  Even in these small numbers there were statistically 
significant changes (albeit detrimental) in lung function seen in the treatment arm, 
suggesting at least some physiological and potentially microscopic anatomical 
changes in the treated areas.  
 
If our contention that this relates to on-going or incompletely resolved inflammation 
at 6 weeks is correct, then the potential for subsequent scarring and volume loss still 
exist, although the lack of long-term changes in clinical situations of large volume 
intrabronchial haemorrhage would suggest this is unlikely to be the case.  Further 
trials are now being conducted with a standardised procedure technique, larger 
numbers, and longer follow-up to assess medium to long term outcomes. 
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CHAPTER  7::   EXHALE  AIIRWAY  STENTS  IIN  EMPHYSEMA  
TRIIAL  
 
Airway bypass is the creation of extra-anatomical pathways between large 
(segmental or subsegmental) airways and emphysematous lung parenchyma.  The 
concept of using extra-anatomical passages for the venting of trapped gas in severe 
emphysema was first proposed by Macklem, who suggested transthoracic 
communications between lung parenchyma and the external environment (Macklem 
1978).  This basic concept was adapted by Joel Cooper and his group at Washington 
University who developed a technique of creating bronchial fenestrations to connect 
the diseased parenchyma with the large airways.  This technique is designed to 
directly target the most severely affected areas of emphysema, but also relies on the 
presence of collateral ventilation to reduce the residual volume of the whole lung, 
and has been shown to improve the mechanical properties of explanted lungs 
(Lausberg 2003; Choong 2008).  
 
Under bronchoscopic control, a needle is used to puncture the airway wall, the tract 
is dilated with a balloon, and a 5mm stent is placed across the airway wall (figure 
7.1).  Experiments in canine models indicated that the patency of plain stents was 
short-lived (all stents occluded at 1 week), but that excellent stent patency rates 
could be achieved with the regular application of mitomycin C (Choong 2005).  
Owing to the impracticality of topical mitomycin C applications in patients, the anti-
proliferative drug paclitaxel was trialled.  These drug eluting stents (DES) had 
patency rates of 100%, 96%, 76%, and 65% at 1, 4, 8, and 12 weeks respectively in 
canine models (Choong 2006).  
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Safety of the procedure using the DES was demonstrated in feasibility studies in 
patients undergoing lobectomies for cancer or lung transplantation (Rendina 2003).  
A Doppler probe was used to detect blood vessels adjacent to the airway wall prior 
to airway puncture, and a second Doppler step immediately prior to stent placement 
was added after a fatal bleed in the multicentre pilot study that followed (Cardoso 
2007).  A cartoon of the procedure is shown in figure 7.2. This pilot study enrolled 35 
patients, with a median of 8 stents per patient, with significant improvements in lung 
function, dyspnoea, exercise capacity, and QoL at 1 month, with the improvements 
in lung function and dyspnoea remaining significant at 6 months. 
 
This preliminary data led to development of the Exhale Airway Stents in Emphysema 
(EASE) trial, a multicentre, randomized, double blind, sham controlled trial assessing 
the efficacy of airway bypass in patients with severe homogeneous emphysema 
(Shah 2011i), in contrast to the valve trials which target patients with heterogeneous 
disease. Randomization was 2:1 treatment to sham, and the trial aimed to recruit a 
minimum of 225 patients and a maximum of 450 patients.  Recruitment at any one 
site was capped by the United States Food and Drug Administration (FDA) at 30 
subjects to avoid bias in the final analysis.  Independent statisticians performed a 
Baysian analysis of the data at set recruitment intervals (at 225 subjects and then 
every 45 subjects), with outcomes of ‘continue recruitment’ or ‘stop recruitment’ at 
each analysis time point.  The trial was stopped prior to maximum recruitment at 315 
subjects on the advice of these statisticians.  A detailed explanation of the theory 
and mathematics of Bayesian analysis is given in section 7.2.11. 
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Although the primary data collection point was at 6 months, blinding was maintained 
until 12 months, with the patient unblinded after all their 12 month assessments. 
The data presented below relate to the 30 patients recruited at the Royal Brompton 
Hospital.  All patients who gave written informed consent underwent screening tests 
as defined below, and were subsequently enrolled or excluded from the trial. 
 
Figure 7.1: Airway bypass stent A) ex vivo and B) placed across the wall in a segmental airway 
 
  
 
 
Figure 7.2: Diagrammatical representation of the bronchoscopic procedure 
 
 
 
A B 
B
A 
A C D 
Doppler Airway puncture Re-doppler Stent placement 
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7.1 ENDPOINTS 
 
The primary endpoint combined a change in FVC and a change in mMRC.  A subject 
had to meet both criteria to be considered a ‘responder’.  For superiority to be 
proven, the probability of a subject in the treatment arm responding must be 
statistically significantly greater than the probability of a patient in the sham arm 
responding.  Analysis was on an intention to treat basis on all subjects who entered 
the operating theatre for their randomised intervention. 
 
Primary Endpoint 
1. A 12% or greater increase in the FVC AND a 1 point or greater fall in the mMRC 
score from baseline to 6 months post-procedure 
 
Secondary Endpoints 
1. To measure the difference between study arms in RV/TLC ratio at 6 months. 
2. To measure the difference between study arms in RV at 6 months. 
3. To measure the difference between study arms in FEV1 at 6 months. 
4. To measure the difference between study arms in FVC at 6 months. 
5. To measure the difference between study arms in the mMRC dyspnoea score at 6 
months. 
6. To measure the difference between study arms on a 6MWT at 6 months. 
7. To measure the difference between study arms in the SGRQ at 6 months. 
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8. To measure the difference between study arms in the change in endurance cycle 
ergometry time at 6 months. 
 
In addition to these protocol-defined endpoints, our site has performed measures of 
inspiratory capacity during cycle ergometry, an additional secondary endpoint 
applied at this site only. 
 
9. To measure the difference between study arms in the change in dynamic 
hyperinflation during cycle ergometry at 6 months. 
 
7.2 METHODS 
 
7.2.1 PATIENT SELECTION CRITERIA 
Patients were predominantly recruited from the Advanced COPD Clinic at the Royal 
Brompton Hospital, after discussion in the COPD multidisciplinary meeting.  The trial 
aimed to recruit ex-smokers with severe airflow obstruction, significant 
hyperinflation (and hence the potential to benefit from a reduction in gas trapping), 
and limiting breathlessness, without any clinical features which would present an 
unacceptable risk during the procedure.  Inclusion and exclusion criteria are detailed 
in tables 7.1 and 7.2. 
 
Screening CT scans were sent to a central radiology laboratory in California (MedQIA 
Radiology Core, Los Angeles) for severity scoring.  A score was generated for both 
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upper and lower lobes (middle lobe excluded) based on the NETT CT scoring criteria 
(Fishman 2003; figure 7.3), with a total score of at least 8 required.  Only patients 
with homogeneous disease were recruited, defined as a difference in scores of less 
than 2 between 2 ipsilateral lobes in at least 1 lung, with a detailed report 
highlighting the areas of most severe emphysema and indicating suitable positions 
for stent placements in each lobe sent to the investigators. 
 
 
 
Table 7.1: Inclusion criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion Criteria 
 Age >35 years 
 Subject is willing to be maintained on standard medical therapy for their emphysema 
 Subject is mentally capable of following study directions 
 Subject willing and able to return for all follow-up and supervised pulmonary rehabilitation  
 Subject is willing and able to comply with all study testing and procedures 
 HRCT scan evidence of homogeneous emphysema; total score ≥8 
 Post-bronchodilator ratio of FEV1/FVC <70% 
 Post-bronchodilator FEV1 <50% of predicted or FEV1 <1 litre 
 Post-bronchodilator RV >180% of predicted 
 Post-bronchodilator TLC >100% of predicted 
 Post-bronchodilator RV/TLC ≥0.65 
 PaO2 ≥45mmHg
* on room air 
 Subject has smoking history of at least 20 pack-years 
 Subject has stopped smoking at least 8 weeks prior to signing informed consent 
 Limiting dyspnoea, scoring ≥2 on the mMRC scale 
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Table 7.2: Excluson criteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion Criteria 
 BMI >31.1 for males and >32.3 for females 
 Ventilator dependent 
 Uncontrolled hypertension (systolic >200 mmHg or diastolic >110 mmHg) 
 >20mg prednisolone/day for a total of >30 days within the past 2 months 
 Resting bradycardia (<50 beats/min) 
 Frequent multifocal premature ventricular complexes; complex ventricular arrhythmia; 
sustained supraventricular tachycardia 
 Clinically significant bronchiectasis 
 Presence of segmental atelectasis, lobar consolidation, significant or unstable pulmonary 
infiltrate on chest radiograph 
 Pneumothorax confirmed on chest radiograph 
 Giant bulla >1/3 volume of the lung on HRCT 
 Change in FEV1 >20% between pre- and post-bronchodilator measurements, or >200mL if 
the subject’s post-bronchodilator FEV1 <1 litre 
 TLco <15% of predicted 
 Arterial pH <7.35 with a PaCO2 >50 mmHg
*, or PaCO2 >60mmHg
* regardless of pH 
 Stroke within last 12 months 
 Myocardial infarction within 6 months 
 Three or more respiratory infections requiring hospitalization in the last 12 months 
 Type I diabetes 
 History of exercise-related syncope 
 Current diagnosis of renal failure 
 Lung cancer or pulmonary nodule requiring surgery 
 Use of a pacemaker or implanted defibrillator 
 Previous LVRS or lobectomy 
 Diagnosed dysrhythmia that might pose a risk during anaesthesia or exercise 
 Congestive heart failure within 6 months and left ventricular ejection fraction <45% 
 Peak pulmonary artery systolic pressure of >45mmHg or mean pressure >35mmHg 
 Known Alpha-1 antitrypsin deficiency 
 
* 7.5mmHg = 1kPa 
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Table 7.3: CT lobar destruction grading 
Grade Percentage Destruction 
0  No destruction 
1  1-25% destruction 
2  26-50% destruction 
3  51-75% destruction 
4  >75% destruction 
 
7.2.2 BLINDING 
Following the signing of the informed consent form and initial assessments, subjects 
were randomised to either the treatment arm or the sham arm by a central study 
computer. Randomization occurred as close to the procedure as possible (usually the 
night before) to minimise the risk of unblinding episodes.  The protocol for both the 
treatment and sham procedures is detailed in section 7.2.10. 
 
The trial required an assessment (A) team and a bronchoscopy (B) team.  The B team 
were unblinded in order to perform the procedure, as were members of staff 
present in the operating theatre at the time of the procedure.  The B team did not 
take part in any post-procedure assessments, but were present at unblinding to 
answer any procedure related questions.   
 
Documentation of the procedure did not specify which arm of the trial the patient 
had entered, except in a specified procedures file kept in a locked cupboard 
accessible only to B team investigators, and recovery room staff were similarly 
unaware of which study arm a patient was in.  All follow-up assessments were 
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performed by the blinded A team.  Lung function and radiology department staff had 
no knowledge of which study arm subjects were allocated to. 
 
A blinding questionnaire was completed by the subject prior to discharge, and at 
each subsequent visit, including the 12 month visit immediately before official 
unblinding.  Any assessor(s) similarly completed a questionnaire on each contact 
with the patient. 
 
7.2.3 TESTING SCHEDULE 
All consented patients underwent screening and baseline testing to assess eligibility 
and to provide values against which testing at subsequent post-procedure visits 
could be compared.  Table 7.4 outlines the schedule of events.  All subjects had to 
complete a course of formal pulmonary rehabilitation before baseline tests were 
performed, to ensure optimal baseline function.  This was repeated in the post-
procedure period to maintain any benefit gained from pre-procedure rehabilitation. 
 
7.2.4 PULMONARY FUNCTION TESTING 
Full pulmonary function testing including spirometry, plethysmographic lung 
volumes and gas transfer measurements were performed at baseline, and again at 
each follow-up visit using a Compact Master Lab system (Jaeger, Germany).  
Measurements of gas transfer (TLco) were not made on post-procedure day 1. 
Following an amendment to the study protocol, day 1 post-procedure pulmonary 
function testing was not performed on subject number 30 at our site. 
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7.2.5 RADIOLOGICAL ASSESSMENTS 
High resolution volume scans of the chest were performed before the procedure and 
again at day 1 and at 6 months.  Additionally, those in the treatment arm had a 
further scan at 12 months after unblinding.  All scans were reconstructed to provide 
overlapping 0.6mm thick slices for in depth analysis.  Scans were sent to a central 
radiology assessment unit in California for scrutiny.  In addition, we have assessed 
stent patency on all 6 month scans performed at our institution. 
 
7.2.6 QUALITY OF LIFE 
Quality of life was assessed at baseline using the SGRQ, and re-assessed for changes 
at each follow-up visit except on post-procedure day 1 (where general anaesthetic 
and the procedure were considered likely to have short-term impacts on QoL).  The 
mMRC scale was also used to get a subjective assessment of breathlessness at each 
visit, including day 1 post-procedure.   
 
7.2.7 EXERCISE TESTING 
7.2.7.1 Cycle ergometry and dynamic hyperinflation assessment 
Incremental and endurance cycle ergometry were performed at baseline using a 
magnetically braked cycle ergometer (Jaeger Ergoline 800).  For this trial, 30% 
oxygen was administered throughout the cycle tests.  Subjects wore a nose clip, and 
gas analysis equipment was attached to a lightweight rubber mouthpiece.  After a 
rest period of 10 minutes and 1 minute of unloaded cycling, the workload was 
increased every minute by either 5W (if FEV1 <1L) or 10W (if FEV1 >1L).  Subjects 
cycled until they could carry on no longer (Tlim), with measures of inspiratory capacity 
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made every minute at rest, during exercise, and for 2 minutes post testing (see 
chapter 2 for details).  A workload of 75% of the maximum workload achieved for at 
least 30 seconds on the incremental protocol was used for the endurance protocol.  
A gap of at least 1 hour was left between the 2 tests to allow adequate recovery.  
Endurance ergometry was repeated at 6 months, using the same workload 
determined at baseline.  Pre- and post-exercise Borg scores for breathlessness and 
RPE were recorded. 
 
7.2.7.2 The 6 minute walking test 
A 6MWT using standard protocols (ATS 2002) was performed along a 30m corridor at 
each visit except the post-procedure day 1 visit, and the distance walked recorded.  
Pre- and post-exercise Borg scores for breathlessness and RPE were recorded, along 
with blood pressure, pulse, and blood oxygen saturation (using an infrared finger 
probe). 
 
7.2.8 ARTERIAL BLOOD GASES 
Arterial blood gas tensions were measured at baseline and again at the 6 month 
follow-up visit, via a radial arterial sample (Rapidlab 348, Bayer, Germany). 
 
7.2.9 STENTS USED 
Each 5mm diameter stent consisted of plastic mounted on a stainless steel 
framework, and coated with paclitaxel (figure 1.6).  The stent was preloaded on to a 
custom made balloon catheter used for dilatation of the stent lumen once in place 
across the airway wall. 
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Table 7.4: Event schedule for the EASE trial 
 
 Screening Baseline Procedure Day 1 1 Month 3 Month 6 Months 12 Months 
History and 
examination 
X X   X X X X 
HRCT 
X   X   X 
X   
(treatment) 
CXR 
X        
Pulmonary 
rehabilitation 
16-20 sessions over 6-10 
weeks pre-baseline 
 After discharge 16 sessions over 8 weeks 
Exhaled CO 
X X    X   
SGRQ 
 X   X X X X 
mMRC 
X X  X X X X X 
Spirometry and 
lung volumes 
X X  X X X X X 
Gas Transfer 
X X   X X X X 
Echocardiogram 
X        
Haematology + 
biochemistry 
X    X X X X 
ABG 
X X     X  
6MWT 
 X   X X X X 
Cycle ergometry 
 X     X  
Dynamic 
hyperinflation 
 X     X  
Begin aspirin 
  X  
(post op) 
     
Intravenous 
antibiotics 
  X      
Begin oral 
antibiotics 
   X     
Blinding 
assessment 
   X X X X X 
 
 
7.2.10 BRONCHOSCOPIC PROCEDURES 
Under general anaesthetic, a fibreoptic bronchoscopy was performed via an 
endotracheal tube in each patient.   
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Up to 6 DES were placed in each treatment arm patient, with a maximum of 2 in any 
one lobe, but avoiding the right middle lobe.  Stents were placed in segmental 
airways, as determined by analysis of the screening CT scan, with a bronchial blocker 
balloon in place (deflated) in case of significant haemorrhage.  The following steps 
constituted the procedure: 
 
1. Check the integrity of the bronchial blocker balloon  
2. Take bronchial washings for microbiology from the right middle lobe 
3. Navigate to an airway identified as being adjacent to an appropriate area of 
emphysema 
4. Find a control blood vessel to check that the Doppler probe is functioning 
5. Use Doppler probe to ensure no blood vessels in area of interest  
6. Make a passage through the airway wall with the transbronchial dilatation needle 
7. Re-check for blood vessels using the Doppler probe 
8. Pass the loaded stent into the passage and use inflation balloon to expand the 
stent 
9. Repeat steps 3 to 8 until all stents placed 
 
Subjects were monitored for at least 1 night after the procedure, and started 75mg 
aspirin daily immediately following the procedure, and continued this for 30 days to 
minimise stent occlusion. Subjects in the sham arm of the trial underwent a similar 
procedure, except that steps 3 to 8 were simulated 6 times in the trachea, with no 
actual airway wall puncture or stent deployment.  A scripted running commentary 
was given by the operator(s) to minimise the risk of unblinding owing to partial 
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anaesthesia.  The bronchoscope was left in the trachea for a total of 1 hour during 
these sham procedures. 
 
7.2.11 BAYESIAN ANALYSIS 
As stated in the introduction, there was a pre-defined maximum recruitment to this 
trial of 450 patients.  Independent statisticians monitored the data when 
recruitment reached 225 subjects and again after every 45 additional subjects in 
order to determine whether more data was needed to answer the study hypothesis 
(i.e. would more data change the outcome given what data was currently available?).  
This analysis was performed using Bayesian statistics.  The foundation of Bayesian 
statistics is Bayes’ theorem, named after the Rev. Thomas Bayes, which was first 
presented posthumously to the Royal Society by his friend Richard Price in 1764.  The 
Bayesian interpretation of probability enables reasoning with uncertain statements. 
To evaluate the probability of a hypothesis, a prior probability (the probability 
estimate for a hypothesis) is specified, which is then updated in the light of new 
relevant data.  The Bayesian interpretation provides a standard set of procedures 
and formulae to perform this calculation, and a summary is given below (taken from 
B. Walsh, 2002.) 
 
Suppose we observe a random variable y and wish to make inferences about another 
random variable , where  is drawn from some distribution p( ). Pr( ) is the prior 
distribution of the possible  values, while Pr( |y) is the posterior distribution of  
given the observed data y.  From the definition of conditional probability, 
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Pr( |y) = Pr(y, ) 
  Pr(y) 
 
Again from the definition of conditional probability, we can express the joint 
probability by conditioning on  to give 
Pr(y, ) =  Pr(y| ) Pr( ) 
 
Putting these together gives Bayes’ theorem: 
Pr( |y) = Pr(y| ) Pr( ) 
       Pr(y) 
 
With n possible outcomes ( 1,···, n), 
Pr( j|y) = Pr(y| j) Pr( j) =         Pr(y| j) 
       Pr(y) 
 
 
 
Finally, the continuous multivariate version of Bayes’ theorem is 
p(Θ|y) =  p(y|Θ)p(Θ)=   p(y|Θ) p(Θ) 
       p(y)    ∫p(y,Θ)dΘ 
 
where Θ = (  (1), (2), ···, (k)) is a vector of k (potentially) continuous variables. 
 
7.3 RESULTS 
 
7.3.1 BASELINE DATA 
Of the 30 subjects at our site, 21 were randomized to the procedure arm and 9 to 
the sham arm of the trial.  Baseline data are represented in table 7.5 as Mean (SD).  
 n 
i=1 
Pr(bi) Pr(y| i) 
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All p values are for unpaired t-tests except sex, for which the chi squared test was 
used, and the mMRC score, presented as Median (Range), for which the Mann-
Whitney U test was used. 
 
Data for the average number of stents placed in treatment patients are presented as 
Median (Range) in table 7.6.  Using the Mann-Whitney U test, there were no 
significant differences between the number of stents placed in any particular lobe, 
region, or lung.  
 
Table 7.5: Baseline data 
 
 Treatment Sham p value 
Number 21 9 - 
Age (y) 64.1 (5.9) 63.3 (7.8) 0.76 
Male 57.10% 33.30% 0.23 
BMI 23.6 (3.3) 23.6 (4.1) 1.00 
FEV1 % predicted 22.3 (6.5) 22.3 (6.3) 0.99 
FVC % predicted 64.9 (14.1) 62.6 (8.4) 0.64 
RV % predicted 258.5 (37.5) 256.1 (39.7) 0.88 
RV/TLC 68.72 (4.52) 69.31 (4.21) 0.88 
FRC % predicted 199.3 (22.9) 199.7 (19.9) 0.96 
TLco % predicted 30.7 (10.3) 21.9 (5.0) 0.02 
mMRC 3 (2-3) 3 (2-3) 0.65 
SGRQ 59.9 (8.4) 60.0 (12.9) 0.97 
6MWD (m) 277.0 (98.6) 277.9 (71.6) 0.98 
Cycle time (s) 304.2 (288.2) 257.6 (85.0) 0.53 
Procedure time (min) 134.8 (28.1) 60.1 (0.3) <0.0001 
Number of stents 6 (4-6) N/A - 
 
Table 7.6 Stent placement by lobes 
 
Total RUL RLL LUL LLL Upper Lower Right Left 
6 (4-6) 1 (0-2) 1 (0-3) 1 (0-2) 2 (1-3) 3 (1-4) 3 (2-5) 3 (1-3) 3 (2-3) 
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7.3.2 PRIMARY ENDPOINT 
5 patients were unblinded by the expectoration of 1 or more stents.  Although 2 of 
these were before primary endpoint data collection (4 months 15 days, 4 months 21 
days), 1 subject died prior to 6 months and had no unblinded follow-up visits.  Figure 
7.3 shows subject numbers remaining in the trial at each data collection time point.  
Twenty treatment subjects and 8 sham subjects were available at the 6 month 
primary endpoint visit. 
 
Figure 7.3: Subjects available for assessment at each follow-up time point 
 
 
 
 
 
 
Using an intention to treat analysis, 4/21 (19.0%) procedures and 3/9 (33.3%) shams 
met the ‘responder’ criteria.  On chi squared testing, there was no significant 
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difference between the 2 arms of the trial (χ2=0.719; df=1; p=0.397), and therefore 
the null hypothesis is accepted. 
 
7.3.3 SECONDARY ENDPOINTS 
Paired t-tests were performed on data at all visits from day 1 through 12 months 
against baseline data within both groups, with unpaired t-tests performed on the 
difference in changes between the two groups.  Graphical representations of the 
data are shown in figure 6.4 as mean with error bars representing the standard 
deviation, and statistically significant changes are marked (*) where they occur. All 
significant p values (p<0.05) are in the direction of improvement.  Individual patient 
data and p values for all t-tests are located in appendix 5. 
 
Initial inspection would suggest that there were at least short term benefits in the 
FVC and RV/TLC ratio in the treatment group, but when changes in the sham group 
(i.e. placebo effect) are taken into account, including seemingly significant p values in 
several instances, there were no significant changes attributable to the treatment in 
any parameters over the course of the trial.   
 
The cycle ergometry data (table 7.7) looks more compelling. In addition to the death 
(treatment arm) and transplant (sham arm), 1 sham refused to perform cycle 
ergometry at 6 months, meaning paired data were available in 20 treatment subjects 
and 7 sham subjects.  A 133.3 second mean increase (+93.6% of baseline mean) in 
Tlim was seen in treated subjects against a mean change of -14.4 seconds (-4.0%) in 
the sham arm.  However, owing to the small numbers and large variances, a 
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statistically significant difference was not detected with t-testing (p=0.17).  Taking an 
absolute increase in cycle time of 60 seconds to represent a ‘responder’, a 2x2 
contingency table can be constructed (table 7.8).  Using Fisher’s exact test, the 
difference between arms remains non-significant (p=0.20). 
 
 
Table 7.7: Endurance cycle ergometry data by subject (in seconds) 
 
 
TREAMENT ARM     SHAM ARM    
           
Subject Baseline 6 months Change %   Subject Baseline 6 months Change %  
1 298 139 -159 -53.4  1 137 172 35 26 
2 260 590 330 126.9  2 373 89 -284 -76 
3 161 174 13 8.1**  3 256 242 -14 -5 
4 192 617 425 221.4  4 311 697 386 124 
5 114 128 14 12.3  5 192 137 -55 -29 
6 208 608 400 192.3  6 331 249 -82 -25 
7 123 140 17 13.8  7 203 116 -87 -43 
8 364 330 -34 -9.3  Mean 257.6 243.1 -14.4 -4.0 
9 254 865 611 240.6  SD 85.0 209.1 202.9 64.6 
10 79 467 388 491.1       
11 1388 468 -920 -66.3             
12 190 350 160 84.2        
13 574 492 -82 -14.3        
14 655 310 -345 -52.7        
15 132 277 145 109.8        
16 309 2110 1801 582.8       
17 308 132 -176 -57.1       
18 178 271 93 52.2       
19 152 139 -13 -8.6       
20 110 108 -2 -1.8       
Mean 302.5 435.8 133.3 93.6  ** Unblinded prior to 6 months 
SD 295.6 446.7 510.3 177.9 
 
 
Table 7.8: 2x2 contingency table for 60 second responders 
 
 Responders Non-responders Total 
Control Arm 1 6 7 
Treatment Arm 9 11 20 
Total 10 17 27 
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Figure 7.4: Pooled outcome data for treatment and sham arms 
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7.3.4 DYNAMIC HYPERINFLATION 
Twenty treatment and 8 sham subjects were alive and transplant free at 6 months.  
DHI data at baseline was not available for 1 treatment subject, and 1 sham subject 
refused to perform the 6 month cycle, leaving complete data sets on 19 treatment 
and 7 sham subjects.  End-expiratory lung volumes (EELV) were calculated by 
measuring the IC and subtracting this from the resting TLC as measured by 
plethysmography prior to ergometry.  
 
Isotime EELV values were compared.  Isotime was defined as the final 30 second 
period achieved on the shortest test.  Data for each group were analysed using 
paired t-tests, and for comparison of changes between the 2 arms an unpaired t-test 
was used.  No difference was seen in pre-intervention EELV between the two groups 
(p=0.33). There were no statistically significant changes in EELV at 6 months in either 
treatment (p=0.86) or sham subjects (p=0.74), and moreover there was no difference 
in the changes between the groups (p=0.70).  Individual patient data is located in 
appendix 5. Figure 7.5 shows graphical representations of all data with means and 
95% confidence intervals. 
 
Figure 7.5: Isotime end expiratory lung volumes on cycle ergometry  
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7.3.5 ADVERSE EVENT PROFILE 
A log of all adverse events (AEs) up to 1 year of follow-up was kept for all 30 subjects.  
Figures are represented in table 7.9 as total (mean; SD).  The most commonly 
occurring AE in both arms was acute exacerbation of COPD, accounting for almost 
half of all AEs (45.4% treatment, 48.9% sham). If AEs documented as pulmonary 
infection rather than COPD exacerbation are included, that proportion rises to over 
60%.  There were no significant differences between the 2 groups in the number of 
AEs or SAEs per subject, either before or after the procedure. 
 
Table 7.9: Adverse events pre-procedure and at 1 year of follow-up 
 
 Treatment group Sham group p value 
Pre-procedure      AEs 10 (0.48;0.75) 7 (0.78;0.83) 0.34 
                         SAEs 2 (0.30;0.10) 1 (0.33;0.11) 0.90 
12 months             AEs 130 (6.19;2.73) 47 (5.22;2.28) 0.36 
                           SAEs 31 (1.48;1.66) 8 (0.89;0.93) 0.33 
 
In order to assess whether there was any relationship between improvement in lung 
function parameters and adverse event profiles, data on time to first exacerbation 
(the predominant AE and one directly relating to the underlying disease being 
treated) were plotted against measures of lung function, and also against the 
number of patent stents at 6 months.  The only significant correlation was seen 
between change in FEV1 and time to exacerbation (p=0.045; r
2=0.205).  Increasing 
numbers of patent stents did not produce a reduction in time to exacerbation, 
whether plotted as fully patent or at least partially patent stents.  Results are shown 
in figure 7.6.  One patient reached 365 days without reporting any COPD 
exacerbations. 
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Figure 7.6: Time to 1
st
 exacerbation by changes in lung function parameters at 6 months 
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7.3.6 STENT PATENCY 
Accurate assessment of Exhale® stent patency on high resolution CT scanning has 
previously been demonstrated (Grgic 2008).  All 6 month CT scans performed on 
treatment subjects at our site were analysed for stent patency by an experienced 
Radiologist.  One subject died prior to 6 month follow-up, and no post-mortem 
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examination was performed, meaning that data were available on only 20 subjects.  
Stent patency rates are shown in table 7.10, and represented graphically in figure 
7.7.   
 
Table 7.10: CT-determined stent patency at 6 months in treatment arm subjects 
 
 Mean Median Minimum Maximum Q25; Q75 
Stents implanted 5.55 6 4 6 5.25; 6 
Patent 1.50 1 0 3 1; 2.75 
Obstructed 2.05 2 0 4 1; 3 
Occluded 1.45 1 0 4 1; 2 
Missing 0.55 0 0 4 0; 1 
 
These findings are supported by the fact that four subjects have subsequently 
undergone fibreoptic bronchoscopy after their 1 year follow-up, and no patent 
stents were seen in any of these subjects.  The implication is that stent occlusion is 
an ongoing process, and it would therefore be reasonable to assume that a vast 
majority of stents will eventually become non-functioning, irrespective of short-term 
patency or clinical response. Most of the observed stent sites were either covered by 
granulation tissue or completely overgrown by airway wall, and some had a thin 
vascular membrane occluding the lumen.  We were unable to identify all the stents 
in spite of guidance from video recordings of the original procedures. It was not 
possible, however, to tell at bronchoscopy whether this was because of stents 
coughed up and swallowed unknowingly, stents falling through the airway wall into 
the lung parenchyma, or simply that the airway wall had grown over the stents 
sufficiently to obliterate any evidence of their presence.  In some cases, the stent 
was apposed by lung tissue, suggesting that an area of trapped gas had been 
emptied, but that there was not sufficient collateral ventilation to maintain patency. 
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Six month data are plotted in figure 7.8 against the number of stents that were at 
least partially open on CT.  Perhaps surprisingly, there are no significant associations 
between any lung function parameters and stent patency, with only very weak 
beneficial trends seen in most cases.  Indeed, there was no difference in the number 
of patent stents in those who met the co-primary endpoint and those who did not 
(3.75 vs 3.50; p=0.76). 
 
Figure 7.7: CT-determined stent patency at 6 months in treatment arm subjects 
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The results for DHI are equally as disappointing, with no significant relationship 
between EELV and number of patent stents in our small treatment population (figure 
7.9a; r2=0.01, p=0.65), a finding that persists even when the sham group is added as 
a ‘no patent stents’ group (figure 7.9b; r2=0.01, p=0.57). 
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Figure 7.8: 6 month clinical data vs CT-determined stent patency  
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Figure 7.9: Relationship between change in isotime EELV and stent patency at 6 months a) in EASE 
trial treatment group and b) in EASE trial treatment and sham subjects combined. 
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7.4 DISCUSSION 
 
The EASE trial remains the largest randomised controlled device trial in patients with 
severe emphysema, and has generated an enormous amount of data.  Results at our 
site have been disappointing.  All procedures were recorded onto DVD and have 
been reviewed since, and a company representative was present at each procedure 
to ensure correct technique and adherence to the study protocol.  No procedural 
problems have been identified that would predispose to technical failure of the 
device or to a poor outcome at our site.  Full results from the trial have now been 
published (Shah 2011ii).  These show significant improvements in multiple lung 
function parameters at one day, and mMRC score and static lung volumes at one 
month of follow-up, but thereafter there is a steady loss of benefit such that by 6 
months results have returned to baseline, except, curiously, mMRC which remains 
significant at 6 months (table 7.11).  In terms of the primary endpoint, there was 
only a significant difference in responders at day 1 post-procedure (table 7.12).  
Unfortunately, cycle ergometry data was not collected at time points earlier than 6 
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months, so benefits in EELV could not be assessed against early changes in lung 
function. 
 
Table 7.11: p values for comparison of changes between groups 
 
 1 day 1 month 3 months 6 months 
FEV1 <0.01 0.49 0.17 0.52 
FVC <0.01 0.52 0.26 0.60 
RV 0.01 0.05 0.51 0.47 
RV/TLC <0.01 0.02 0.67 0.68 
mMRC 0.79 0.02 0.36 0.03 
 
Table 7.12: Overall responder rates (FVC + mMRC) 
 
 1 day 1 month 3 months 6 months 
Sham 5.3% 10.5% 11.3% 11.2% 
Treatment 16.2% 13.7% 11.1% 14.4% 
p value 0.01 0.47 1.00 0.57 
 
Certainly these results are in line with our 3 and 6 month data, but we did not see 
the reported early overall improvements in our cohort of patients.  One possibility is 
the effects of a small sample size, particularly in the sham arm where 3 of 9 patients 
had a substantial placebo effect.  The procedural skill of the bronchoscopist (or lack 
thereof) could also have played a role, but as mentioned above, no obvious 
deficiency has been identified.   
 
The only difference in baseline characteristics seen in this trial was the percentage 
predicted TLco, which was statistically significantly higher in the treatment arm.  In 
order to assess whether a higher baseline TLco could have affected outcomes, plots 
of baseline TLco against changes in 6 month outcomes were made for all treatment 
arm patients (figure 7.10).  Surprisingly, baseline TLco was significantly correlated 
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with improvements in the 6MWD (r2=0.34 ; p=0.007), with trends to improvements 
in hyperinflation (RV/TLC: r2=0.18 ; p=0.06), and cycle ergometry (r2=0.19 ; p=0.05).  
These results would suggest that treatment arm patients should, if anything, have 
had an additional advantage over sham patients in meeting trial endpoints, but the 
fact there was no difference between the groups at 6 months could even imply that 
treatment was detrimental.  One other implication from this data, albeit a small 
sample size, is that we may be intervening in some patients too late in their disease 
course, and that patients at the very severe end of the spectrum have to some 
degree missed the boat.  A similar finding was seen in the NETT, with lower pre-
operative TLco being a predictor of poor outcomes (Fishman 2003).  
 
When analysing the EELV data, there is a significant correlation between changes in 
EELVi on exercise and Tlim (r
2=0.24; p=0.04) in the treatment group (figure 7.11).  This 
implies that a change in bike time is in part due to a reduction in the EELV on 
exercise, or at least a reduction in the rate of rise of EELV.  However, this says 
nothing about its relationship to stent patency, which we have already seen does not 
significantly affect either Tlim or EELVi.  
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Figure 7.10: 6 month clinical data vs baseline percent predicted TLco in treatment arm patients  
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Figure 7.11: Changes in isotime EELV against changes in cycle time  
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Since the preliminary results were released, Broncus Technologies have been looking 
for early signals that might be used in the future to predict a subgroup of patients 
with higher response rates.  In depth analysis of baseline CT scans in treatment 
subjects by Joel Cooper, presented at the American Thoracic Society Meeting 2010 
(unpublished data), has identified 3 subgroups of patient based on degree of 
destruction, and emphysema gradient throughout the lungs.  There was a striking 
difference between groups in overall changes in volumes, and changes per stent 
implanted, in all lobes.  A greater degree of macroscopic destruction and a greater 
difference in the percentage of emphysema between upper and lower lobes (within 
the confines of the definition of homogeneous emphysema) predicted a greater 
change in lobar volumes, independently of baseline lung function, smoking history, 
age, exercise tolerance, or severity of breathlessness. 
 
One factor that certainly played a part in the negative results in this trial was the 
large placebo response, both in our cohort and worldwide.  There was a fairly 
consistent responder rate across follow-ups in the treatment arm, but a progressive 
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rise in the sham arm over the first 3 months (5.3% to 11.3%).  If the placebo 
responder rate had not increased throughout the trial, there is every possibility that 
we would now be hailing a revolutionary new product.   
 
There is an argument that the wrong primary endpoints were identified for this trial.  
The aim of airway bypass is to reduce the amount of gas trapping in those with 
severe emphysema, and thus to reduce RV.  An outcome measure that directly 
measured this (rather than the indirect measure of FVC – where RV=TLC-FVC) could 
therefore potentially have resulted in different results.  However, in our subset of 30 
subjects, even if one took any decrease in RV alone without any mMRC criteria as the 
primary endpoint, the data still do not produce a statistically significant outcome 
(χ2=1.163; df=1; p=0.281*).    Calculations using other RV reductions are shown in 
table 7.13.  It has more recently been suggested that the minimal clinically important 
change in RV in severe emphysema lies between 310ml and 430ml (Hartman 2012), 
making the >400ml reduction figures the most interesting.  
 
Table 7.13: Comparison of responders by differing RV criteria alone 
 
 Treatment Sham Chi squared P value 
RV reduction >400ml 6/20 1/8 0.933 0.334 
RV reduction >200ml 9/20 3/8 0.131 0.717 
RV reduction >0ml* 12/20 3/8 1.163 0.281 
 
Large placebo responses were also seen in the AIR2 trial of bronchial thermoplasty, 
with both trials randomising 2:1 in favour of the real treatment.  A situation is 
created where subjects have a greater chance of being randomised to treatment, 
and this is reflected in subjects’ presumptions about which arm of the trial they are 
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in, and their expectation of better health outcomes.  Evidence also suggests that the 
greater the perceived potential value of a placebo, the greater the placebo effect 
(Waber 2008), and there are few interventions with a greater perceived benefit than 
surgery (or in this case, intervention under general anaesthetic), and placebo surgery 
has been shown to be as good as established surgical treatments in several trials 
(Cobb 1959; Dimond 1958; Cobb 1959; Moseley 2002).   
 
An association exists between exacerbation frequency and GOLD staging (Faganello 
2010), which grades disease severity by FEV1, and this fits with our follow-up data.  
The time to first exacerbation and change in FEV1 in our cohort were both 
independent of stent patency, but the data suggest that interventions reducing 
airflow obstruction over a prolonged duration can lead to reduction in exacerbation 
rates.  This finding is in line with results from the Understanding Potential Long-Term 
Impacts on Function with Tiotropium (UPLIFT) trial (Tashkin 2008), in which there 
was a sustained improvement in FEV1 in the treatment group versus placebo 
(although not a reduction in the rate of FEV1 decline) and an increase in time to first 
exacerbation. However, whether this was a direct effect of tiotropium or related to 
lung function improvements is impossible to say. 
 
There currently remains no proven non-pharmaceutical intervention available that 
has been demonstrated to improve lung function and health outcomes in patients 
with homogeneous emphysema, although some early success has been reported in a 
small pilot study of transthoracic pneumonostomy (Moore 2010).  Although there 
were modest beneficial changes in spirometry and gas trapping, these did not 
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translate into improvements in exercise tolerance or QoL.  The authors postulate 
that recovery from the initial thoracic surgical procedure was to blame, and a 
multicentre trial is currently underway that includes immediate post-procedure 
pulmonary rehabilitation.  Endobronchial lung volume reduction coiling looks more 
promising, however, and is addressed in detail in chapter 8.   
 
7.5 CONCLUSIONS 
 
All available data at this site would suggest that the use of Exhale drug-eluting stents 
for the treatment of severe homogeneous emphysema produces no significant 
benefit in terms of exercise tolerance, lung function, or dyspnoea at any time point 
up to 1 year.  Although early improvements in lung function and breathlessness were 
apparent from the worldwide multi-centre results, these were not sustained beyond 
1 month, and medium to long term results are in line with our findings.  The lack of 
response appears to be a result of an ongoing process of stent occlusion as the 
airway wall attempts to repair itself, but the lack of convincing correlations between 
outcomes and stent patency at our site suggests that there are other factors 
involved in treatment success.  Further work is needed to determine the exact 
nature of the airway reaction to stent placement, and to identify better 
antiproliferative drugs with which to coat the stents (for example sirolimus, which is 
used to good effect in coronary artery stents), although the cost of repeating such a 
large trial any time soon is likely to be prohibitive. 
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CHAPTER  8::   ENDOBRONCHIIAL  LUNG  VOLUME  
REDUCTIION  COIILS  IIN  THE  TREATMENT  OF  SEVERE  
EMPHYSEMA  
 
The previous chapters have described methods for bronchoscopic lung volume 
reduction that rely on the presence (airway bypass) or absence (endobronchial 
valves) of significant collateral ventilation.  There are now a number of products in 
clinical trials which aim to achieve volume reduction independently of the degree of 
collateral ventilation (Slebos 2012; Herth 2011; Snell 2011), and this chapter 
discusses the use of one of these, the lung volume reduction coil (LVRC; PneumRx 
Inc, Redwood, CA). 
 
The LVRC is an implantable device delivered via the working channel of a standard 
bronchoscope under conscious sedation, and is designed to mechanically compress 
emphysematous lung tissue in the area of deployment.  The implants derive their 
strength and structural properties from the nitinol wire used for their construction.  
Owing to their spring-like properties, they are also intended to tension the 
surrounding tissue, reducing compliance and increasing elastic recoil forces holding 
the airways open.  They are delivered into the airways straight, and once released 
return to their original shape – said to resemble the seam of a baseball (figure 8.1).  
Under bronchoscopic control, a guide wire and catheter delivery system are used to 
place a number of coils into target airways (figure 8.2; see sections 8.3.9 and 8.3.11).   
 
A first in man study (Herth 2010) with 11 patients and 21 procedures under general 
anaesthetic demonstrated the safety of the procedure, with no severe adverse 
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events and, perhaps surprisingly, no pneumothoraces.  This may have related to the 
relatively small number of coils inserted at each procedure (4.9+/-0.6) compared to 
later trials. 
 
A subsequent prospective, non-randomised, efficacy study in 16 patients with 
heterogeneous emphysema (Slebos 2012) demonstrated statistically significant 
benefits in SGRQ (-14.9 points), FEV1 (+14.9%), FVC (+13.4%), RV (-11.4%), and 
6MWD (+84.4m).  A median of 10 coils were implanted per lung, with 12 patients 
having both lungs treated in sequential procedures.  One pneumothorax, 2 
pneumonias, 6 COPD exacerbations, 4 episodes of chest pain, and 21 reports of mild 
haemoptysis occurred over the first month of follow-up, with a further 3 pneumonia, 
and 14 COPD exacerbations up to 6 months.  
 
These preliminary results informed the design of a randomised controlled trial, 
designed to evaluate the safety and effectiveness of the LVRC in patients with severe 
emphysema.  The inclusion criteria (see table 8.1) allowed for patients with either 
heterogeneous or homogeneous disease to be enrolled, as preliminary data from the 
Netherlands (personal correspondence, DJ Slebos) had suggested similar responses 
in both groups.  Randomization was 1:1 treatment to control, with control patients 
crossing over to the treatment arm at the end of the control phase (3 months after 
control ‘treatment’ 2 – see section 8.3.3) such that overall recruitment was designed 
to be 2:1 in favour of the treatment arm. 
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The completed trial included follow-up out to 12 months, but this thesis only reports 
results up to 3 months of follow-up, the latest point at which inter-group 
comparative data is available. 
 
Figure 8.1: A lung volume reduction coil 
 
 
Figure 8.2: Diagrammatical representation of the bronchoscopic procedure 
        
              
 
8.1 ENDPOINTS 
 
The primary endpoint in this study was the difference between the groups in the 
change in the SGRQ.  Although not originally mandated in the study protocol, for this 
thesis a responder analysis has been conducted, where an 8 point fall in the SGRQ 
Bronchoscopy 
Catheter retraction LVRC delivery 
Guide wire Delivery catheter Target airway 
LVRC released Multiple LVRCs  
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(the value used in the NETT study – twice the minimal clinically important difference 
(MCID) as the trial was unblinded) identifies a ‘responder’.  This analysis will 
determine if the probability of a subject in the treatment arm responding is 
statistically significantly greater than the probability of a patient in the control arm 
responding.   
 
Primary Endpoint 
1. To assess the difference between study arms in the change in the SGRQ  
2. To assess the difference between study arms in SGRQ responder rates  
 
Secondary Endpoints  
1. To measure the difference between study arms in the change in FEV1  
2. To measure the difference between study arms in the change in RV 
3. To measure the difference between study arms in the change in TLC  
4. To measure the difference between study arms in the change in modified MRC 
dyspnoea score 
5. To measure the difference between study arms in the change in the 6 minute 
walk test  
 
Safety Objective 
1. To identify the number and type of potential device-related and procedure-
related adverse effects attributed to the use of LVRCs  
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8.2 DETERMINATION OF SAMPLE SIZES 
 
The number of patients needed to demonstrate statistical significance (α<0.05, 
β=0.84) of the difference in the proportion of patients reporting an improvement in 
SGRQ of 4 points or more is estimated to be 42.  This is based on an estimated 
treatment effect of 0.6 (i.e. 60% treated patients report an SGRQ improvement >4), 
based on pilot data (Slebos 2012) and a change of 0.2 in the control group (i.e. 20% 
Control patients report an SGRQ change >4), an estimation of placebo effect.  Since 
we are testing the superiority of the treatment group a one-sided test is appropriate. 
The study therefore aimed to recruit 45 patients to allow for incomplete data sets or 
drop-outs.  This thesis reports the results of the first 20 patients recruited to the 
trial. 
 
8.3 METHODS 
 
8.3.1 PATIENT SELECTION CRITERIA 
Patients were predominantly recruited from the COPD clinics at the Royal Brompton 
Hospital and Chelsea and Westminster Hospital, but referrals from outside hospitals 
via Dr. Shah’s practice were also considered for enrolment. The trial aimed to recruit 
ex-smokers with severe airflow obstruction and limiting breathlessness, without any 
clinical features which would present an unacceptable risk during the procedure. 
Inclusion and exclusion criteria are detailed in tables 8.1 and 8.2.  
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Following initial discussion at a COPD multidisciplinary team meeting, if a subject was 
identified as potentially suitable, they were offered entry into the study.  If bullae 
greater than 2.5cm in diameter were present on the CT scan, the patient was 
excluded from enrolment, owing to the need for lung parenchyma to be present for 
compression and retensioning by the LVRCs.  
 
Table 8.1: Inclusion criteria 
 
 
 
 
Table 8.2: Exclusion criteria 
 
 
 
Table 8.2: Exclusion criteria 
 
 
 
 
 
 
 
 
 
 
Inclusion Criteria 
 Age ≥35 years 
 Ex-smoker with smoking cessation confirmed by exhaled CO levels 
 Emphysema on CT scan (unilateral or bilateral, heterogeneous or homogeneous) 
 Moderate to severe airflow obstruction FEV1 <45% Predicted 
 Severe dyspnoea – mMRC  ≥2 
 TLC ≥100% predicted 
 6MWD >140 metres 
 Optimum COPD treatment for at least 6 weeks  
 Patient has stopped smoking for a minimum of 8 weeks prior to entering the 
study 
Exclusion Criteria 
 Patient unable to provide informed consent 
 TLCO <20% predicted  
 Evidence of other disease that may compromise survival 
 History of recurrent clinically significant respiratory infection  
 Clinically significant bronchiectasis 
 Large bulla more than 1/3 of hemithorax volume on CT scan 
 Prednisolone dose greater than 20mg a day 
 Significant pulmonary hypertension – RVSP >50mmHg 
 Prior LVRS or lobectomy 
 Inability to tolerate bronchoscopy under deep sedation or anaesthesia 
 Female of childbearing age with positive pregnancy test 
 Participated in a study of investigational drug or device in prior 30 days 
 Subject taking clopidogrel or anticoagulants and unable to abstain for 5 days pre-
procedure 
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8.3.2 RANDOMISATION 
Following the signing of the informed consent form and initial assessments, subjects 
were randomised to either the treatment arm or the sham arm (1:1) by the opening 
of pre-filled, sequentially numbered, sealed envelopes. 
   
8.3.3 TESTING SCHEDULE 
All consented patients underwent baseline testing to assess eligibility and to provide 
values against which testing at subsequent post-procedure visits could be compared.  
Table 8.3 outlines the schedule of events.  In addition to those visits in table 8.3, a 
telephone call was made to all patients 1 week after each procedure to check on 
health status.  Subjects in the control arm underwent an identical testing schedule, 
except that the treatment visits consisted solely of a history and physical 
examination in order ensure an equal number of physician contacts with patients in 
both study arms.  
 
To avoid excess radiation exposure, a CT scan was not performed at the 3 month 
control visit on the assumption that no parenchymal changes would have occurred 
since enrolment, and likewise no post-treatment chest radiographs were requested. 
 
8.3.4 PULMONARY FUNCTION TESTING 
Full pulmonary function testing including spirometry, plethysmographic lung 
volumes and gas transfer measurements were performed at baseline, and again at 1 
month following each treatment visit, as well as at 3, 6, and 12 months following the 
second treatment using a Compact Master Lab system (Jaeger, Germany).  
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Table 8.3: Event schedule for the LVRC trial 
 
 
8.3.5 RADIOLOGICAL ASSESSMENTS 
High resolution volume scans of the chest were performed before the procedure and 
again at 3, 6, and 12 months after the second treatment.  All scans were 
reconstructed to provide overlapping 6mm thick slices every 3mm for in depth 
analysis.  Baseline scans were analysed using Pulmo-CMS software (Medis Specials, 
Leiden, the Netherlands) to provide a density map of the lungs, allowing a 
determination of the degree and distribution of emphysematous destruction for 
treatment planning (see chapter 2, section 2.10).   Figure 8.3 shows a typical graph 
produced following density mapping.  The y axis represents the degree of 
emphysematous destruction, taken as the percentage of lung with a density of less 
than -950HU on any given CT slice (termed the Relative Area, or RA), with CT slice 
 Baseline Treatment 1 1 month Treatment 2 1 Month 3 Months 
History and 
examination 
X X X X X X 
HRCT 
X     X 
CXR 
X 
X  
(post op) 
 
X  
(post op) 
  
SGRQ 
X  X  X X 
mMRC 
X  X  X X 
Spirometry and 
lung volumes 
X  X  X X 
Gas Transfer 
X  X  X X 
6MWT 
X  X  X X 
Electrocardiogram 
X      
Echocardiogram 
X      
Haematology + 
biochemistry 
X      
ABG 
X     X 
Begin oral 
antibiotics 
 X  X   
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number on the x axis (lung bases on the left, apices on the right).  Lines represent the 
left lung (red), right lung (blue), and both lungs combined (green). 
 
Heterogeneous disease produced a slope-like profile (as in figure 8.3), with a greater 
degree of destruction in the upper portions of the lung than the lower, or vice versa.   
Previous work had suggested that the greater the gradient of the slope, the greater 
the improvement following regional LVRC deployments (Kemp 2010).  The ‘ideal’ 
heterogeneous lung was deemed to have a RA at 25% of the way through the lung 
half (or twice) that at 75% of the way through the lung.  Homogeneous disease was 
defined as a density profile showing a plateau above 50% destruction throughout the 
lung(s), but without bullae.  Significant areas of bullous disease excluded the patient 
from the trial, as this would prevent retensioning of lung tissue. 
 
Figure 8.3: Example of Pulmo assessment graph for treatment planning 
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In heterogeneous disease, the lung with the greater degree of heterogeneity was 
treated first, on the assumption that this would represent the better potential 
improvement in lung function.  Similarly, in homogeneous disease, the lung with the 
higher degree of destruction was treated first.  If a patient was shown to have one 
lung with a heterogeneous distribution of disease and one with a homogeneous 
distribution, the heterogeneous lung was treated first, owing to the greater body of 
evidence for lung volume reduction in this group.   
 
8.3.6 QUALITY OF LIFE 
Quality of life was assessed at baseline using the SGRQ, and re-assessed for changes 
at each follow-up visit.  The mMRC scale was also used to get a subjective 
assessment of breathlessness at each non-treatment visit.   
 
8.3.7 THE 6 MINUTE WALKING TEST 
A 6MWT using standard protocols (ATS 2002) was performed along a 30m corridor at 
each non-treatment visit, and the distance walked recorded.  Pre- and post-exercise 
Borg scores for breathlessness and RPE were recorded, along with blood pressure, 
pulse, and blood oxygen saturation (using an infrared finger probe). 
 
8.3.8 ARTERIAL BLOOD GASES 
Arterial blood gas tensions were measured at baseline and again at the 3 month 
follow-up visit in both arms of the trial, via a radial arterial sample (Rapidlab 348, 
Bayer, Germany). 
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8.3.9 LVRC DELIVERY SYSTEM 
LVRC deployment was achieved using a dedicated sterile, disposable, single-use 
(single-patient) delivery system composed of 4 parts (figure 8.4), namely a soft 
tipped flexible guide wire, a delivery catheter, a loading cartridge, and locking 
forceps.  The guide wire served as a guide for the delivery catheter by identifying 
appropriate airways to treat, and by supporting the catheter to help guide it to a 
delivery site.  The cartridge is designed to straighten the implant before delivery, 
allowing it to pass down the delivery catheter, whilst the forceps grip the proximal 
end of the LVRC and deliver it through the catheter, allowing controlled placement 
and release of the device.   
 
Figure 8.4: Components of the Delivery System 
 
Guide 
wire 
 
Catheter 
 
Cartridge 
 
Forceps 
 
 
 
8.3.10 COILS USED 
The LVRC implants were available in seven lengths to accommodate anatomical 
variations –70mm, 85mm, 100mm, 125mm, 150mm, 175mm and 200mm, although 
no subjects in this trial were treated with implants of less than 100mm.  Ten 
millimetres of the proximal end of the implant is floppy, to minimize trauma to the 
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airway wall, whilst the proximal end is shaped like a ball to allow grasping by the 
forceps for placement and removal.  The distal and proximal ends of the implant are 
designed to reside in airways with an inner diameter of 2mm and 6mm respectively.   
 
The choice of coil size for each deployment was made by measuring the length of the 
target airway under fluorescence imaging using radio-opaque markers 25mm apart 
on the guide wire.  On deployment, the LVRC tends to migrate distally, and therefore 
devices were ‘oversized’ by 50mm to allow the proximal end to remain visible in the 
larger airways at bronchoscopy.  This permitted relatively straight forward 
identification of the coil if removal became necessary. 
 
8.3.11 BRONCHOSCOPIC PROCEDURES 
The procedure is designed to be performed using a therapeutic bronchoscope, with a 
2.8mm working channel, and fluoroscopy for visualization beyond the bronchoscope 
(figure 8.5).  Using conscious sedation and local anaesthetic, a fibreoptic 
bronchoscopy was performed via an endotracheal tube in each subject.  Two 
subjects were unable to tolerate awake bronchoscopy, and the procedures were 
therefore performed under general anaesthetic. 
 
LVRCs were placed in segmental or subsegmental airways, as determined by analysis 
of the screening CT scan and ease of catheter insertion during the procedure.  The 
aim was to leave an even spread of devices throughout the treatment lobe, with a 
target of 8 to 10 LVRCs per treatment (figure 8.6).  The following steps constituted 
the procedure: 
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1. Identify a target segmental or subsegmental airway in the treatment lobe 
2. Insert guide wire into deployment catheter and pass both down the working 
channel of the bronchoscope 
3. Advance catheter until the tip is in the desired airway 
4. Advance guide wire under fluoroscopic guidance to measure the target airway, 
ensuring that the guide wire is as straight as possible and away from the pleura 
5. Gently advance catheter over guide wire – stop if resistance is felt 
6. Withdraw guide wire leaving catheter in situ 
7. Load appropriately sized LVRC into loader cartridge using dedicated forceps, and 
attach cartridge and forceps to the end of the catheter 
8. Advance LVRC using forceps until the distal end just emerges from the catheter 
9. Withdraw catheter without withdrawing LVRC 
10. Release proximal end of LVRC by unlocking and opening forceps 
11. Repeat until all target airways treated 
 
Figure 8.5: Coil deployment under fluoroscopic guidance 
 
 
 
 
 
 
 
 
 
Tip of  
bronchoscope 
LVRC-being 
deployed out 
of the delivery 
catheter 
Tip of delivery  
catheter 
Tip of forceps 
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The LVRC can be removed by reversing the deployment procedure: re-capturing the 
proximal end of the implant with the forceps and then advancing the catheter 
distally over the implant whilst maintaining the relative position of the implant to the 
bronchoscope. 
 
A chest radiograph was performed 1 hour after the procedure to check LVRC 
placement and to exclude pneumothorax (figure 8.6).  Subjects were monitored for 
at least 1 night after the procedure, and began a 1 week course of oral antibiotics 
and prednisolone as prophylaxis against COPD exacerbations. Subjects in the control 
arm of the trial attended for a physical examination and review of their clinical status 
in lieu of LVRC implantation. 
 
Figure 8.6: Post-procedure chest radiograph showing bilateral upper lobe LVRC placement 
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8.4 RESULTS 
 
8.4.1 BASELINE DATA 
Of the 20 subjects reported here, 10 were randomized to the treatment arm and 10 
to the control arm of the trial.  All control subjects crossed over to the treatment 
arm 3 months after control treatment 2, and therefore control baseline data are 
available on 10 subjects and treatment baseline data on 20 subjects.  For crossover 
subjects, the 3 month control data was used as treatment baseline data.  Baseline 
data are represented in table 8.4, with values presented as Mean (SD).  All p values 
are for unpaired t-tests except for sex, for which the chi squared test was used. 
 
Table 8.4: Baseline data 
 
 Control Treatment p value 
Number 10 20 - 
Age (y) 65.4 (8.9) 64.5 (7.4) 0.79 
Male 70% 65% 0.63 
BMI 24.8 (4.8) 24.2 (4.3) 0.74 
FEV1 % predicted 30.2 (5.4) 27.5 (6.4) 0.26 
FVC % predicted 92.4 (12.2) 85.3 (18.4) 0.28 
RV % predicted 239.9 (88.1) 224.8 (49.3) 0.55 
TLC % predicted 132.4 (12.6) 134.9 (11.9) 0.61 
FRC % predicted 182.5 (19.0) 206.1 (67.8) 0.29 
TLco % predicted 32.0 (10.0) 32.5 (10.4) 0.90 
mMRC 2 (2-3) 2 (2-4) 0.25 
SGRQ 53.6 (10.7) 60.2 (9.9) 0.11 
6MWD (m) 349.8 (132.4) 312.7 (100.8) 0.40 
 
8.4.2 PRIMARY ENDPOINT 
One subject died after treatment 1 but before any follow-up (death deemed 
unrelated to the procedure), and 1 treatment subject withdrew from the trial after 1 
month of follow-up and before treatment 2.  One data set from 1 month post 
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treatment 1 was not available owing to a prolonged hospital admission, and 1 
subject refused static lung volume measurements at 1 month post treatment 2 
(which includes airway resistance and gas transfer measurements).  Complete data 
sets were available for all other visits in both arms of the trial.  Figure 8.7 shows 
subject numbers remaining in the trial at each data collection time point.  Data on 18 
treatment subjects and 10 control subjects were therefore available at the 3 month 
primary endpoint visit. Raw data for individual subjects can be found in appendix 6.   
 
Figure 8.7: Subjects available for assessment at each follow-up time point 
 
 
 
 
 
There was a statistically significant and clinically beneficial change in the SGRQ in the 
treatment arm at 3 months (-7.9±12.5; p=0.02), in contrast to a clinically detrimental 
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but statistically non-significant change in the control arm (5.0±11.3; p=0.19).  When 
comparing changes between the 2 arms, there was a very significant difference in 
the change in SGRQ in favour of treatment (p=0.006), suggesting that LVRC 
treatment leads to improvements in respiratory health related QoL.  This 
relationship held true at each of the 3 follow-up visits (p=0.001; p=0.003; p=0.006).  
Data are represented graphically in figure 8.8 as mean with error bars denoting 
standard deviation. 
 
Using an intention to treat analysis, 9/20 (45.0%) treatments and 1/10 (10.0%) 
controls met the ‘responder’ criteria.  On chi squared testing, there was a highly 
significant difference between the 2 arms of the trial (χ2=6.144; df=1; p=0.007), and 
therefore the null hypothesis is rejected. 
 
Figure 8.8: Changes in SGRQ 
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8.4.3 SECONDARY ENDPOINTS 
Paired t-tests were performed on data at all visits from 1 month post treatment visit 
1  through 3 months post treatment visit 2 against baseline data within both groups 
(two-tailed looking for any changes), with unpaired t-tests performed on the 
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difference in changes between the two groups (one-tailed looking for superiority as 
mandated in the protocol), except for paired changes in mMRC score, where the 
Wilcoxon ranked sum test was used. 
 
There were no changes in measured endpoints in the control arm of the trial, except 
an unexpected fall in the TLC (and FRC) at 1 month post treatment 1 (mean -256mls; 
p=0.02).  There were, however, statistically significant changes in the direction of 
improvement in all secondary endpoints in the treatment arm at all follow-up time 
points, except for the mMRC score at 1 month post-procedure 1 (see table 8.5).   
There were marked changes at 3 months in the FEV1 (mean 140mls, 19.2%; 
p<0.0001), the RV (mean -543mls, -10.5%; p=0.003), and 6MWD (mean 66.4m, 
21.9%; p=0.0002).   
 
When comparing data from the 2 arms of the study, there was a very highly 
significant difference in the changes in FEV1 (p=0.0001), a highly significant 
difference in the change in 6MWD (p=0.001), and significant differences in the 
changes in RV (p=0.02) and the mMRC score (p=0.045) at 3 months in favour of the 
treatment.  The change in TLC, however, became non-significant owing to the fall in 
the mean value seen in the control data (p=0.12).   Significant differences in FEV1 and 
6MWD were seen at all 3 follow-up visits, and in the RV and mMRC score from 1 
month post-treatment 2.  Values for each parameter are shown in table 8.5 as Mean 
(SD), except for mMRC in tables a) and b) shown as Median (Range).  Graphical 
representations of the data are shown in figure 8.9 as mean with error bars 
representing the standard deviation, and statistically significant differences in 
 218 
measured changes are marked (*) where they occur.  Some non-endpoint data is 
also displayed (changes in FVC, FRC, RV/TLC, expiratory airways resistance (Raw Ex), 
TLco).   All individual data can be found in appendix 6. 
 
Table 8.5: Secondary and non-endpoint data - a) control, b) treatment, c) changes control v treatment 
 
b) Baseline T1 1m p value T2 1m p value 3 months p value 
FEV1 0.73(0.17) 0.85(0.19) 0.0001
* 0.87(0.17) <0.0001** 0.87(0.18) <0.0001** 
RV 5.17(1.34) 4.73(1.23) <0.0001** 4.47(1.04) 0.004†† 4.63(1.19) 0.003†† 
TLC 8.13(1.49) 8.03(1.49) 0.04† 7.89(1.53) 0.03† 7.93(1.48) 0.03† 
6MWD 312.7(100.8) 358.8(122.9) 0.0004* 376.6(119.2) <0.0001** 370.2(105.0) 0.0002* 
mMRC 2(02-4) 2(0-3) 0.07 2(0-3) 0.02† 2(0-4) 0.04† 
FVC 2.88(0.67) 3.14(0.68) 0.007†† 3.17(0.69) 0.002†† 3.14(0.61) 0.003†† 
FRC 6.19(1.39) 5.98(1.34) 0.001†† 5.84(1.33) 0.005†† 5.72(1.35) 0.007†† 
RV/TLC 62.26(6.68) 58.48(6.76) <0.0001** 56.59(5.31) 0.001†† 57.60(6.03) 0.0008* 
Raw Ex 1.07(0.55) 0.87(0.37) 0.03† 1.03(0.41) 0.39 0.86(0.41) 0.04† 
TLco 2.69(0.93) 2.81(0.84) 0.12 2.72(0.78) 0.97 2.75(0.81) 0.74 
 
c) T-C T1 1m p value T-C T2 1m p value  T-C 3m p value 
FEV1 17.5(8.6) 0.03
† 25.5(6.2) 0.0002* 26.5(6.2) 0.0001* 
RV -4.0(2.4) 0.06 -9.8(5.0) 0.03† -8.0(3.7) 0.02† 
TLC 1.4(1.3) 0.14 -1.4(2.3) 0.28 -2.0(1.7) 0.12 
6MWD 16.2(7.2) 0.02† 30.7(7.4) 0.0002* 29.5(8.7) 0.001†† 
mMRC# -0.4(0.3) 0.10 -0.8(0.4) 0.02† -0.6(0.3) 0.045† 
FVC 13.1(6.2) 0.02† 19.6(4.9) 0.0003* 16.0(4.5) 0.0007* 
FRC -1.1(1.9) 0.28 -3.4(3.4) 0.16 -6.4(3.9) 0.06 
RV/TLC# -5.4(2.1) 0.01† -8.4(3.3) 0.01† -4.2(1.9) 0.02† 
Raw Ex -10.1(11.5) 0.20 3.0(13.1) 0.41 -10.3(14.7) 0.24 
TLco 4.7(5.8) 0.21 -1.8(6.6) 0.40 3.3(6.8) 0.31 
pO2 - - - - 0.1(3.5) 0.49 
pCO2 - - - - 2.1(2.8) 0.23 
#
absolute value 
† 
p<0.05; 
†† 
p<0.01; 
* 
p<0.001; 
** 
p<0.0001 
a) Baseline T1 1m p value T2 1m p value 3 months p value 
FEV1 0.80(0.17) 0.82(0.18) 0.66 0.77(0.13) 0.31 0.77(0.18) 0.33 
RV 4.77(0.98) 4.56(1.02) 0.05 4.77(1.30) 0.99 4.67(0.86) 0.41 
TLC 7.97(1.51) 7.72(1.46) 0.002†† 7.90(1.69) 0.72 7.91(1.50) 0.23 
6MWD 349.8(132.4) 341.9(110.0) 0.79 342.1(132.2) 0.22 338.8(109.9) 0.53 
mMRC 2(2-3) 2(1-3) 1.00 2.5(1-3) 0.76 2(2-4) 0.85 
FVC 3.17(0.72) 3.10(0.80) 0.63 2.92(0.58) 0.07 3.04(0.72) 0.06 
FRC 5.94(1.15) 5.73(1.10) 0.02†† 5.88(1.55) 0.79 5.85(1.27) 0.50 
RV/TLC 59.98(5.25) 59.14(6.58) 0.50 59.95(5.20) 0.99 59.15(3.24) 0.55 
Raw Ex 1.09(0.44) 1.01(0.38) 0.46 1.03(0.34) 0.52 1.01(0.41) 0.54 
TLco 2.65(0.99) 2.73(1.03) 0.49 2.78(0.98) 0.31 2.69(1.03) 0.69 
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Figure 8.9: Secondary endpoint data and non-endpoint measurements 
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8.4.4 ADVERSE EVENT PROFILE 
A log of all adverse events (AEs) up to 3 months of follow-up after the second lung 
was treated was kept for all 20 subjects.  Figures are represented in table 8.6 as total 
(mean; SD).  The most commonly occurring AE in both arms was acute exacerbation 
of COPD, accounting for over half of all AEs (53.7% treatment, 66.7% sham). There 
were no significant differences between the 2 groups in the number of AEs or SAEs 
per subject, nor in the number of COPD exacerbations. 
 
Table 8.6: Adverse events at 3 months of follow-up 
 
 Treatment group Control group p value 
AEs 42 (2.05;1.28) 12 (1.20;0.92) 0.07 
SAEs 
COPD 
15 (0.75;1.16) 
22 (1.10;0.97) 
1 (0.10;0.32) 
8 (0.80;0.79) 
0.10 
0.40 
 
 
8.5 DISCUSSION 
 
Although this trial was not blinded and caution is needed when interpreting the data 
(especially subjective data such as the SGRQ), some of the treatment changes 
reported here are dramatic, with very impressive p values given the small numbers 
involved.  Even though the power calculation required 42 sets of data, the benefits 
were such that with fewer than half this number statistically significant changes were 
seen in spirometry, plethysmography, exercise capacity, and symptom scores. 
 
One significant problem with this trial is the choice of the SGRQ as the primary 
outcome measure.  How the patient feels is clearly very important in the evaluation 
of any treatment, however this trial was non-blinded and as such there was the 
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potential for a significant placebo effect to occur.  The SGRQ is an entirely subjective 
questionnaire (to the extent where it is not permitted to provide any help with 
answering the questions), and scores are highly susceptible to placebo responses.  
Unfortunately, this endpoint was rather curiously dictated by the FDA in agreement 
with PneumRx Inc.  This issue was raised with the company at the time of protocol 
finalisation and submission for ethical review by our site, but we were unable to 
persuade them to pursue a change in primary endpoint to a more objective measure 
of lung function with the FDA.  Nonetheless, the impressive changes in secondary 
(objective) endpoints do lend weight to the argument that the reported changes in 
quality of life are real. 
 
A double-blind sham controlled study would be the ideal study design, but there are 
significant problems with masking which study arm patients are in with such 
radiographically obvious implants.  Similarly, it was felt that introducing 2 sham 
bronchoscopies into the control arm was unjustified given the reported adverse 
event rate in the sham arm of the EASE trial (see chapter 7).  This meant it was not 
possible to delineate which early AEs were associated with the LVRCs or the 
bronchoscopy itself, but in clinical practice this distinction is not so relevant (patients 
would have to endure the bronchoscopy to have the LVRCs implanted) and given the 
problems with blinding would likely have added little useful information at the 
expense of greater risk to those in the control arm of the study. 
 
The procedure is designed to be performed in 2 treatments, but there appears to be 
little additional benefit in the treatment group from treatment 2 on top of that 
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gained from treatment 1.  Indeed, there were no statistically significant benefits in 
any measured parameter between 1 month post treatment 1 and 1 month post 
treatment 2, either within the treatment group or when comparing changes 
between groups (table 8.7), except for the change in 6MWD in the treatment group.  
This was not significant at 3 months when comparing the change to that seen in the 
control group, and certainly did not reach the level required for clinical significance 
(absolute mean increase 17.8m).  There are a number of possible reasons for this.  
Firstly, by deliberately selecting the lung deemed to be the most likely to benefit 
from LVRC implantation, it follows that one would not expect the same level of 
improvement from the second treatment as from the first.  This is supported by data 
from one patient who appeared to derive no benefit from treatment 1, but had 
significant changes in lung function following treatment 2 (figure 8.10), suggesting 
that we had perhaps identified the ‘wrong’ lung for treatment 1.  Secondly, it could 
be that treatment of the second lung in some way reduces the treatment effect on 
the other lung, although there is no sound physiological explanation for this.   
 
Table 8.7: Changes in outcome measures attributable to treatment 2 
 
  T2-T1 Treatment p value  T2-T1 Control p value TvC p value 
SGRQ# 0.75(12.19) 0.80 0.12(6.95) 0.96 0.88 
FEV1 2.88(18.26) 0.89 -5.05(14.85) 0.17 0.26 
RV -0.98(12.14) 0.52 5.00(20.53) 0.53 0.36 
TLC -0.26(4.68) 0.82 2.01(6.78) 0.33 0.32 
6MWD 6.98(14.19) 0.04† 0.56(25.97) 0.99 0.41 
mMRC# -0.29(0.69) 0.12 0.10(0.57) 0.77 0.07 
FVC 1.74(14.17) 0.78 -3.14(15.69) 0.39 0.41 
FRC -0.41(7.40) 0.74 1.76(11.39) 0.50 0.56 
RV/TLC# -0.85(5.13) 0.52 0.81(7.71) 0.75 0.51 
Raw Ex 23.31(39.38) 0.14 5.68(25.58) 0.80 0.22 
TLco -3.69(11.38) 0.14 2.34(6.03) 0.43 0.14 
#
absolute value 
† 
p<0.05 
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Figure 8.10: Changes in lung function in subject 09 
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One other potential explanation is that the treatment effect is actually relatively 
short lived, as it was in chapter 7 for airway bypass, and that the benefits of 
treatment 1 have largely disappeared by the time testing after treatment 2 is 
performed.  This would, however, require the LVRCs to either lose their mechanical 
properties (desperately unlikely), or for them to tear through lung parenchyma such 
that they no longer provide additional elastic recoil or mechanical compression.  
Against both of these explanations is that there is not a return to baseline at 3 
months after treatment 2 (there is no reason why the effects of treatment 2 should 
persist but not treatment 1), and CT scans at 3 months do not suggest parenchymal 
damage from the implants.  When the second lung is treated and recoil forces of 
both lungs come into equilibrium, the reduction in the hyperinflation of the second 
treated lung may be offset by a reduction in the compressive effects in the first lung.  
As the relative difference in recoil properties of the lungs is reduced, this potentially 
leads to a smaller overall effect from treatment 2.  This, together with the fact that 
the remodelled thoracic cage in these patients is likely to provide a limit to the 
amount of short-term total volume reduction (in time there may be further 
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remodelling on account of altered pulmonary mechanics and volume changes), 
provides a possible explanation with some physiological basis. 
 
The relative contribution of lung retensioning/airway splinting and lung compression 
to the outcomes of treatment has generated lively debate.  It is likely that both 
mechanisms play their part in the overall treatment effect, but it is very difficult to 
separate the two with the data that we have.  On CT images there certainly seems to 
be compressive atelectasis of lung parenchyma immediately adjacent to the LVRCs, 
but this is not dramatic and is unlikely on its own to account for some of the large 
volume changes seen.  A well spaced fan of devices within a treatment lobe should 
provide a relatively even degree of retensioning to that lobe, which might in turn be 
expected to hold open the smaller, collapsible, airways during expiration.  This would 
allow improved expiratory airflow and a reduction in gas trapping, with a gradual 
reduction in the RV with time.  A consequence of this airway splinting would be a 
reduction in the measured expiratory airway resistance (Raw Ex), but this was not 
seen in this group of patients as a whole (p=0.24 vs control).  Figure 8.11 shows 
changes in Raw Ex against changes in RV for treatment patients, and although the 
line trends in the right direction, there is no significant correlation between the two 
(r2=0.10; p=0.20).  Nonetheless, some patients did have really quite dramatic 
changes in Raw Ex at the final data collection point (the largest being a -64.4% 
change), and it will be interesting to analyse the entire trial dataset when it becomes 
available. 
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Figure 8.11: Correlation between changes in Raw Ex and RV 
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The implants are designed to be removable, however this can in practice be very 
difficult.  In spite of every effort to leave the proximal end of the implant visible at 
bronchoscopy, not infrequently the LVRC disappeared from view on release.  A 
number of coils were repositioned during this trial, but only at the time of the 
original procedure in cases of too proximal deployment, or prior to being released 
from the forceps.  Therefore, our policy during consent was to tell potential subjects 
that the procedure was to be considered irreversible, unlike endobronchial valve 
treatment.  Participants in this trial had all either been turned down for or refused 
LVRS, but if LVRC implantation becomes a mainstream treatment in the future, it is 
possible that it will be seen as a potential bridge to formal LVRS.  The irreversibility of 
the procedure has the potential to make bilateral stapled LVRS difficult, as the staple 
line will pass through the more proximal portions of the implants, and may mean 
that it has to be considered as a definitive alternative to other LVR techniques. 
 
Although not statistically significant in the patient group presented here, there was 
an almost doubling in the mean number of AEs (p=0.07) and a greater than seven-
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fold increase in the mean number of SAEs (p=0.10) in the treatment group, but 
cautious interpretation is needed owing to the small numbers.  Indeed, there was 
only 1 SAE in the entire control group.  Whether this ratio is seen across the trial as a 
whole remains to be seen, but the figures in table 8.6 do suggest a trend towards an 
excess of AEs following treatment.  Pilot studies demonstrated a propensity to COPD 
exacerbation following treatment, but the prescription of antibiotics and steroids as 
prophylaxis against this resulted in at worst a marginal increase in events in this trial 
(1.1 vs 0.8 per patient; p=0.40), without any reported side-effects.  Of those COPD 
exacerbations, however, a greater percentage of those occurring in the treatment 
arm were recorded as severe events (12.5% control vs 22.7% treatment), although 
the difference is again not statistically significant.   
 
The one obvious difference between the two groups, however, is in pneumothorax 
rates, with no events in the control arm and 6 in the treatment arm (38 procedures; 
pneumothorax rate 15.8%).  Four of these occurred at or immediately following the 
procedure (i.e. they were identified on fluoroscopy or the post-procedure chest 
radiograph), 1 at 3 weeks, and 1 at 1 month following the second procedure.  Three 
of the procedure-related events resolved rapidly with fine bore intercostal tube 
drainage and did not lead to a delay in discharge. 
 
Although the number of pneumothoraces appears high, two thirds of them were 
peri-procedural in nature, and caused no on-going issues after resolution.  One has 
to remember that with lung volume reduction surgery (against which BLVR is 
compared), all patients leave the operating theatre with a large bore drain in situ, 
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and this can remain in place for a number of days.  Whilst the rate in this series is 
higher than that reported with other BLVR devices, this should not be seen as a 
significant safety issue.  Indeed, pneumothorax may even enhance the effect of the 
procedure.  The treated lobe is likely to remain at least partially collapsed following 
drainage owing to the greater compliance of the non-treated lobe, which will expand 
first to fill the hemithorax. 
 
The one death during the trial occurred between treatment 1 and the first follow-up 
appointment, but was not considered to have been related to LVRC implantation.  
The subject in question was admitted to her local hospital with influenza B infection, 
and developed a subsequent secondary bacterial hospital acquired pneumonia with 
a vancomycin resistant enterococcus (VRE).  She was subsequently transferred to our 
institution, where she was found to also have multiple pulmonary emboli (PEs).  In 
spite of anticoagulation with low molecular weight heparin, she required intubation 
for rapid cardio-respiratory collapse, with gross right ventricular strain on 
echocardiogram.  Thrombolysis for life-threatening PE was given, and she was 
transferred to the intensive care unit.  The development of neurological signs 
prompted a CT scan of the brain, which showed multiple cerebral infarcts 
characteristic of emboli, and treatment was withdrawn.  It is likely that an 
undiagnosed patent foramen ovale or similar cardiac defect allowed the right to left 
movement of a shower of emboli at the time of thrombolysis, resulting in multiple 
areas of cerebral infarction.   
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Although it was deemed unlikely that the procedure had any bearing on the 
development of influenza B (the precipitating event), one interesting aspect of the 
case was the culturing of aspergillus in the sputum following transfer to our 
institution.  Subsequent to the follow-ups reported here, a number of subjects have 
cultured aspergillus in their sputum (private correspondence, Z Zoumot), which 
would otherwise be unusual in a cohort of COPD patients otherwise fit enough to 
participate in trials such as this.   Fungi such as aspergillus and candida are known to 
colonise foreign bodies in non-sterile tissues, and the presence of the LVRC implants 
may be encouraging colonisation in these patients.  Whilst there is no evidence that 
the aspergillus is causing disease in these cases, this is an area of potential concern 
that requires monitoring over the coming months and years.  Given the probable 
permanent nature of a least a proportion of LVRCs, if outright infection were to 
occur as a result of implant colonisation, it would be very difficult, even impossible, 
to achieve eradication of the fungus whilst the implants remained in situ (unlike 
other implants such as endobronchial valves). 
 
This thesis only reports on controlled data, and as such only extends to 3 months 
after the second procedure.  As such, it is not possible to comment on the duration 
of benefit that a patient can expect from the procedure beyond this time.  Full trial 
data will give details out to one year following treatment 2 (roughly 13 months after 
the initial treatment), but there will not be comparative control data.   The relatively 
short duration of control follow-up is a weakness of this study, as it does not allow 
any assessment of medium or long-term benefits of treatment with LVRCs, although 
this is being addressed in a large multicentre study in the USA for the purposes of 
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FDA approval with control follow-up out to 1 year.  This is a particularly important 
issue given the dramatic decline in response seen in the EASE trial after initially 
promising results (Shah 2011ii). 
 
There does not, however, appear to be any reduction in the treatment response at 
the 3 month follow-up visit, and indeed some parameters were continuing to 
improve at that time (e.g. FEV1, TLC, FRC).  The lack of change following the second 
procedure was perhaps a little disappointing, but the fact that an excellent 
treatment response can be achieved with only one procedure has the benefits of 
reduced risk for the patient and reduced cost for the health provider, making 
widespread uptake of the technique more feasible.  A second procedure could then 
be performed in some patients perhaps years later, when their symptoms had 
progressed or, if it is to occur, the treatment effect from the first procedure has 
worn off. 
 
8.6 CONCLUSIONS 
 
Treatment with multiple LVRCs produces both statistically and clinically significant 
changes in lung function, exercise capacity as measured by the 6MWT, and symptom 
scores in patients with severe emphysema early after the procedure, with effects 
lasting at least 3 months, although treatment of both lungs does not appear to 
confer any advantage over treatment of one lung alone, at least when treatments 
are scheduled close together.  Further work is required to clarify the reasons behind 
this, and also to determine the optimal number of coils to implant at each 
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procedure.  Longer term follow-up data at 6 and 12 months are awaited to 
determine the durability of the treatment and its medium term safety, but the 
evidence reported here suggests that the LVRC is an effective and safe method of 
inducing bronchoscopic lung volume reduction.  A large, multi-centre, randomised, 
double blind study is now needed to provide conclusive evidence of the procedure’s 
benefit. 
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CHAPTER  9::   DIISCUSSIION  
 
This thesis has presented data on a number of bronchoscopic lung volume reduction 
techniques and technologies, with a range of outcomes.  The data are predominantly 
negative, and several methodological issues mean that it is difficult to directly 
compare techniques.  The variety of endpoints used was to a large extent an 
unfortunate consequence of the involvement of a variety of external entities in the 
development of commercial protocols, and attempts to influence decisions in this 
regard were unsuccessful.  Similarly, sample sizes are too small to draw any firm 
conclusions, and the lack of control data in some of the studies presents significant 
problems with data interpretation.  Nonetheless, there are some useful points to be 
taken away from this work, especially in regard to collateral ventilation, and the 
formation of accessory airways.  Perhaps the most promising data, albeit relatively 
short-term in nature, has come from the LVRC study in chapter 8 and it will be 
interesting to see if medium and longer term outcomes match those seen in this 
thesis.  There is certainly the need for more long-term controlled data in this regard, 
and this is being addressed in a larger study in the USA (the ‘RENEW’ study, PneumRx 
Inc.). 
 
An ideal set of studies would have tested the same devices and techniques as in this 
thesis, but with uniformity across the protocols.  This would require at least the 
following: 
1. Standard outcome measures using identical testing protocols 
Changes in lung function are easy to measure, and are reliable when performed 
correctly.  Some measure of functional ability is also important (after all this is at 
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least in part what the patient is interested in), as it is difficult to accurately infer 
the magnitude of improvements in quality of life, symptoms, exercise tolerance, 
and morbidity with any specific change in lung function.   
2. Adequate follow-up time 
A minimum of 12 months of follow-up data, and ideally longer. 
3. Robust blinded control data 
4. Sham procedures in the control arm  
There has been some concern raised over the AE event rate in the EASE trial and 
there has been reluctance to include sham procedures in recent trials.  The 
inclusion of a sham procedure does allow correction for placebo response, 
allows a distinction to be made between procedure and device related events, 
and allows collection of more meaningful quality of life (subjective) data, but 
does come at a cost to the patients that is hard to justify.  However, explicit 
statements concerning all risks should be part of the consent process for any 
trial. 
5. Adequate numbers to allow firm conclusions to be drawn 
6. The absence of commercial influence 
This is important in protocol design, and removes the potential for selective 
statistical analysis that has been a problem in a number of commercial 
pharmaceutical trials.  
 
The post hoc nature of this thesis meant that adhering to identical protocols was 
impossible.  Work is already underway by colleagues to address some of the issues 
raised with studies present here, including the running of an MRC funded trial 
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specifically looking at endobronchial valves in those without collateral ventilation 
(sham controlled, double blinded), and involvement in the (commercial) RENEW 
study with 1 year controlled LVRC data.  A second autologous blood injection study 
was set up with longer term (6 month) follow-up, but has since been abandoned 
owing to a continued lack of response in favour of the more promising intrabullous 
blood injections (Zoumot 2013).  
 
Although the results in this thesis are somewhat disappointing overall, there has 
been a significant volume of work form other institutions around the world 
published to suggest that significant benefits to patients can be obtained with 
bronchoscopic lung volume reduction, and a number of techniques and devices are 
now available on the open market, at least in Europe.  These initial studies have all 
demonstrated similar results, and for those new to the field it can be difficult teasing 
out which products are likely to be of greatest benefit to their patients. 
 
Collateral ventilation certainly seems important to the success of some of these 
techniques (blocking devices and accessory airways).  One practical approach is to 
stratify techniques based on their relationship to collateral ventilation, dividing them 
into three distinct groups - reliant on its absence, reliant on its presence, and 
theoretically independent of it.  There are, however, a number of ways in which the 
various BLVR techniques can be categorised, either by mode of action or by patient 
(sub)group, and these groupings are outlined below (tables 9.1 and 9.2) and 
discussed in more detail in this chapter. 
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We know from the NETT study that a distinct population of emphysema patients, 
those with upper lobe predominant disease and low exercise tolerance, can benefit 
from formal LVRS, but this leaves the majority of severe emphysema patients with 
no options other than transplantation (a very limited resource).  In spite of that trial 
defining a population who could benefit from such surgery, there has been a 
dramatic decline in the number of LVRS procedures performed in the USA, and this 
has led to the huge expansion in investment in BLVR techniques.  The ideal device or 
technique would achieve similar results to LVRS, be simple to perform with few 
adverse events, be applicable to a wide range of patients, be reversible if necessary, 
demonstrate sustained benefits in a number of outcomes, and be cost effective 
(particularly important for publicly funded healthcare systems such as the NHS).  
Does such a technique exist? Perhaps the closest to this ideal to date is the lung 
volume reduction coil (although it falls down heavily on price – approximately 
£10,000 per lung), but all of the methods listed below achieve only some of these 
goals. 
 
There is a conspicuous lack of (positive) pivotal trial data on which to base treatment 
decisions for virtually all the techniques so far investigated, although a number of 
techniques are in the planning or launch phase of such studies.  It is, however, in the 
opinion of the author, becoming clear that it is not the actual method of volume 
reduction per se that counts, rather the choice of device based on patient 
characteristics.  To illustrate this, the results of a number of recent trials are 
compared in table 9.3, and demonstrate very similar outcomes.  Entry criteria were 
largely similar, with all results being at 3 months of follow-up.  Some techniques 
 235 
claim better results with certain outcome measures (e.g. LVRCs compare very well in 
the 6MWD, possibly owing to their effect on dynamic hyperinflation, and hydrofoam 
gel treatment seems to provide a more dramatic change in FEV1).  Whether this 
simply represents statistical variation is unclear, but if these results hold true in 
larger controlled studies, then they may allow further tailoring of products to 
individuals. 
Table 9.1: Stratification of BLVR methods by technique/device characteristics 
Airway occlusion    Reversible     
Intrabronchial valves    Intrabronchial valves    
Zephyr endobronchial valves    Zephyr endobronchial valves    
      Transthoracic pneumonostomy  
Accessory airways         
Airway bypass     Potentially reversible    
Transthoracic pneumonostomy  Lung volume reduction coils   
      Airway bypass* 
Sclerosants/inflammatory         
AeriSeal foam     Irreversible     
Autologous blood +/- clotting agents  AeriSeal foam     
Thermal vapour ablation   Autologous blood +/- clotting agents  
        Thermal vapour ablation   
Compressive devices         
Lung volume reduction coils  
 
Table 9.2: Stratification of BLVR method by patient characteristics 
Heterogeneous disease   Collateral ventilation present 
Intrabronchial valves    Airway bypass 
Zephyr endobronchial valves   Transthoracic pneumonostomy 
AeriSeal foam 
Autologous blood +/- clotting agents  Collateral ventilation absent 
Thermal vapour ablation   Intrabronchial valves 
      Zephyr endobronchial valves 
Homogeneous disease 
Airway bypass     Collateral ventilation irrelevant 
Transthoracic pneumonostomy  Lung volume reduction coils  
AeriSeal foam  
Any distribution     Thermal vapour ablation  
Lung volume reduction coils   Autologous blood +/- clotting agents  
(Intrabronchial/endobronchial valves?) 
(Sclerosant therapies?) 
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Table 9.3: Comparison of results at 3 months from trials of various BLVR technologies 
 FEV1 TLVR 6MWD SGRQ 
Endobronchial Valves 
(Herth 2012i) 
23% -753mls 31m -10.0 
Volume Reduction 
Coils (Shah 2013) 
12% N/A 70m -10.5 
Thermal Vapour 
(Snell 2012) 
17% -716mls 24m -11.0 
AeriSeal Hydrofoam 
Gel (Kramer 2012) 
31% -895mls N/A -8.0 
TLVR- Target lobe volume reduction 
Certainly the unidirectional valve systems are the most widely studied devices – the 
airway blockers.  Although considered to be a positive study by some, when one 
looks at the overall VENT data for Zephyr valves it is singularly disappointing.  
Changes in measured endpoints, although statistically significant, are modest at best 
in clinical terms, and do not reach clinical significance (i.e. MCIDs).  This was largely 
in part as a result of procedural incompetency and a lack of understanding of the 
predictive value of HRCT in determining the absence of collateral ventilation.  More 
recent results using the Chartis system are substantially more encouraging (Herth 
2012i), and trials are now underway in the USA (for the purpose of FDA approval) 
and the UK to further characterise the potential benefits.   
 
The debate over what valve placement strategy to pursue should now have been 
settled, with very poor evidence for any benefit whatsoever with bilateral 
incomplete occlusions, from work undertaken for this thesis, the multicentre study 
by Ninane et al (Ninane 2012), and results from the Heidleberg group (Eberhardt 
2012).  The debate about how best to predict collateral ventilation, however, has not 
been conclusively settled.  Is a good quality CT scan enough to decide who will 
benefit from a technically accurate procedure?  Chartis appears to have an excellent 
 237 
negative predictive value - 100% of those with Chartis-determined CV failed to 
respond to valves – but only a 75% positive predictive value (Gompelmann 2010; 
Herth 2012i).  Interestingly, a recent study presented at the European Respiratory 
Society annual meeting in 2011 from Heidleberg indicated that HRCT was a better 
predictor of response than Chartis (Gompelmann 2011ii).  The Chartis system 
predicted response 74% of the time, HRCT 77% of the time, and where there was 
disagreement between the methods, HRCT predicted correctly a greater percentage 
of the time (55% vs 45%).  However, no data on how they disagreed (i.e. which 
predicted response and which didn’t) was published.  Where both methods agreed, 
response was predicted in 88% of cases, suggesting that a combined Chartis and 
systematic HRCT analysis may be the best strategy. 
 
The relatively simple technique, reversibility of treatment, and significant body of 
experience with valves means that these should probably be considered before 
other devices in patients put forward for BLVR.  A suggested algorithm for lung 
volume reduction is presented later in this chapter (figure 9.1).  The other 
techniques have yet to enter clinical practice, except in a few specialist centres 
worldwide where special authorisation has been granted (similar to the exceptional 
treatment application process in the UK).  A pivotal trial of the AeriSeal system is 
about to begin, and PneumRx has recently received the go-ahead from the FDA to 
run their pivotal trial of the LVRC, and they are currently recruiting centres.  It will be 
several years before the results of these trials are known, however, and there is not 
yet enough data in the literature to justify using either of these techniques in routine 
clinical practice.   
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Autologous blood lung volume reduction may be a slightly different case to the 
others.  The easy availability, low cost, and lack of device related complications mean 
it may be used as the primary procedure in many patients.  Although the limited data 
presented in this thesis does not suggest any response in disseminated emphysema, 
more recent data presented at the National Heart and Lung Institute’s Advances in 
Respiratory Medicine conference (Zoumot 2012) demonstrated dramatic reductions 
in residual volume when used for giant bullous disease.  Kanoh and colleagues 
(Kanoh 2008) had already demonstrated such a response, but crucially Zoumot and 
colleagues did not use any additional clotting products in their procedures.  Success 
potentially provides the benefits of bullectomy without the surgical risk, and failure 
would not hinder any subsequent surgical intervention. 
 
Another relatively straight forward technique using a catheter based system for 
delivering thermal energy to emphysematous lung has been developed (Uptake 
Medical, Tustin, CA).  This Bronchoscopic Thermal Vapour Ablation (BTVA) 
technology uses steam to induce tissue remodelling and scarring, resulting in volume 
loss in the target area.  The steam is delivered via the central channel of a simple 
endobronchial balloon catheter, and the procedure is in many ways the same as 
autologous blood lung volume reduction.  Animal studies demonstrated a dose 
dependent reduction in volumes of treated lobes (Emery 2010), and whilst this was 
not demonstrated in a first-in-human trial, there were clinically significant 
improvements in the SGRQ (-15.3 points) and a reduction in the MRC dyspnoea score 
of 0.5 points, together with a 16% improvement in gas transfer (Snell 2009).  This 
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trial demonstrated the feasibility and safety of the technology, and very recent 
clinical trial data has become available in upper lobe predominant disease (Snell 
2012), demonstrating significant changes from baseline in FEV1 (+141ml), RV (-
406ml), 6MWD (+46.5m), SGRQ (-14.0 points), and mMRC dyspnoea score (-0.9 
points) at 6 months of follow-up (see also table 9.3 for a summary of 3 month 
results). 
 
The concept of accessory airway formation to reduce gas trapping was tackled via 2 
different approaches, one venting air into the larger non-collapsible airways 
(Broncus Technologies, Inc., Mountain View, CA), the other taking the more extreme 
option of venting directly through the chest wall (Portaero, Inc., Cupertino, CA).  This 
second method involves the surgical creation of a transthoracic pneumonostoma 
through which a small plastic tube is inserted to maintain patency and vent air.  A 
pilot study reported changes in lung function measures, although not in exercise 
capacity or quality of life (Moore 2010), and a larger multicentre trial was initiated.  
This has yet to formally report any results, but maintenance of tract patency has 
been a particular issue, in much the same way as with the airway bypass stents in the 
EASE trial (Shah 2011ii).  One major downside with this technique is the remaining 
need for an initial thoracic surgical procedure and its attendant risks (indeed the first 
patient ended up requiring a period on the intensive care unit, although the 
procedure has been modified since then), meaning that this technique can be 
considered to be only ‘less invasive’ rather than ‘minimally invasive’.  Some of the 
pilot study patients subsequently required multiple tract dilatations, and it appears 
that the tracts can close off very rapidly indeed (within a small number of hours).   
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Whilst the theory of additional airways appears sound, the practical aspects of 
implementing that theory have been more challenging than anticipated.  These 
investigations have not, however, been futile.  The principle has been established, in 
particular with the early EASE trial follow-up results, and the technique for airway 
bypass has recently been adopted for use in the investigation of pulmonary nodules, 
allowing direct access to parenchyma not otherwise accessible via the bronchoscope 
(Sterman 2012). 
 
Several companies have invested many millions of dollars in developing their 
technologies, and only time will tell which products become a commercial success.  
Most products are able to claim a particular niche subgroup of patients for whom 
their product is best (valves in those with UL disease and absent collateral ventilation 
for example), but there is considerable overlap, and as more data becomes available, 
companies are claiming success with ever widening indications.  Certainly it is 
difficult to see thermal vapour ablation and hydrofoam gel existing alongside each 
other in the long term, as their mode of action is very similar and patient groups 
identical, unless there is a fairly healthy market for BLVR in the future (the same goes 
for the 2 valve technologies).  The number of patients suitable for BLVR has recently 
been estimated for the United States and European Union by Orbees Medical, a 
marketing company, based on patient subgroups in published data, and their 
analysis is shown below in table 9.4 (e-mail marketing survey, numbers in 1000s).   
The process for arriving at these figures is not apparent, and whether they have 
considered those who would be best served by surgical LVR is not stated, but they 
certainly give an indication of the potential market for each technology.  
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Table 9.4: Potential patient pools for different BLVR technologies. 
Technology Patient population USA* EU* Comments 
 
Pulmonx valves 
 
Heterogeneous or homogeneous 
emphysema without collateral 
ventilation 
145 101 Neglects the market in 
persistent airleaks. 
 
Spiration valves 
 
Heterogeneous or homogeneous 
emphysema without collateral 
ventilation 
145 101 Neglects the market in 
persistent airleaks. 
 
PneumRx LVRCs 
Heterogeneous or homogeneous 
emphysema independent of 
collateral ventilation 
591 410 No comment made on 
patients with bullous 
disease. 
 
AeriSeal system 
Upper lobe predominant 
heterogeneous  or upper lobe 
homogeneous emphysema 
377 262 This division makes 
little sense.  Collateral 
ventilation irrelevant. 
 
Uptake BTVA 
Upper lobe predominant 
heterogeneous emphysema 
226 157 Should have the same 
applicability as the 
AeriSeal system. 
*Potential patient numbers in 1000s 
 
One factor that could restrict access to BLVR is pricing, and publicly funded 
healthcare systems such as the NHS may not be able to afford to offer some or any 
of these technologies.  For 2012/2013, commissioning groups will have to reimburse 
hospitals between £5396 and £8271 for LVRS (Department of Health, 2012), 
depending on the degree of comorbidities and complications, whereas prices for 
BLVR can far exceed this – for example £20000 for bilateral LVRC treatment, €10800 
for bilateral AeriSeal treatment (€2700 per segment, 2 segments per lung), and 
£1500-1600 per valve inserted (usually 2-5 per lobe) plus £650 for collateral 
ventilation measurements, together with any costs associated with performing the 
procedures.  Whilst there may be good reasons for using BLVR over LVRS, such as 
disease distribution or comorbidities, it is unappealing to commissioning groups to 
pay more for a procedure with less substantial evidence of benefit than LVRS.  
Companies need to highlight those groups who are not appropriate for LVRS and 
perform robust safety and cost effectiveness analyses if they are to persuade people 
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to part with such huge sums of money, and that is now one of the major challenges 
faced by the field.  Prices may come down once products are in more widespread 
use, but investors need to see returns on their investments before this is likely to 
happen. 
 
In the UK, BLVR has usually been performed in the context of clinical trials in patients 
who have either been turned down for or declined LVRS.  The reversibility of 
endobronchial valves and the huge mortality and morbidity benefit over LVRS make 
a case for these being offered to suitable patients before LVRS.  If no benefit is 
derived through failure of volume loss, then LVRS remains an option (with or without 
valve removal), whereas success removes the substantial risk of death and long 
hospital stay, and all the downstream effects of prolonged bed rest and inactivity.  A 
lack of response in spite of significant volume loss and atelectasis might suggest that 
LVRS would not be of any benefit anyhow, and again will have saved a potentially 
futile operation.  The algorithm in figure 9.1 incorporates this perhaps controversial 
approach to LVR. Other methods require more robust evidence of benefit and/or 
reversibility (impossible with destructive methods) before they can be considered 
ahead of LVRS in those with upper lobe predominant disease. 
 
Pivotal trial data is certainly needed to establish BLVR as a routine treatment option, 
but this is several years away for all but endobronchial valves (and even with these, a 
more tightly controlled FDA-approved trial is to be undertaken in the USA to 
demonstrate improved outcomes over the VENT).  Ultimately what is needed are 
large randomised trials of the various BLVR techniques against each other, including 
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LVRS in those with upper lobe heterogeneous emphysema, but these are unlikely 
ever to be performed owing to the huge investment, both of time and money, that 
would be required to demonstrate differences between methods with similar 
results.  Nonetheless, retrospective analysis of clinical data with time may weed out 
the underperforming technologies, leaving a suite of interventions that allows the 
interventional physician to offer some form of treatment to almost all patients with 
severe emphysema.  Refinement of techniques and patient populations should 
ensure that BLVR has a place in the future treatment of this patient population, but 
whether the numbers are out there to sustain or justify the cost and investment 
remains to be seen.  Nonetheless, BLVR represents one of the few interventions 
shown to benefit those with emphysema, and future work should clarify the best 
patient populations and ideal treatment methods. 
 
 
Footnotes for figure 9.1 
1
Bullous disease in this context means a bulla greater than 2.5cm in the treatment lobe or greater 
than 10cm in the non-treatment lobe.  These criteria are those used by PneumRx Inc to determine 
whether a subjects CT scan passes screening for entry into their trials.  The explicit rationale for these 
figures is not available.  The evidence for LVRCs in homogeneous disease is greater than with other 
technologies (Shah 2013), and therefore in the absence of bullous disease should currently be the 
treatment of choice.  Subjects recruited to AeriSeal hydrofoam trials had both bullous and non-
bullous disease, and there are no reports of a difference in outcome between the 2 phenotypes. 
 
2
The preferred method of using endobronchial valves in homogeneous bullous disease is supported 
by the data from the European arm of the VENT (Herth 2012ii), where the degree of heterogeneity did 
not appear to impact on the primary outcome measure.  This does conflict with VENT data (Sciurba 
2010), but on the whole there is more evidence for the use of endobronchial valves than for AeriSeal 
hydrofoam.
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Figure 9.1: Suggested algorithm for BLVR 
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APPENDIIX  2::   RAW  DATA  FOR  CHAPTER  3  
 
2.i: Lung function data for upper lobe subjects 
 
Subject   FEV1 FVC RV TLC RV/TLC TLCOc 
3 0 1.29 4.03 4.69 9.09 51.63 4.01 
 3 1.03 4.00 5.18 8.86 58.51 4.16 
  6 1.12 3.87 4.98 9.21 54.07 3.83 
4 0 0.74 3.17 5.86 9.24 63.38 2.42 
 3 0.73 3.03 6.38 9.35 68.23 2.56 
  6 1.05 3.62 5.24 9.04 57.91 2.91 
5 0 0.65 3.32 4.78 8.32 57.42 3.86 
 3 0.71 3.23 4.82 8.14 59.30 4.78 
  6 0.54 2.67 5.28 8.80 65.32 4.49 
8 0 0.73 1.80 3.87 5.66 68.45 1.42 
 3 0.82 1.73 3.70 5.51 67.25 1.86 
  6 0.90 2.01 3.57 5.41 65.98 1.96 
10 0 1.18 4.51 4.61 9.32 49.46 3.73 
 3 1.21 4.64 3.79 8.57 44.21 3.99 
  6 1.26 4.29 4.13 8.46 48.77 3.20 
11 0 1.13 4.37 4.40 8.72 50.44 2.44 
 3 0.77 3.37 5.43 8.60 63.11 2.22 
  6 0.70 3.44 5.38 8.68 61.96 2.42 
14 0 0.99 3.40 4.51 8.25 54.72 3.61 
 3 0.81 2.99 5.01 8.21 61.06 3.11 
  6 1.07 3.70 4.76 8.52 55.91 3.36 
15 0 1.76 5.20 4.49 9.70 46.28 6.80 
 3 2.04 4.48 4.83 9.59 50.38 6.19 
  6 2.02 4.26 3.76 8.29 45.38 5.86 
16 0 0.69 2.74 3.65 6.71 54.32 2.49 
 3 0.71 2.43 3.68 6.24 58.99 2.99 
  6 0.67 2.22 4.04 6.54 61.72 2.65 
17 0 0.75 3.26 4.44 7.76 57.22 4.28 
 3 0.70 2.80 5.08 7.83 64.87 3.63 
  6 0.72 2.59 4.91 7.97 61.63 3.92 
18 0 0.58 2.64 7.27 9.91 73.31 2.75 
 3 0.54 2.54 7.70 10.08 76.38 2.63 
  6 0.68 2.61 7.48 10.37 72.14 2.94 
19 0 1.52 3.45 3.76 7.27 51.77 3.89 
 3 1.53 3.66 3.73 7.90 47.21 4.71 
  6 1.37 3.07 4.56 7.87 57.98 3.95 
20 0 0.72 2.94 7.13 10.54 68.21 3.92 
 3* 0.59 2.34 8.03 10.56 76.05 3.82 
  6 W W W W W W 
21 0 0.96 2.74 4.08 6.86 59.39 2.62 
 3 0.78 2.25 4.17 6.52 63.91 3.09 
  6 0.67 2.37 4.61 6.89 66.85 2.55 
22 0 0.66 2.20 4.05 6.08 66.64 3.07 
 3 0.66 2.05 4.73 6.71 70.48 3.79 
  6 0.58 1.88 4.64 6.45 72.02 3.21 
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23 0 1.74 4.76 5.27 9.95 52.96 2.50 
 3 1.68 4.83 5.43 10.07 53.89 2.41 
  6 1.88 5.03 5.36 10.45 51.32 2.70 
24 0 0.56 2.88 5.02 7.65 65.60 2.15 
 3 0.50 2.31 5.27 7.66 68.80 2.41 
  6 0.56 2.73 5.16 7.71 66.97 2.17 
25 0 0.65 2.58 4.50 7.44 60.52 2.58 
 3 0.65 2.98 4.45 7.20 61.85 2.86 
  6 0.62 2.52 4.32 6.86 63.04 2.70 
29 0 0.53 2.23 5.13 7.45 68.83 1.34 
 3 0.50 2.37 4.99 7.33 68.15 1.35 
  6 0.49 2.64 4.68 7.29 64.17 1.74 
31 0 0.76 2.90 5.00 7.91 63.21 1.44 
 3 0.69 2.65 5.35 7.95 67.27 1.44 
  6 0.74 2.71 5.53 8.20 67.38 1.99 
32 0 0.56 2.03 3.65 5.53 65.96 2.59 
 3 0.52 1.76 3.89 5.69 68.30 2.62 
  6 0.46 1.76 4.23 5.89 71.82 2.50 
33 0 1.10 3.40 4.40 7.79 56.49 3.26 
 3 1.03 3.08 4.61 7.71 59.84 2.99 
  6 0.81 3.05 4.84 7.93 60.96 3.11 
34 0 0.60 2.00 4.03 6.29 64.10 1.43 
 3 0.53 1.93 3.93 5.93 66.17 1.27 
  6 0.62 2.07 3.82 5.95 64.15 1.69 
35 0 0.52 1.81 4.87 6.74 72.18 1.77 
 3 0.46 1.13 4.95 6.48 76.47 1.39 
  6 0.50 1.54 4.97 6.73 73.85 2.05 
36 0 0.71 2.60 8.03 10.63 75.53 2.11 
 3 0.60 2.69 7.59 10.41 72.92 2.34 
  6 0.91 3.94 5.94 9.64 61.62 3.83 
37 0 0.74 2.24 4.75 7.25 65.52 2.15 
 3 0.55 2.50 4.87 7.23 67.45 2.38 
  6 0.65 2.64 4.11 7.08 57.97 2.63 
 
 
 
2.ii: Blood gas, walk, and symptom score data for upper lobe subjects 
 
Subject   pO2 pCO2 6MWT SGRQ mMRC 
3 0 10.40 4.48 332 72.4 2 
 3 10.14 4.73 330 66.7 2 
  6 9.86 4.53 315 67.2 2 
4 0 8.92 6.01 342 59.5 3 
 3 8.39 5.99 374 46.8 3 
  6 8.78 5.30 414 44.2 2 
5 0 10.01 4.46 388 65.6 2 
 3 10.32 4.26 422 53.4 2 
  6 11.19 4.88 222 83.4 3 
8 0 6.24 5.40 239 55.1 3 
 3 7.25 5.44 218 49.3 1 
  6 7.60 5.71 209 41.2 3 
 270 
10 0 10.05 4.43 420 37.2 2 
 3 9.81 4.51 532 39.8 2 
  6 9.34 4.46 517 39.5 2 
11 0 7.56 4.70 413 32.6 3 
 3 7.15 5.11 333 30.0 2 
  6 8.19 5.35 312 40.3 2 
14 0 9.99 4.99 331 47.1 2 
 3 9.86 4.91 272 71.7 3 
  6 9.54 4.92 382 47.4 2 
15 0 8.61 4.98 483 52.8 3 
 3 8.87 3.93 477 27.3 1 
  6 9.55 4.42 496 36.2 1 
16 0 8.66 5.60 272 58.1 2 
 3 9.74 5.60 315 59.9 2 
  6 9.38 5.69 306 67.8 2 
17 0 10.56 5.99 273 51.2 2 
 3 11.06 5.88 208 62.4 2 
  6 12.71 4.79 202 67.0 2 
18 0 11.01 5.78 167 49.7 3 
 3 10.53 5.65 165 54.9 2 
  6 10.64 6.63 200 61.5 3 
19 0 11.51 4.43 171 69.6 2 
 3 10.20 4.77 194 60.4 3 
  6 10.69 5.24 144 61.7 2 
20 0 9.53 4.86 188 70.2 2 
 3* W W W W 4 
  6 W W W W W 
21 0 10.15 5.97 492 50.0 2 
 3 7.91 5.54 505 50.0 2 
  6 8.71 5.53 486 37.8 1 
22 0 11.32 4.92 254 61.7 3 
 3 10.14 5.14 308 73.2 2 
  6 9.36 5.08 211 60.5 2 
23 0 6.11 4.54 288 48.5 3 
 3 6.29 4.98 291 49.2 3 
  6 6.17 4.78 280 50.7 3 
24 0 8.30 5.47 276 58.5 3 
 3 7.96 6.17 245 59.6 2 
  6 7.61 5.62 311 55.4 2 
25 0 9.87 5.28 414 50.3 2 
 3 9.77 5.25 408 51.2 2 
  6 11.35 5.45 424 47.6 2 
29 0 7.87 5.61 236 47.6 2 
 3 7.62 5.96 236 38.5 2 
  6 8.05 5.81 299 35.1 2 
31 0 7.70 5.69 234 75.1 2 
 3 6.61 5.90 180 77.1 3 
  6 7.52 5.48 139 79.2 4 
32 0 9.50 4.39 347 60.8 2 
 3 9.88 5.22 185 75.6 3 
  6 9.03 5.75 240 54.7 4 
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33 0 10.77 5.14 401 47.8 2 
 3 10.37 5.19 372 55.8 2 
  6 9.94 4.93 334 63.7 2 
34 0 7.69 4.24 195 74.7 3 
 3 9.51 4.37 217 64.0 3 
  6 9.03 4.12 240 56.3 2 
35 0 10.35 5.10 232 63.2 2 
 3 9.98 5.38 235 60.7 2 
  6 9.34 5.52 236 48.7 3 
36 0 8.61 5.52 177 69.6 3 
 3 8.76 6.30 161 74.9 2 
  6 9.65 5.04 267 63.3 2 
37 0 10.78 4.33 207 72.8 2 
 3 9.56 4.86 228 60.2 2 
  6 10.64 4.42 177 63.3 3 
 
 
 
2.iii: Cycle ergometry data for upper lobe subjects 
 
Subject   Cycle (s) W VO2 max VE max Borg 
3 0 148 45 12.9 46.21 0/7 
 6 150 45 11.8 49.71 0.5/7 
4 0 151 30 12.3 32.55 0.5/5 
 6 225 30 12.5 33.03 2/4 
5 0 139 30 12.3 28.22 0.5/4 
 6 99 30 9.3 18.89 0.5/9 
8 0 214 15 10.8 22.90 1/3 
 6 291 15 9.6 24.70 0/4 
10 0 248 50 13.9 36.82 0/5 
 6 414 50 14.4 40.95 0/4 
11 0 246 45 12.8 51.10 1/4 
 6 129 45 10.4 34.92 0.5/3 
14 0 180 45 13.8 40.59 0/5 
 6 198 45 13.3 37.75 0/5 
15 0 228 70 16.3 51.88 0/3 
 6 231 70 15.8 50.74 0/3 
16 0 223 30 11.2 27.76 2/7 
 6 111 30 11.7 24.32 0.5/5 
17 0 210 30 15.4 29.97 0/5 
 6 161 30 13.9 26.28 1/5 
18 0 102 10 8.1 22.13 1/9 
 6 78 10 7.6 17.91 2/6 
19 0 652 20 11.9 58.20 0.5/3 
 6 308 20 10.3 35.93 4/5 
20 0 68 20 9.0 22.05 2/8 
 6 W W W W W 
21 0 263 35 18.8 28.17 0/4 
 6 172 35 16.4 22.04 0/5 
22 0 450 15 12.9 24.00 0.5/10 
 6 152 15 11.4 20.80 0.5/9 
 272 
23 0 168 45 10.7 55.32 0/5 
 6 190 45 12.5 61.66 0.5/4 
24 0 127 20 12.0 20.45 1/5 
 6 187 20 13.2 23.16 2/9 
25 0 234 35 16.1 27.41 0/7 
 6 138 35 14.5 24.27 0.5/7 
29 0 100 15 8.4 18.50 0/5 
 6 100 15 8.4 18.73 0/6 
31 0 143 25 12.6 27.77 2/9 
 6 54 25 13.7 28.22 3/8 
32 0 171 20 14.0 28.09 0/5 
 6 98 20 13.8 21.99 0.5/9 
33 0 191 45 15.0 31.54 0.5/9 
 6 128 45 13.8 31.24 0.5/9 
34 0 83 10 8.9 22.98 2/7 
 6 191 10 8.7 19.92 3/5 
35 0 140 20 10.7 19.51 0.5/10 
 6 149 20 10.7 20.57 0.5/10 
36 0 163 20 7.3 25.47 0.5/8 
 6 762 20 8.7 31.59 2/5 
37 0 139 25 11.5 31.52 0.5/9 
 6 105 25 10.5 27.93 0.5/5 
 
 
2.iv: Muscle strength data for upper lobe subjects 
 
Subject   Sniff MIP MEP MVC Twitch 
3 0 73.9 81.6 121.0 45.7 16.8 
 3 77.1 79.7 144.3 55.0 14.8 
  6 61.9 61.6 138.6 38.5 12.0 
4 0 59.2 49.9 108.3 44.8 12.3 
 3 64.3 69.0 99.0 49.0 12.0 
  6 79.5 75.8 95.6 38.8 17.8 
5 0 61.5 74.4 169.5 26.6 7.8 
 3 72.6 71.1 126.9 29.3 10.7 
  6 61.5 70.6 136.9 30.5 7.5 
8 0 49.6 50.6 62.8 10.4 6.6 
 3 64.0 54.8 66.2 BP BP 
  6 65.0 54.8 61.2 BP BP 
10 0 63.6 70.0 73.3 34.6 8.3 
 3 73.2 103.1 75.2 33.0 9.5 
  6 73.2 102.9 64.5 40.1 14.0 
11 0 80.0 77.2 110.5 24.4 9.0 
 3 58.4 67.3 90.3 32.5 13.1 
  6 58.0 66.5 83.6 25.0 9.5 
14 0 96.1 94.1 131.0 45.4 19.6 
 3 92.3 93.4 137.0 30.1 12.6 
  6 100.7 100.5 127.1 34.9 14.6 
15 0 84.8 91.7 92.3 35.3 17.9 
 3 96.3 119.4 89.3 52.7 22.2 
  6 94.8 82.7 94.7 36.6 15.6 
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16 0 83.6 99.0 71.1 23.6 11.8 
 3 83.7 88.4 59.9 25.6 16.0 
  6 70.4 68.0 74.7 22.2 7.4 
17 0 66.6 75.6 124.2 35.5 11.7 
 3 58.0 57.0 99.6 36.8 15.0 
  6 83.1 68.7 97.1 33.4 15.4 
18 0 44.0 50.2 106.8 32.5 11.0 
 3 42.4 47.4 113.1 31.7 15.2 
  6 35.0 32.6 95.3 27.8 18.4 
19 0 49.4 44.7 88.6 35.9 24.6 
 3 54.7 52.1 98.9 37.1 R 
  6 51.7 49.6 103.3 R R 
20 0 68.4 44.0 83.0 32.9 13.4 
 3* W W W W W 
  6 W W W W W 
21 0 41.3 62.1 70.7 23.7 9.1 
 3 62.5 67.9 69.5 20.6 10.2 
  6 74.8 73.3 88.5 24.7 12.4 
22 0 70.2 64.4 83.6 29.5 13.6 
 3 74.1 47.8 74.9 17.9 6.2 
  6 60.9 65.9 73.1 19.1 8.0 
23 0 44.9 43.2 65.7 38.9 14.8 
 3 74.8 62.6 101.0 41.1 13.3 
  6 75.3 71.9 109.2 42.6 14.5 
24 0 57.2 66.1 58.5 25.0 5.9 
 3 43.2 61.8 37.7 19.1 8.0 
  6 53.0 61.7 51.3 21.9 8.1 
25 0 64.1 76.6 79.1 27.1 10.2 
 3 55.3 68.8 92.5 24.7 7.5 
  6 51.1 54.6 92.9 26.1 6.9 
29 0 50.8 59.6 85.3 23.0 10.1 
 3 47.9 52.9 80.4 23.0 8.5 
  6 53.1 57.0 78.0 23.1 8.5 
31 0 59.6 83.3 89.6 24.1 10.5 
 3 69.9 94.9 102.0 28.3 11.0 
  6 48.5 63.3 80.3 23.8 11.4 
32 0 60.9 65.2 92.4 19.3 5.2 
 3 62.8 65.3 128.9 18.7 7.4 
  6 48.7 57.2 126.9 18.4 5.1 
33 0 80.1 59.2 93.5 42.4 10.7 
 3 64.6 86.0 90.3 25.0 8.3 
  6 64.3 60.2 90.9 26.8 6.1 
34 0 50.4 51.6 82.8 16.6 11.2 
 3 54.3 67.1 111.7 24.4 10.8 
  6 53.5 71.3 111.3 28.0 10.7 
35 0 68.3 56.7 63.0 SP SP 
 3 67.2 70.9 72.7 NB NB 
  6 63.7 68.9 72.5 NB NB 
36 0 50.6 65.3 86.7 41.0 14.4 
 3 41.0 59.8 86.8 33.8 15.8 
  6 68.1 85.1 88.6 34.6 14.3 
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37 0 102.4 78.2 105.6 25.6 6.1 
 3 70.6 66.9 137.9 25.9 6.1 
  6 56.6 79.7 134.0 25.2 5.7 
 
 
 
2.v: Lung function data for non-upper lobe subjects 
 
Subject   FEV1 FVC RV TLC RV/TLC TLCOc 
1 0 0.61 1.75 5.21 7.04 74.07 1.40 
 3 0.75 1.91 5.15 7.03 73.24 1.78 
  6 0.71 2.02 4.33 6.31 68.64 1.85 
4 0 0.66 2.74 4.51 7.13 63.23 3.73 
 3 0.59 2.28 4.37 7.24 60.43 3.01 
  6 0.56 2.23 5.81 7.89 73.59 2.37 
5 0 0.79 3.67 8.58 12.03 71.32 3.60 
 3 0.87 3.15 8.72 11.87 73.43 3.27 
  6 0.87 3.22 9.01 12.05 74.71 3.24 
8 0 1.26 5.52 3.98 9.71 41.02 2.67 
 3 1.15 4.60 5.05 9.90 50.99 2.47 
  6 1.17 4.63 5.17 10.13 51.09 2.70 
9 0 0.51 1.85 4.64 6.48 71.69 1.94 
 3 0.50 2.01 3.33 5.61 59.33 1.90 
  6 0.55 2.31 3.54 5.83 60.77 2.38 
11 0 0.69 3.15 3.95 7.05 56.08 3.00 
 3 0.60 2.44 4.65 7.17 64.87 3.06 
  6 D D D D D D 
 
 
 
2.vi: Blood gas, walk, and symptom score data for non-upper lobe subjects 
 
Subject   pO2 pCO2 6MWT SGRQ mMRC 
1 0 6.49 5.05 204 71.8 3 
 3 7.31 5.85 269 65.7 2 
  6 6.92 5.60 309 60.5 2 
4 0 7.95 4.89 432 51.6 3 
 3 8.66 5.15 414 56.2 2 
  6 7.14 5.26 124 65.7 4 
5 0 9.08 5.37 312 66.9 3 
 3 8.50 4.84 315 49.6 2 
  6 8.53 5.20 313 51.5 3 
8 0 7.68 4.04 438 42.0 2 
 3 7.85 4.54 376 53.2 3 
  6 7.28 4.81 372 55.1 3 
9 0 6.73 5.26 142 64.0 3 
 3 7.95 4.85 114 60.2 2 
  6 7.27 4.65 158 57.4 2 
11 0 8.13 5.25 171 87.6 4 
 3 7.94 6.45 271 50.1 2 
  6 D D D D D 
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2.vii: Cycle ergometry data for non-upper lobe subjects 
 
Subject   Cycle (s) W VO2 max VE max Borg 
1 0 160 5 12.9 21.62 2/9 
 6 395 5 11.5 26.38 0.5/7 
4 0 168 30 15.2 25.00 0.5/9 
 6 43 30 10.0 19.56 3/9 
5 0 147 30 10.6 26.43 0.5/6 
 6 163 30 8.2 24.24 0.5/8 
8 0 172 45 12.3 43.81 1/7 
 6 110 45 9.8 34.59 1/4 
9 0 179 5 11.6 18.97 0/4 
 6 67 5 11.3 18.77 0/9 
11 0 139 15 12.8 25.85 0.5/9 
 6 D D D D D 
 
 
 
2.viii: Muscle strength data for non-upper lobe subjects 
 
Subject   Sniff MIP MEP MVC Twitch 
1 0 46.8 44.3 75.1 15.9 4.3 
 3 55.0 57.7 76.8 14.9 5.9 
  6 58.6 46.6 78.6 13.4 6.2 
4 0 73.0 67.8 126.7 24.3 10.8 
 3 72.9 60.6 104.5 28.6 12.2 
  6 66.4 56.3 74.2 20.2 9.9 
5 0 45.5 76.2 126.6 34.8 15.6 
 3 40.8 65.4 110.0 38.5 17.2 
  6 31.4 60.0 112.2 38.4 13.4 
8 0 84.6 93.4 136.2 45.7 13.4 
 3 95.5 126.2 164.2 41.2 12.8 
  6 102.0 135.4 161.7 52.8 10.9 
9 0 66.6 50.1 88.0 20.1 3.4 
 3 61.7 60.7 79.3 15.8 2.2 
  6 61.9 61.1 76.5 16.3 5.7 
11 0 34.5 55.1 73.0 21.7 13.0 
 3 40.4 41.8 68.3 26.1 11.7 
  6 D D D D D 
 
2.ix: Abbreviations 
 
BP = Back pain 
D = Dead 
NB = No baseline values available therefore test not performed 
R = Refused 
SP = Shin pain 
W = Withdrew 
* = Data obtained at 6 weeks post procedure 
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APPENDIIX  3::   RAW  DATA  FOR  CHAPTER  4  
 
3.i: Individual patient data for upper lobe complete occlusions 
 
Subject Visit Site BMI FEV1 FVC RV TLC RV/TLC TLCOc 6MWT SGRQ mMRC 
U3 Trial end RUL 27.3 1.12 3.87 4.98 9.21 54.07 3.83 315 67.2 2 
  3 months   27.3 1.18 3.88 5.31 9.31 57.07 3.95 338 64.4 2 
U14 Trial end Ling 28.6 1.07 3.70 4.76 8.52 55.91 3.36 381 47.4 2 
  3 months   28.4 0.92 2.93 5.22 8.62 60.56 3.54 R 63.4 2 
U16 Trial end Ling 26.2 0.67 2.22 4.04 6.54 61.72 2.65 306 67.8 2 
  3 months   29.4 0.60 2.23 3.57 6.26 57.01 2.27 303 67.5 2 
U17 Trial end Ling 24.2 0.72 2.59 4.91 7.97 61.63 3.92 202 67.0 2 
  3 months   24.9 0.98 3.31 4.18 7.52 55.64 2.93 201 68.5 2 
U19 Trial end RUL 28.1 1.37 3.07 4.56 7.87 57.98 3.95 144 61.7 2 
  3 months   25.8 1.56 3.19 4.59 7.88 58.23 U R 65.7 3 
U22 Trial end Ling 23.5 0.58 1.88 4.64 6.45 72.02 3.21 211 60.5 2 
  3 months   23.9 0.90 2.93 3.72 6.45 57.59 3.16 354 47.4 0 
U23 Trial end Ling 24.2 1.88 5.03 5.36 10.45 51.32 2.70 280 50.7 3 
  3 months   24.4 1.77 4.74 5.87 10.24 57.30 2.66 244 55.8 3 
U24 Trial end Ling 19.5 0.56 2.73 5.16 7.71 66.97 2.17 311 55.4 2 
  3 months   19.5 0.55 2.66 5.28 7.84 67.28 2.18 318 51.0 3 
U25 Trial end Ling 23.7 0.62 2.52 4.32 6.86 63.04 2.70 424 47.6 2 
  3 months   23.7 0.54 2.28 4.74 7.05 67.18 2.65 352 60.1 2 
U29 Trial end RUL 25.2 0.49 2.64 4.68 7.29 64.17 1.74 299 35.1 2 
  3 months   25.2 0.50 2.51 4.89 7.43 65.88 1.47 239 25.3 2 
U31 Trial end RUL 17.8 0.76 2.90 5.00 7.91 63.21 1.44 234 75.1 2 
  3 months   D D D D D D D D D D 
U32 Trial end LUL 22.5 0.56 2.03 3.65 5.53 65.96 2.59 347 60.8 2 
  3 months   21.2 0.46 1.62 4.12 5.82 70.85 2.86 210 61.4 3 
U33 Trial end Ling 22.1 0.81 3.05 4.84 7.93 60.96 3.11 334 63.7 2 
  3 months   22.5 0.95 3.04 4.63 7.56 61.22 3.17 376 63.4 2 
U34 Trial end Ling 27.9 0.62 2.07 3.82 5.95 64.15 1.69 240 56.3 2 
  3 months   28.1 0.55 1.96 4.06 6.10 66.55 1.26 189 85.7 4 
 
3.ii: Individual patient data for lower lobe complete occlusions 
 
Subject Visit Site BMI FEV1 FVC RV TLC RV/TLC TLCOc 6MWT SGRQ mMRC 
N5 Trial end LLL 23.8 0.87 3.22 9.01 12.05 74.71 3.24 313 51.5 3 
  3 months   24.0 0.94 3.39 9.16 12.35 74.16 3.01 366 43.0 2 
N9 Trial end RLL 22.3 0.55 2.31 3.54 5.83 60.77 2.38 158 57.4 2 
  3 months   20.8 0.40 1.56 3.73 5.59 66.72 1.84 180 55.9 2 
 
3.iii: Abbreviations 
 
D = Dead 
Ling = Lingula  
LLL = Left lower lobe 
LUL = Left upper lobe 
R = Refused 
RLL = Right lower lobe 
RUL = Right upper lobe 
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APPENDIIX  4::   RAW  DATA  FOR  CHAPTER  6  
 
4.i: Lung function data for treatment subjects 
 
FEV1 FVC RV  TLC RV/TLC  TLCOc  
0 6 0 6 0 6 0 6 0 6 0 6 
AB01 0.76 0.70 2.89 2.94 4.60 4.69 7.49 7.39 61.41 63.40 2.60 1.91 
AB05 0.84 0.67 3.40 2.98 6.62 7.32 9.81 10.26 67.49 71.28 1.20 1.24 
AB09 1.04 0.83 3.46 2.70 5.34 5.78 9.03 8.94 59.16 64.73 5.17 4.75 
AB11 0.53 0.56 2.93 2.76 7.36 7.43 10.04 10.21 73.27 72.79 1.81 1.76 
AB12 0.66 0.60 2.20 1.70 4.41 4.66 6.85 7.03 64.42 66.32 2.96 2.65 
 
4.ii: Non-lung function data for treatment subjects 
 
6MWT SGRQ mMRC pO2 pCO2 
0 6 0 6 0 6 0 6 0 6 
AB01 289 240 30.95 41.26 3 3 7.70 7.63 5.60 5.85 
AB05 303 200 58.09 63.43 3 3 9.99 7.85 6.07 5.45 
AB09 362 314 42.81 42.27 2 2 8.83 9.53 4.24 4.35 
AB11 118 120 62.18 58.67 3 3 9.92 8.65 5.54 6.63 
AB12 272 254 61.18 69.10 2 2 9.70 8.40 5.30 5.47 
 
4.iii: Lung function data for treatment subjects 
 
4.iv: Non-lung function data for treatment subjects 
 
6MWT SGRQ mMRC  pO2  pCO2  
0 6 0 6 0 6 0 6 0 6 
AB04 221 180 61.51 71.18 3 4 7.14 8.32 6.08 5.58 
AB06 247 255 58.31 62.05 3 3 6.68 7.05 7.01 7.06 
AB07 183 200 49.63 50.68 3 3 8.11 10.40 5.68 5.03 
AB08 100 201 74.09 75.37 3 3 8.74 9.38 5.57 6.46 
AB10 275 267 58.00 57.42 2 3 8.06 7.46 4.42 4.10 
 
 
 
FEV1  FVC RV  TLC RV/TLC TLCOc  
0 6 0 6 0 6 0 6 0 6 0 6 
AB04 1.16 0.94 3.81 3.59 5.43 5.91 9.19 9.76 59.06 60.59 2.94 2.46 
AB06 0.52 0.49 2.62 2.54 6.69 6.23 9.01 8.94 74.28 69.73 2.68 3.02 
AB07 0.44 0.63 2.04 2.39 8.45 7.15 10.57 9.93 79.92 72.01 2.64 3.94 
AB08 0.55 0.51 2.14 2.18 4.69 4.55 7.09 7.17 66.19 63.41 2.00 2.09 
AB10 1.10 1.23 3.46 4.09 4.32 4.07 8.01 8.30 53.94 49.06 1.54 1.51 
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APPENDIIX  5::   RAW  DATA  FOR  CHAPTER  7  
 
5.i: Spirometric values for treatment arm subjects 
 
  
  
FEV1           FVC           
pre D1 1m 3m 6m 12m pre D1 1m 3m 6m 12m 
101 0.58 0.42 0.49 0.67 0.67 0.62 2.85 1.95 1.98 2.97 2.54 2.35 
102 0.84 0.75 0.81 0.91 0.78 0.79 2.88 2.89 2.72 3.10 3.00 2.87 
103 0.42 0.43 0.43 0.45 0.38 0.40 2.13 2.23 2.49 2.01 1.94 2.13 
104 0.60 0.64 0.58 0.62 0.64 0.49 1.95 2.06 2.06 2.23 2.31 1.76 
105 0.60 PM 0.49 0.47 0.43 0.39 2.11 PM 2.14 1.82 2.11 1.74 
106 0.52 PM 0.50 0.60 0.59 0.51 2.27 PM 2.40 2.57 2.47 2.39 
115 0.79 0.80 0.83 0.72 0.56 0.71 2.23 3.02 3.13 2.87 1.90 2.79 
118 0.64 0.58 0.54 0.64 0.58 0.65 3.84 4.41 3.50 3.84 3.63 3.57 
119 1.08 1.14 SI 1.27 1.37 1.01 3.76 3.89 SI 4.11 4.51 3.69 
120 0.50 PM 0.57 0.67 0.59 0.51 1.53 PM 3.17 2.84 2.73 2.59 
125 0.94 1.11 0.78 0.75 0.75 0.76 3.42 4.29 3.73 2.69 2.85 2.71 
127 0.54 SOB 0.51 0.58 0.47 0.42 2.33 SOB 2.12 2.43 2.11 1.54 
129 0.63 0.65 0.96 0.97 0.91 1.06 1.77 1.88 2.82 2.95 2.84 3.04 
131 0.94 1.20 0.89 1.02 0.96 0.89 2.99 3.37 2.75 2.91 2.88 2.69 
136 0.55 0.46 0.56 0.54 0.47 0.47 1.88 1.66 1.98 2.02 1.79 1.69 
138 0.80 PM 0.86 0.80 0.74 0.69 2.57 PM 3.02 2.98 3.12 2.82 
140 0.62 0.72 0.69 0.65 0.66 0.61 2.72 3.35 3.09 3.09 3.31 2.74 
143 0.57 0.93 0.64 0.58 0.51 D 1.63 2.86 2.40 1.85 1.60 D 
144 0.51 0.81 0.54 0.67 0.67 D 2.38 3.83 2.91 2.84 3.10 D 
146 0.37 PT 0.36 0.37 0.32 D 1.46 PT 1.57 1.59 1.28 D 
151 0.57 PC 0.59 0.58 D D 2.10 PC 2.34 2.59 D D 
 
5.ii: Lung volume measurements for treatment arm subjects 
 
  
  
RV           RV/TLC         
pre D1 1m 3m 6m 12m pre D1 1m 3m 6m 12m 
101 6.06 6.91 6.50 6.07 6.34 6.69 67.42 76.79 71.02 67.51 71.82 76.13 
102 4.18 4.82 4.72 4.47 4.54 4.71 57.87 60.64 65.04 60.46 60.29 63.40 
103 6.51 5.92 6.02 6.53 6.84 6.76 76.77 71.35 72.39 77.79 77.43 78.46 
104 4.50 4.88 4.43 4.36 4.42 5.19 72.54 70.53 68.47 66.02 66.73 77.81 
105 4.28 PM 4.62 4.30 4.52 4.40 65.73 PM 68.48 66.84 68.32 68.47 
106 5.47 PM 5.16 5.30 5.05 5.55 70.39 PM 70.04 69.96 67.89 68.17 
115 5.29 5.47 5.26 5.51 7.25 5.45 70.17 69.88 64.28 67.57 78.82 65.45 
118 8.30 7.05 9.16 9.13 8.45 8.38 69.11 60.76 72.17 71.67 68.32 69.29 
119 5.81 6.63 SI 5.48 5.18 6.08 60.50 65.16 SI 55.77 53.29 61.62 
120 6.59 PM 5.71 6.41 6.24 7.12 72.32 PM 63.53 69.39 69.43 74.88 
125 6.66 4.89 6.75 7.11 7.54 7.11 65.88 52.60 65.95 70.06 72.13 71.13 
127 5.04 5.13 5.28 4.41 4.77 5.69 70.92 76.56 72.01 65.01 69.26 77.00 
129 5.68 5.52 5.03 5.02 4.65 4.99 67.37 70.78 62.04 62.03 59.48 61.45 
131 5.77 4.98 5.76 5.84 5.71 5.10 66.60 56.99 66.62 65.86 65.23 62.27 
136 4.85 4.58 4.08 4.17 4.56 4.46 73.97 74.63 68.36 68.01 72.92 74.03 
138 5.76 PM 4.26 4.78 5.17 4.78 65.70 PM 54.23 59.71 61.97 58.95 
140 7.64 7.51 7.18 7.41 7.16 8.15 70.41 71.68 69.59 71.38 70.17 75.24 
143 4.54 3.68 4.46 4.24 4.51 D 70.69 55.53 67.18 67.62 70.56 D 
144 5.16 5.31 5.38 5.61 4.59 D 63.88 59.79 61.74 63.69 59.68 D 
146 5.05 PT 4.91 5.27 5.39 D 73.37 PT 70.18 74.02 78.83 D 
151 6.26 PC 6.79 6.36 D D 71.49 PC 75.49 69.88 D D 
 279 
5.iii: Gas transfer measurements for treatment arm subjects 
 
  
  
TLCO         
pre 1m 3m 6m 12m 
101 4.37 3.18 3.78 3.30 3.74 
102 2.45 2.18 2.40 2.15 2.30 
103 1.97 2.25 2.02 1.79 2.58 
104 2.39 2.51 3.37 3.03 2.04 
105 1.86 1.89 1.86 1.97 1.49 
106 3.20 2.95 2.95 3.34 3.00 
115 2.75 3.25 3.15 2.87 3.89 
118 2.72 2.55 2.84 2.97 2.77 
119 6.14 SI 6.47 6.53 5.88 
120 3.42 3.92 3.28 3.67 2.92 
125 2.17 2.03 2.07 1.89 1.86 
127 2.83 2.90 3.10 2.75 1.96 
129 3.68 4.07 4.52 4.17 4.37 
131 3.98 3.70 3.78 3.78 4.33 
136 2.54 2.31 2.47 1.89 1.69 
138 5.05 5.54 4.73 5.99 5.65 
140 2.31 2.46 2.54 2.34 2.16 
143 2.21 2.92 2.39 2.02 D 
144 1.93 2.17 2.40 2.00 D 
146 1.40 1.53 1.28 1.42 D 
151 2.85 2.34 2.65 D D 
 
5.iv: Exercise performance and breathlessness scores treatment arm subjects 
 
  Walk         Bike   mMRC         
  pre 1m 3m 6m 12m pre 6m pre D1 1m 3m 6m 12m 
101 276 120 195 180 180 298 139 2 3 4 3 3 3 
102 354 314 339 342 321 260 590 2 2 3 3 2 3 
103 180 171 111 75 135 161 174 3 3 3 4 3 3 
104 315 375 387 360 183 192 617 3 2 0 1 2 4 
105 210 180 120 162 180 114 128 3 3 3 3 3 3 
106 180 225 228 187 190 208 608 3 2 2 3 3 3 
115 240 309 279 114 303 123 140 3 1 2 1 4 1 
118 141 171 150 180 134 364 330 3 2 3 2 3 2 
119 330 462 531 538 477 254 865 2 2 1 1 1 1 
120 306 314 372 348 240 79 467 2 ? 2 2 3 2 
125 300 312 299 180 255 1388 468 3 3 2 2 2 2 
127 370 339 393 362 195 190 350 2 3 3 2 3 2 
129 529 567 576 582 489 574 492 2 4 1 1 1 2 
131 309 324 337 359 342 655 310 2 1 3 1 2 2 
136 240 254 239 249 179 132 277 3 4 3 2 3 4 
138 452 510 539 503 531 309 2110 3 2 1 1 1 1 
140 232 224 246 191 165 308 132 3 3 1 3 3 3 
143 300 325 330 225 D 178 271 2 2 2 2 2 D 
144 164 191 168 120 D 152 139 3 4 3 4 3 D 
146 142 104 136 112 D 110 108 3 3 3 3 3 D 
151 246 258 342 D D 339 D 2 2 2 2 D D 
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5.v: Spirometric values for sham arm subjects 
 
  FEV1           FVC           
  pre D1 1m 3m 6m 12m pre D1 1m 3m 6m 12m 
109 0.41 0.38 0.45 0.46 0.42 D 2.11 2.01 1.95 2.10 1.89 D 
116 0.44 0.44 0.37 T T T 1.92 2.12 2.09 T T T 
121 0.46 0.42 0.54 0.49 0.51 0.58 1.62 1.71 1.66 1.64 1.64 2.19 
126 0.83 0.78 0.95 0.90 0.86 0.86 2.72 2.93 3.27 3.00 3.15 2.77 
130 0.56 0.64 0.72 0.70 0.68 0.66 2.13 2.60 2.61 2.67 2.76 2.48 
135 0.44 0.35 0.44 0.34 0.30 0.42 1.61 1.09 1.68 1.29 1.18 1.40 
139 1.13 0.88 1.11 1.08 0.94 0.97 3.14 2.78 3.21 3.19 2.86 3.12 
142 0.47 0.58 0.59 0.59 0.62 0.52 1.49 2.28 2.14 2.51 2.60 2.11 
147 0.70 0.70 0.75 0.75 0.74 0.69 2.15 2.43 2.66 2.75 2.63 2.31 
 
5.vi: Lung volume measurements for sham arm subjects 
 
  RV           RV/TLC         
  pre D1 1m 3m 6m 12m pre D1 1m 3m 6m 12m 
109 5.80 5.97 5.86 6.44 6.45 D 75.47 75.60 73.92 75.76 77.38 D 
116 4.67 4.44 4.33 T T T 69.68 68.33 68.14 T T T 
121 3.84 3.83 4.22 4.07 4.09 3.42 70.38 68.31 70.29 69.11 69.48 63.81 
126 5.90 5.02 5.68 5.58 5.57 5.30 67.50 60.14 63.79 64.27 63.08 60.52 
130 5.98 5.48 5.55 5.13 5.13 6.07 72.72 70.21 69.45 67.02 67.39 72.69 
135 4.44 4.35 3.91 4.21 4.99 4.51 73.34 78.86 70.20 75.28 81.55 76.77 
139 5.51 6.07 5.42 5.84 5.64 5.82 62.05 68.76 60.57 67.18 64.40 65.77 
142 4.88 4.76 4.39 4.53 4.56 4.90 66.91 68.34 63.97 63.59 63.25 69.92 
147 5.64 5.77 5.61 5.69 5.75 6.35 65.72 70.41 67.72 68.63 68.91 74.84 
 
5.vii: Gas transfer measurements for sham arm subjects 
 
  TLCO         
  pre 1m 3m 6m 12m 
109 1.63 2.10 1.60 1.37 D 
116 1.60 1.75 T T T 
121 1.15 1.17 1.40 1.38 1.60 
126 2.08 2.46 2.56 1.91 2.26 
130 2.48 2.96 2.97 2.90 3.12 
135 2.14 2.11 1.66 H 1.35 
139 2.86 3.00 2.99 2.91 3.01 
142 1.74 1.85 2.03 2.06 1.69 
147 1.88 1.88 1.85 2.18 1.78 
 
5.viii: Exercise performance and breathlessness scores treatment arm subjects 
 
  Walk         Bike   mMRC         
  pre 1m 3m 6m 12m pre 6m pre D1 1m 3m 6m 12m 
109 270 276 264 225 D 137 172 3 2 2 2 3 D 
116 150 239 T T T 168 T 3 3 2 T T T 
121 330 333 352 329 329 373 89 3 3 3 2 3 3 
126 246 306 333 276 280 256 242 3 3 3 1 2 1 
130 241 285 333 303 354 311 697 3 1 3 2 2 3 
135 309 313 261 145 159 192 137 2 4 2 2 3 3 
139 408 425 403 409 390 331 249 2 1 1 2 2 1 
142 301 339 380 297 267 203 116 3 4 3 3 2 2 
147 246 253 284 200 175 198 R 2 3 2 2 2 3 
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5.ix: Unpaired t-tests on changes between groups 
 
FEV1     RV/TLC    
 t df p   t df p 
1 day 1.35 21 0.19  1 day -0.96 22 0.35 
1 month -1.36 27 0.19  1 month 0.09 27 0.93 
3 months 0.05 27 0.96  3 months -0.86 27 0.40 
6 months -0.40 26 0.70  6 months -0.55 26 0.58 
12 months -1.15 22 0.26  12 months 0.13 22 0.90 
         
FVC     TLCO    
 t df p   t df p 
1 day 0.81 21 0.43  1 month -1.45 27 0.16 
1 month 0.19 27 0.85  3 months -0.63 27 0.54 
3 months -0.04 27 0.97  6 months -1.17 25 0.25 
6 months -0.39 26 0.70  12 months -0.82 22 0.42 
12 months -0.81 22 0.43      
     Bike    
RV      t df p 
 t df p  6 months 1.40 25 0.17 
1 day -0.06 22 0.95      
1 month 0.48 27 0.64  Walk    
3 months -0.20 27 0.84   t df p 
6 months -0.23 26 0.82  1 month -1.29 28 0.21 
12 months 0.56 22 0.58  3 months -0.68 27 0.50 
     6 months -0.05 26 0.96 
     12 months -0.46 22 0.65 
 
5.x: Paired t-tests on changes within groups 
 
a) Treatment     b) Sham    
FEV1     FEV1    
  t df p     t df p 
1 day -1.65 13 0.12  1 day 0.87 8 0.41 
1 month -1.03 19 0.32  1 month -2.14 8 0.06 
3 months -1.86 20 0.08  3 months -1.36 7 0.22 
6 months -0.08 19 0.94  6 months -0.21 7 0.84 
12 months 1.00 16 0.33  12 months -0.45 6 0.67 
         
FVC     FVC    
  t df p     t df p 
1 day -2.31 13 0.04  1 day -0.88 8 0.41 
1 month -2.14 19 0.05  1 month -2.78 8 0.02 
3 months -2.71 20 0.01  3 months -1.80 7 0.12 
6 months -1.50 19 0.15  6 months -1.16 7 0.29 
12 months 0.05 16 0.96  12 months -1.86 6 0.11 
         
RV     RV    
  t df p     t df p 
1 day 0.92 14 0.37  1 day 0.79 8 0.46 
1 month 0.84 19 0.41  1 month 1.89 8 0.10 
3 months 0.82 20 0.42  3 months 0.38 7 0.72 
6 months 0.09 19 0.93  6 months 0.14 7 0.90 
12 months -1.04 16 0.31  12 months -0.16 6 0.88 
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RV/TLC     RV/TLC    
  t df p     T df p 
1 day 1.10 14 0.29  1 day -0.38 8 0.71 
1 month 1.63 19 0.12  1 month 2.88 8 0.02 
3 months 2.21 20 0.04  3 months 0.32 7 0.76 
6 months 0.46 19 0.65  6 months -0.10 7 0.92 
12 months -1.05 16 0.31  12 months -0.37 6 0.73 
         
TLCO     TLCO    
  t df p     T df p 
1 month -0.29 19 0.77  1 month -3.04 8 0.02 
3 months -1.06 20 0.30  3 months -1.22 7 0.26 
6 months -0.25 19 0.80  6 months -1.29 6 0.24 
12 months 0.51 16 0.62  12 months -0.43 6 0.68 
         
Bike     Bike    
 t df p    T df p 
6 months -1.17 19 0.26  6 months 0.19 6 0.86 
         
Walk     Walk    
 t df p   T df p 
1 month -0.91 20 0.37  1 month -2.95 8 0.02 
3 months -1.70 20 0.11  3 months -1.80 7 0.12 
6 months 0.57 19 0.58  6 months 0.87 7 0.41 
12 months 1.44 16 0.17  12 months 0.583 6 0.58 
 
5.xi: End expiratory lung volumes on isotime exercise 
 
a) Treatment     b) Sham    
 EELV B EELV 6m  EELV   EELV B EELV 6m  EELV 
102 5.591 6.132 0.541  109 6.567 7.491 0.924 
103 7.510 7.899 0.389  121 4.549 5.026 0.477 
104 5.117 5.402 0.285  126 6.849 7.471 0.622 
105 5.575 5.448 -0.127  130 7.146 6.187 -0.959 
106 6.424 6.085 -0.339  135 5.185 5.158 -0.027 
115 6.593 7.985 1.392  139 7.178 7.046 -0.132 
118 10.457 10.938 0.481  142 6.180 5.862 -0.318 
119 7.319 7.259 -0.060      
120 7.927 7.403 -0.524      
125 8.166 9.084 0.918      
127 5.617 5.576 -0.041      
129 5.854 5.915 0.061      
131 6.548 6.932 0.384      
136 5.314 4.979 -0.335      
138 7.494 6.415 -1.079      
140 9.005 8.443 -0.562      
143 5.648 5.227 -0.421      
144 7.544 6.368 -1.176      
146 5.899 5.617 -0.282      
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5.xii: Number of stents per treatment subject and appearance on CT at 6 months  
 
 
No. of 
Stents 
Missing Occluded Obstructed Patent 
101 4 4 0 0 0 
102 6 1 1 4 0 
103 6 1 1 2 2 
104 6 1 1 3 1 
105 6 0 1 4 1 
106 6 0 1 3 2 
115 6 1 2 3 0 
118 6 0 4 1 1 
119 5 0 2 2 1 
120 6 0 1 2 3 
125 6 0 1 4 1 
127 4 0 1 1 2 
129 4 1 0 0 3 
131 6 0 1 2 3 
136 4 0 0 2 2 
138 6 0 2 1 3 
140 6 0 3 3 0 
143 6 1 2 2 1 
144 6 0 1 2 3 
146 6 1 4 0 1 
151 6 D D D D 
 
5.xiii: Abbreviations 
 
D = Dead 
H = Considered too hypoxic for test 
PC = No data owing to protocol change 
PM = Pneumomediastinum 
PT = Pneumothorax 
R = Refused 
SI = Staff illness precluded testing 
SOB = Declined as too short of breath 
T = Transplanted 
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APPENDIIX  6::   RAW  DATA  FOR  CHAPTER  8  
 
6.i: Spirometry and airways resistance in treatment subjects 
 
FEV1       FVC       Raw Ex     
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
1 0.73 0.85 0.83 0.78 3.43 3.59 3.26 3.69 0.68 0.58 0.79 0.50 
2 0.58 0.73 0.72 0.73 1.70 1.90 1.81 1.81 1.38 0.96 1.24 1.02 
5 0.92 1.10 W W 3.67 3.86 W W 0.73 0.45 W W 
6 0.78 0.86 0.92 1.04 3.76 4.08 4.05 3.52 1.55 0.81 0.90 0.52 
7 0.80 0.89 0.79 0.79 2.25 2.28 2.59 2.46 0.72 0.72 1.02 0.64 
8 0.62 0.82 0.83 0.80 3.12 2.91 3.08 3.14 1.23 0.66 1.09 1.33 
9 0.77 0.77 0.88 1.02 3.12 3.40 3.93 3.60 1.37 0.89 1.35 0.64 
10 0.72 D D D 2.72 D D D 0.92 D D D 
11 0.56 0.94 0.82 0.83 3.29 4.15 4.24 3.87 1.46 0.72 1.23 0.91 
12 0.57 0.77 0.71 0.82 2.06 2.70 2.57 2.56 0.93 0.97 1.37 1.52 
13 0.44 0.53 0.49 0.45 2.29 3.10 2.67 2.68 2.86 1.69 2.13 1.90 
15 0.50 0.60 0.69 0.77 2.36 2.55 2.86 3.14 0.95 1.20 1.03 0.95 
16 0.90 1.08 0.88 1.07 2.74 2.74 3.00 3.06 0.38 0.38 0.69 0.48 
17 0.67 0.63 0.84 0.89 2.63 2.69 2.72 3.08 1.63 1.62 0.93 0.58 
18 0.69 0.58 0.88 0.74 2.45 2.54 3.37 3.35 0.80 0.93 0.60 0.58 
19 0.97 U 1.28 1.25 2.95 U 3.92 3.86 0.72 U 0.63 0.62 
20 0.92 1.01 1.13 1.02 3.62 3.67 3.64 3.50 0.47 0.42 0.44 0.66 
21 1.00 1.12 0.99 1.00 4.15 4.27 3.79 3.75 0.94 0.92 1.34 1.27 
22 0.61 1.13 0.98 0.70 1.91 3.05 2.14 2.02 0.98 0.62 R 0.92 
23 0.89 0.94 0.95 1.02 3.31 3.12 3.50 3.44 0.67 1.08 0.65 0.37 
 
6.ii: Lung volumes in treatment subjects 
 
RV       TLC       RV/TLC       
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
1 4.68 3.57 4.10 3.86 8.21 7.53 7.73 7.77 57.04 47.35 53.03 49.70 
2 3.09 2.65 2.89 2.71 5.13 4.69 4.70 4.61 60.36 56.56 61.45 58.85 
5 5.50 4.86 W W 8.96 8.91 W W 61.39 54.55 W W 
6 4.25 4.22 3.87 4.27 7.95 8.10 8.11 8.29 53.44 52.17 47.71 51.51 
7 3.94 3.72 3.82 4.02 6.53 6.26 6.57 6.60 60.25 59.38 58.08 60.91 
8 4.40 3.88 3.41 3.58 7.36 7.20 6.73 6.75 59.83 53.95 50.66 52.95 
9 5.23 5.14 4.00 4.33 8.47 8.75 7.96 7.95 61.76 58.71 50.24 54.44 
10 3.72 D D D 6.64 D D D 56.01 D D D 
11 5.28 4.70 4.57 4.61 8.87 9.07 8.74 8.65 59.56 51.83 52.30 53.26 
12 4.51 4.01 3.85 4.04 6.87 6.67 6.61 6.89 65.63 60.15 58.26 58.71 
13 6.63 6.18 6.01 6.31 9.16 8.99 9.09 8.99 72.39 68.76 66.18 70.20 
15 3.90 3.67 3.70 3.41 6.24 6.47 6.22 6.51 62.49 56.69 59.51 52.42 
16 4.99 4.51 4.57 4.52 7.80 7.54 7.60 7.54 63.98 59.81 60.14 59.99 
17 4.17 4.09 4.14 3.51 6.78 6.88 7.05 6.78 61.47 59.50 58.78 51.79 
18 9.06 7.89 6.62 6.84 11.55 10.83 10.88 10.82 78.37 72.85 60.85 63.22 
19 5.12 U 3.86 3.97 8.63 U 7.94 7.94 59.31 U 48.58 50.08 
20 5.64 5.46 5.01 6.11 9.67 9.64 9.13 9.86 58.32 56.64 54.91 61.91 
21 5.46 4.85 6.26 6.16 9.69 9.31 10.26 9.96 56.29 52.10 61.00 61.83 
22 7.18 6.48 R 6.08 9.24 9.12 R 8.09 77.71 71.05 R 67.81 
23 5.24 5.21 5.30 4.99 8.79 8.60 8.78 8.72 59.61 60.57 60.36 57.23 
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6.iii: Exercise performance and symptom scores in treatment subjects 
 
Walk       SGRQ       mMRC       
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
1 390 439 442 428 67.1 42.1 40.3 35.1 2 2 2 2 
2 237 260 300 315 41.4 43.4 41.0 36.5 4 3 3 4 
5 393 414 W W 53.2 35.4 W W 2 2 W W 
6 287 313 320 225 63.5 44.3 38.6 47.5 2 2 2 2 
7 357 366 390 409 61.2 39.4 34.7 53.8 3 3 1 3 
8 288 397 388 359 50.6 40.5 53.8 41.7 2 3 3 1 
9 420 480 477 407 58.1 36.8 36.9 65.8 2 1 1 1 
10 480 D D D 62.6 D D D 3 D D D 
11 420 510 468 464 53.0 37.8 67.5 58.0 2 0 0 0 
12 300 481 480 454 66.3 49.5 39.9 54.5 4 2 1 2 
13 229 270 270 268 66.7 32.5 58.4 69.4 2 2 2 3 
15 288 318 342 369 83.8 67.9 57.0 59.4 2 2 2 2 
16 430 578 636 561 51.2 50.2 52.1 53.5 2 2 1 2 
17 150 150 148 244 60.3 53.1 58.6 32.4 3 2 2 3 
18 240 330 417 377 53.7 57.1 49.9 56.6 3 2 1 2 
19 273 U 444 470 47.7 U 33.6 39.6 2 U 1 1 
20 417 450 464 522 61.4 52.6 43.8 54.0 2 2 2 2 
21 136 136 208 224 63.8 69.1 54.3 54.8 2 2 3 2 
22 164 212 221 217 78.0 85.9 87.5 91.5 3 3 3 3 
23 354 355 363 350 59.6 36.2 36.8 41.1 3 3 2 1 
 
6.iv: FRC and measures of gas exchange in treatment subjects 
 
FRC       TLCOc       pO2   pCO2   
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 3 0 3 
1 6.07 5.19 5.47 5.51 4.49 4.38 4.23 3.71 10.39 10.66 3.87 3.87 
2 3.48 3.61 3.32 3.46 1.56 1.49 1.61 1.49 8.70 9.02 4.36 4.14 
5 6.45 6.05 W W 2.38 2.58 W W 10.06 W 4.64 W 
6 6.18 5.80 5.90 5.93 1.56 1.72 1.41 1.30 6.99 6.84 6.06 5.83 
7 4.75 4.59 4.97 4.97 2.66 2.43 2.63 2.72 10.66 9.42 4.44 4.54 
8 5.75 5.24 4.80 4.88 2.16 2.43 2.71 2.50 6.87 7.44 5.88 5.98 
9 6.26 6.32 5.24 5.78 1.79 2.26 2.14 2.10 9.38 8.77 5.00 4.61 
10 4.49 D D D 2.63 D D D 9.40 D 5.20 D 
11 7.34 6.68 6.67 6.57 3.48 3.05 2.85 2.92 10.21 11.31 5.16 5.02 
12 5.42 4.82 4.80 5.24 1.75 2.65 2.48 2.68 7.70 9.73 5.75 5.71 
13 7.62 7.70 7.64 7.79 2.72 3.09 2.77 2.15 7.70 6.86 6.96 6.58 
15 4.76 4.80 4.82 4.57 1.90 2.29 2.08 2.48 10.20 8.93 5.40 5.24 
16 5.68 5.37 5.53 5.48 4.24 4.31 3.89 4.31 9.52 10.91 4.79 4.98 
17 5.27 5.12 5.43 4.81 2.25 2.42 2.32 2.79 10.59 10.32 4.38 4.03 
18 9.77 9.40 8.90 8.5 2.04 2.14 2.51 2.44 8.30 8.50 5.30 5.40 
19 6.10 U 5.16 5.06 3.02 U 3.52 3.52 10.17 8.35 4.71 4.88 
20 6.95 7.01 6.60 7.18 2.47 2.49 2.38 2.52 8.80 9.30 5.59 5.20 
21 7.27 6.52 7.41 7.42 4.25 3.77 3.85 3.98 9.83 8.97 5.07 5.52 
22 7.75 6.91 R 6.08 2.52 2.97 R 2.32 9.60 8.90 4.90 5.54 
23 6.44 6.53 6.59 3.73 4.00 4.05 2.89 3.60 8.00 8.43 4.92 4.81 
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6.v: Spirometry and airways resistance in control subjects 
 
 FEV1       FVC       Raw Ex     
 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
2 0.57 0.53 0.63 0.58 1.60 1.51 1.59 1.70 0.76 0.95 1.29 1.38 
6 0.84 0.77 0.70 0.78 3.87 3.59 3.59 3.76 1.29 1.50 1.05 1.55 
9 0.81 0.66 0.73 0.77 3.18 3.04 3.38 3.12 1.64 0.92 1.23 1.37 
10 0.79 0.84 0.85 0.72 2.95 3.02 3.04 2.72 0.78 0.74 0.81 0.92 
11 0.67 0.86 0.56 0.56 3.29 4.20 2.45 3.29 1.66 1.11 1.41 1.46 
15 0.66 0.70 0.65 0.50 2.62 2.65 2.69 2.36 1.73 1.63 1.49 0.95 
16 0.77 1.02 0.94 0.90 2.90 2.74 2.94 2.74 0.79 0.64 0.44 0.38 
19 1.03 0.92 0.87 0.97 3.51 2.99 3.03 2.95 0.72 0.64 0.76 0.72 
20 0.77 0.76 0.77 0.92 3.75 2.98 3.04 3.62 0.63 0.57 0.68 0.47 
21 1.13 1.16 0.95 1.00 4.05 4.30 3.48 4.15 0.92 1.38 1.14 0.94 
 
 
6.vi: Lung volumes in control subjects 
 
RV       TLC       RV/TLC       
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
2 3.54 3.26 2.89 3.09 5.28 4.94 4.59 5.13 67.11 65.94 63.03 60.36 
6 4.09 4.26 4.27 4.25 8.00 7.76 7.94 7.95 51.09 54.92 53.80 53.44 
9 4.99 5.08 4.31 5.23 8.17 8.07 7.82 8.47 61.07 62.95 55.06 61.76 
10 3.91 3.31 3.69 3.72 6.77 6.50 6.81 6.64 57.75 50.87 54.12 56.01 
11 5.43 4.74 7.32 5.28 8.83 8.74 10.38 8.87 61.44 54.27 70.53 59.56 
15 3.57 3.40 3.57 3.90 6.28 6.10 6.32 6.24 56.81 55.66 56.55 62.49 
16 4.99 5.00 4.93 4.99 7.86 7.75 7.80 7.80 63.57 64.46 63.14 63.98 
19 5.30 5.32 5.28 5.12 8.68 8.56 8.60 8.63 61.13 62.05 61.40 59.31 
20 6.60 6.43 5.62 5.64 9.93 9.28 9.31 9.67 66.46 69.30 60.37 58.32 
21 5.30 4.83 5.80 5.46 9.94 9.48 9.42 9.69 53.37 50.95 61.50 56.29 
 
 
6.vii: Exercise performance and symptom scores in control subjects 
 
Walk       SGRQ       mMRC       
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 
2 240 253 249 237 43.8 44.9 51.7 41.4 2 3 3 4 
6 232 312 240 287 53.9 56.2 58.1 63.5 3 3 3 2 
9 444 454 456 420 35.8 35.7 35.2 58.1 2 1 1 2 
10 482 487 471 480 52.6 49.4 56.6 62.6 2 2 2 3 
11 384 441 388 420 56.6 69.5 59.9 53.0 2 2 3 2 
15 308 309 308 288 68.5 61.4 61.2 83.8 2 2 2 2 
16 575 320 540 430 48.0 51.9 47.2 51.2 2 1 1 2 
19 260 298 222 273 61.7 68.3 61.4 47.7 2 3 2 2 
20 420 420 419 417 46.5 58.1 53.2 61.4 2 2 3 2 
21 153 125 128 136 68.9 63.7 75.8 63.8 3 3 3 2 
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6.viii: FRC and measures of gas exchange in control subjects 
 
FRC       TLCOc       pO2   pCO2   
0 1 (1) 1 (2) 3 0 1 (1) 1 (2) 3 0 3 0 3 
2 3.99 3.86 3.36 3.48 1.39 1.32 1.30 1.56 8.77 8.70 4.88 4.36 
6 6.02 6.02 5.72 6.18 1.93 1.56 1.59 1.56 7.08 6.99 6.03 6.06 
9 5.87 5.77 5.52 6.26 1.97 2.21 2.22 1.79 9.80 9.38 5.31 5.00 
10 4.85 4.58 4.57 4.49 2.46 2.62 2.61 2.63 9.79 9.40 5.02 5.20 
11 6.84 6.74 8.49 7.34 2.95 3.62 3.50 3.48 10.61 10.21 5.62 5.16 
15 4.69 4.31 4.56 4.76 1.80 2.19 2.37 1.90 8.05 10.20 5.06 5.40 
16 5.78 5.97 5.45 5.68 3.92 4.21 4.35 4.24 9.64 9.52 5.35 4.79 
19 6.67 6.46 6.45 6.10 3.09 2.81 3.07 3.02 10.84 10.17 5.58 4.71 
20 7.58 7.01 7.24 6.95 2.51 2.43 2.73 2.47 10.00 8.80 4.90 5.59 
21 7.08 6.54 7.45 7.27 4.52 4.32 4.02 4.25 10.13 9.83 5.11 5.07 
 
 
6.ix: Abbreviations 
 
D = Dead 
R = Refused 
U = Unavailable for testing 
W = Withdrew for non-clinical reasons 
 
 
 
